Clinical Focus


  • Critical Care Medicine

Academic Appointments


Professional Education


  • Board Certification: College of Intensive Care Medicine, Intensive Care Medicine (2020)
  • Fellowship: Royal College of Emergency Medicine (2014) United Kingdom
  • Board Certification: Royal College of Emergency Medicine, Emergency Medicine (2008)
  • Residency: St. George Hospital Critical Care Dept (2006) Australia
  • Medical Education: University of Manchester Medical School (2002) England
  • FFICM, London Deanery, Critical Care Medicine (2014)
  • FRCEM, London Deanery, Emergency Medicine (2014)
  • PhD, Imperial College, London, Respiratory Physiology (2013)
  • MB ChB, University of Manchester, Medicine (2002)
  • BSc, University of Manchester, Biological Sciences (2001)

All Publications


  • Real-time Subgrouping of Sepsis and Systemic Inflammatory Syndromes. Critical care clinics McMullan, R., Bhavani, S. V., Sinha, P. 2026; 42 (4): 839-855

    Abstract

    Biological heterogeneity in sepsis and related systemic inflammatory syndromes has constrained therapeutic advancement and reduced the efficiency of conventional trial designs. Reproducible host response-derived sepsis subgroups recur across clinical, protein biomarker-based, and transcriptomic dimensions. A practical route to the implementation and evaluation of real-time subgrouping is a 2-stage pipeline that combines assessment of sepsis subgroup eligibility with subsequent classification. Priorities for future work are embedding classifiers and diagnostic platforms with high validity into clinical workflow so that prospective clinical trials can test their clinical utility.

    View details for DOI 10.1016/j.ccc.2026.05.008

    View details for PubMedID 42686300

  • Virus reactivation in acute and long COVID-19. Nature Maguire, C., Chen, J., Rouphael, N., Morse, B. A., Hoch, A., Pickering, H., Phan, H. V., Glascock, A., Chu, V., Dandekar, R., Corry, D., Kheradmand, F., Baden, L. R., Sekaly, R. P., McComsey, G. A., Haddad, E. K., Cairns, C. B., Pulendran, B., Fernandez-Sesma, A., Simon, V., Metcalf, J. P., Agudelo Higuita, N. I., Messer, W. B., Davis, M. M., Nadeau, K. C., Kraft, M., Bime, C., Schaenman, J., Erle, D., Calfee, C. S., Atkinson, M. A., Brakenridge, S. C., Ehrlich, L. I., Montgomery, R. R., Shaw, A., Hough, C. L., Hafler, D., Augustine, A. D., Becker, P. M., Peters, B., Ozonoff, A., Kim-Schulze, S., Krammer, F., Bosinger, S. E., Eckalbar, W., Altman, M. C., Wilson, M., Guan, L., Kleinstein, S. H., Smolen, K. K., Reed, E. F., Levy, O., Maecker, H., Hunt, P., Steen, H., Diray-Arce, J., Langelier, C. R., Melamed, E. 2026

    Abstract

    Chronic viral infections are ubiquitous in humans, with individuals carrying multiple viruses that can reactivate during physiological stress, including severe illness1. Notably, SARS-CoV-2 infection has been shown to reactivate chronic viruses such as Epstein-Barr virus and cytomegalovirus, yet the full extent, temporal dynamics and immunological impact of viral reactivation in COVID-19 remain incompletely understood2-7. Here, leveraging multi-omic longitudinal data from 1,154 hospitalized patients with COVID-19 from the Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) study, we reveal significant reactivation of Herpesviridae and Anelloviridae during acute COVID-19, with distinct temporal dynamics for different viruses, and demonstrate that reactivation correlates with disease severity, host immune effects and clinical outcomes. Although our results do not establish causation between virus reactivation and clinical outcomes, we highlight the prevalence of chronic viral reactivation during acute COVID-19 and long COVID. Our findings challenge the prevailing view that chronic viral reactivation is primarily a consequence of immunosuppression, demonstrating that reactivations occur frequently in immunocompetent individuals during severe illness and in association with increased systemic inflammation. Additionally, we demonstrate persistence of viral reactivation in convalescence, and report an association of Anelloviridae with long COVID. This study provides immune, transcriptomic and metabolomic signatures of viral reactivation that could inform future strategies to prognosticate and treat acute COVID-19 and long COVID.

    View details for DOI 10.1038/s41586-026-10740-z

    View details for PubMedID 42557313

    View details for PubMedCentralID 9888380

  • Inflammatory trajectories as intermediate endpoints: signal, surrogate, or solution? AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE van der Heijden, W. A., Sinha, P. 2026; 212 (8): 1683-1685

    View details for DOI 10.1093/ajrccm/aamag291

    View details for Web of Science ID 001837589300036

    View details for PubMedID 42275171

  • Global Viral Lower Respiratory Disease Episodes, Hospitalisations, and Clinical Outcomes by Aetiology, 2010-2021 INFECTIOUS DISEASES AND THERAPY Maslova, E., Rafferty, Q., Lei, J., Wang, C., Suba, J., Pasovic, M., Ewald, S., Del Castillo, D., Lupton, C., Qiao, Y., Fageras, M., Sinha, P., Gillespie, C. W. 2026; 15 (9): 2523-2543

    Abstract

    Viral lower respiratory tract disease (LRTD) is a major cause of global morbidity and mortality, but pathogen-specific estimates remain limited. We aimed to quantify the global burden of viral LRTD episodes, hospitalisations, and severe clinical outcomes by aetiology from 2010 to 2021.We used the Global Burden of Disease (GBD) 2021 modelling framework to generate estimates of viral LRTD incidence, hospitalisations, and clinical outcomes from 2010 to 2021 for 204 countries and territories, 21 regions, and seven super-regions. Aetiology-specific estimates were generated for five viral categories: influenza, respiratory syncytial virus (RSV), human metapneumovirus (hMPV), SARS-CoV-2, and "other" viral pathogens. Data inputs included surveillance systems, clinical informatics, published literature, surveys, and vital registration. Viral LRTD incidence was estimated using DisMod-MR 2.1, a GBD Bayesian meta-regression tool for disease incidence. We then applied location-specific admission scalars, adjusted for healthcare access, to derive hospitalisations. Aetiology-specific clinical outcome proportions-including intensive care unit (ICU) need, invasive mechanical ventilation (IMV) need, and in-hospital mortality-were estimated using meta-regression-Bayesian, regularised, trimming models. These were then applied to the hospitalisation estimates. COVID-19 incidence and hospitalisations were estimated using established GBD COVID-19 methods. All estimates are reported with 95% uncertainty intervals (UIs).Globally, viral LRTD episodes increased from 82.3 million (95% UI 76.4-88.2) in 2010 to 94.9 million (88.8-101.2) in 2019, while episode rates remained relatively stable at approximately 1200 per 100,000 population. Over the same period, hospitalisation rates increased by 40%, from 103.7 (96.1-111.4) to 145.4 (134.6-156.4) per 100,000 population. In 2020 and 2021, the emergence of SARS-CoV-2 resulted in sharp increases in burden, with episodes exceeding 1.1 billion in 2020 and 1.5 billion in 2021. During this period, 2020-2021, episode and hospitalisation rates associated with influenza, RSV, and hMPV declined by nearly 50%. Between 2010 and 2019, global rates of ICU need increased from 16.1 (14.3-18.0) to 23.7 (21.0-26.6) per 100,000 population, IMV need from 7.5 (6.7-8.4) to 11.2 (10.0-12.6), and in-hospital mortality from 9.4 (8.4-10.5) to 13.9 (12.3-15.6). In 2020-2021, SARS-CoV-2 dominated severe outcomes, with in-hospital mortality reaching 87.7 (83.3-92.2) per 100,000 population in 2021. Across the study period, older adults consistently experienced the highest rates of severe outcomes, and substantial regional variation was observed.Before 2020, global incidence of viral LRTD was stable; however, hospitalisations and severe outcomes increased substantially, suggesting rising clinical severity and healthcare demand. The COVID-19 pandemic profoundly altered the global viral LRTD landscape, driving unprecedented increases in hospitalisations, intensive care use, and mortality, while suppressing other respiratory viruses in the years 2020 and 2021. These findings demonstrate a substantial burden of severe viral LRTD globally, with marked age and regional variations, underscoring the importance of sustained aetiology-specific surveillance, adequate healthcare capacity, and equitable access to preventive and therapeutic interventions.

    View details for DOI 10.1007/s40121-026-01406-4

    View details for Web of Science ID 001823436500001

    View details for PubMedID 42471508

    View details for PubMedCentralID PMC13476213

  • The ARDS, Pneumonia, and Sepsis (APS) Consortium: Rationale, Design, and Feasibility of a National Platform for Phenotyping Critical Illness Syndromes. Chest Self, W. H., Calfee, C. S., Brown, S. M., Moss, M., Ware, L. B., Hyzy, R. C., Meyer, N. J., Reilly, J. P., Harhay, M. O., Shashaty, M. G., Sandsmark, D. K., Auriemma, C. L., Jones, T. K., Prescott, H. C., Dickson, R. P., Nelson, K., McSparron, J. I., Lagina, M., Denstaedt, S. J., Admon, A. J., Patel, B. K., Wolfe, K. S., Hite, R. D., Hudock, K. M., Bastarache, J. A., Koyama, T., Kerchberger, V. E., Ely, E. W., Jackson, J. C., Sinha, P., Mudd, P. A., Kraft, B. D., Fremont, R. D., Singh, R., Aggarwal, N. R., Jolley, S. E., Burnham, E. L., Mantelli, R. A., Janssen, W. J., Moore, C. M., Douglas, I. S., Peterson, R., Peltan, I. D., Barkauskas, C. E., Pratt, E. H., Harris, E. S., Scharfstein, D. O., Needham, D. M., Sahetya, S. K., Parker, A. M., Iwashyna, T. J., Shenderov, K., Matthay, M. A., Alipanah-Lechner, N., Magee, L., Shwartzman, T., Lin, C., Weingart, M. F., Langelier, C. R., Chao, O., Hendrickson, C. M., Kornblith, L. Z., Chak, S., Bardillon, K., Rodriguez, K. H., Rogers, A. J., Moore, A. R., Levitt, J. E., Vojnik, R., Perez, C., Lindsell, C. J., Shotwell, M. S., Blette, B. S., Imhoff, B. W., Rice, T. W., Rhoads, J. P., Womack, K. N., Merkel, A. R., Ahmad, L. N., Zhao, X., Grandon, I. E., Gong, M. N. 2026

    Abstract

    To enhance biological understanding of acute respiratory distress syndrome (ARDS), pneumonia, and sepsis and accelerate therapeutic development in these areas, the National Institutes of Health developed the ARDS, Pneumonia, and Sepsis (APS) Consortium.Is the APS Consortium study rapidly generating data and biospecimens from a large cohort of critically ill adults with ARDS, pneumonia, and sepsis that will facilitate phenotyping of these syndromes?The APS Consortium Phenotyping Study is a multicenter longitudinal prospective observational cohort study aimed at enrolling 4,000 critically ill adults with ARDS, pneumonia, and/or sepsis over 4 years. Data and biospecimens are collected to characterize many aspects of each participant's chronic health, acute illness, and long-term recovery to facilitate phenotyping-that is, subclassifying ARDS, pneumonia, and sepsis into precise biologically-based subsets with shared pathophysiology. Feasibility of the study was assessed by evaluating the first 1,000 participants in terms of recruitment pace, participant characteristics, biospecimen collection, and proportion with confirmed ARDS, pneumonia, and sepsis based on expert adjudication.The first 1,000 participants were recruited ahead of schedule in less than 13 months. Median age was 64 years, 75% received vasopressors, 50% received invasive mechanical ventilation, and 25% died in the hospital within 4 weeks of enrollment. Biospecimen collection rates were high, with 99% of participants with blood, 98% with upper respiratory swabs, 37% with lower respiratory samples, 80% with urine, and 65% with gastrointestinal samples. Expert adjudication resulted in 40% classified with ARDS, 52% with pneumonia, and 89% with sepsis.The APS Consortium Phenotyping Study is producing a cohort of critically ill adults with ARDS, pneumonia, and sepsis with high severity of disease and a rich set of data and biospecimens. The study will continue to full enrollment of 4,000 participants.Clinicaltrials.gov NCT06521502.

    View details for DOI 10.1016/j.chest.2026.05.053

    View details for PubMedID 42442528

  • Effects of inflammatory phenotypes in acute respiratory distress syndrome on mortality and partitioning of lung and chest wall mechanics in patients in the USA and Canada: a retrospective cohort study LANCET RESPIRATORY MEDICINE Pensier, J., Fosset, M., Paschold, B., von Wedel, D., Sharif, M., Braeuer, B. L. P., D Sahli, S., Novack, V., Goodspeed, V., Sarge, T., Jung, B., Amato, M. B. P., Sinha, P., Talmor, D., Schaefer, M. S., Baedorf-Kassis, E. 2026; 14 (7): 609-619

    Abstract

    Inflammatory phenotypes of acute respiratory distress syndrome (ARDS) predict outcomes and can respond differently to treatment strategies. We aimed to establish whether these phenotypes differ in respiratory mechanics and in response to lung-protective ventilation strategies.In this retrospective cohort study, data from two cohorts were harmonised. Patients with moderate-to-severe ARDS with oesophageal manometry data from the EPVent-2 trial (14 hospitals across the USA and Canada) and a retrospective cohort at Beth Israel Deaconess Medical Center (Boston, MA, USA) were merged and lung mechanics were compared. Patients had to be aged 18 years or older, have moderate to severe ARDS, and be monitored with oesophageal manometry. To analyse the primary outcome of 60-day mortality after ARDS onset, we used multivariable Cox models for each inflammatory phenotype to study the associations between measures of lung-protective ventilation (driving pressure, transpulmonary driving pressure, and end-expiratory transpulmonary pressure) and 60-day mortality in all patients who had complete data for all variables.Between Jan 1, 2008, and Jan 31, 2024, 5778 patients were assessed for eligibility (200 in the EPVent-2 cohort and 5578 in the BIDMC cohort). Of these patients, 890 were included in this study cohort (200 from the EPVent-2 trial and 690 from the retrospective cohort), of whom 424 (48%) had the hyperinflammatory phenotype and 466 (52%) had the hypoinflammatory phenotype. 232 (55%) patients in the hyperinflammatory group and 136 (29%) patients in the hypoinflammatory group died within 60 days (p<0·0001). The effects on 60-day mortality were more pronounced among patients with the hypoinflammatory phenotype than the hyperinflammatory phenotype for high respiratory system driving pressure (≥15 cm H2O; adjusted hazard ratio 2·01 [95% CI 1·39-2·91] vs 1·46 [1·11-1·94]; pinteraction=0·033) and high transpulmonary driving pressure (≥12 cm H2O; 2·36 [1·64-3·39] vs 1·18 [0·84-1·60]; pinteraction=0·0010). In addition, having an end-expiratory transpulmonary pressure within plus or minus 2 cm H2O was protective among the hypoinflammatory (0·66 [0·46-0·93]) but not the hyperinflammatory phenotype (0·97 [0·73-1·27]). Excess mortality among the hyperinflammatory phenotype was mediated by extrapulmonary organ failure (proportion mediated 46% [+17 to +79]) but not respiratory failure (0% [-3 to +4]).Our findings suggested that in ARDS, the association between lung-protective mechanical ventilation and 60-day mortality is greater in patients with the hypoinflammatory phenotype than the hyperinflammatory phenotype, therefore patients with hypoinflammatory ARDS could be an important target population for enrichment of future clinical trials. However, our findings do not support different ventilation strategies based on phenotype. Although both phenotypes present with similar lung mechanics, extrapulmonary organ failure is the key driver of excess mortality among patients with the hyperinflammatory phenotype.Société Française d'Anesthésie-Réanimation, the University Hospital of Montpellier, Philippe Foundation, the Department of Anesthesia at Beth Israel Deaconess Medical Center, and Jeffrey and Judy Buzen.

    View details for DOI 10.1016/S2213-2600(26)00045-7

    View details for Web of Science ID 001815665000001

    View details for PubMedID 42155495

  • Bedside identification of subphenotypes in acute respiratory failure (PHIND): a multicentre, observational cohort study LANCET RESPIRATORY MEDICINE Reddy, K., Sinha, P., Antcliffe, D. B., McDowell, C., Bradley, P. A., Black, L., Murphy, L., Barbaras, J., Conlon, J., Camporota, L., Ostermann, M., Hopkins, P., Szakmany, T., Cherian, S., Welters, I., Brealey, D., Parekh, D., Rostron, A. J., Bos, L. D. J., Nichol, A., Shankar-Hari, M., Gordon, A. C., Delucchi, K., O'Kane, C. M., Matthay, M. A., Calfee, C. S., McAuley, D. F., PHIND Investigators 2026; 14 (7): 589-600

    Abstract

    Acute respiratory distress syndrome (ARDS) is a clinically defined, biologically heterogeneous condition with no proven disease-modifying therapies. Retrospective analyses have identified two biologically distinct subphenotypes (hyperinflammatory and hypoinflammatory) of ARDS, with differing outcomes and responses to therapy. Rapid identification of these subphenotypes in an actionable timeframe has previously not been possible. The PHIND study aimed to prospectively identify these subphenotypes and to demonstrate differing 60-day mortality.The PHIND study was a prospective, multicentre, observational cohort study conducted in intensive care units (ICUs) within the National Health Service in the UK and the Health Service Executive in Ireland. Adult patients aged 18 years and older with ARDS or acute hypoxaemic respiratory failure (AHRF) were enrolled within 72 h of onset of the syndrome. Eligible patients were required to be receiving invasive mechanical ventilation, non-invasive ventilation, or high-flow nasal oxygen. Plasma interleukin (IL-6) and soluble TNF receptor-1 (TNFR1) were quantified at enrolment using a near-patient benchtop immunoanalyser (Randox multiSTAT) with a run time of approximately 1 h. Together with plasma bicarbonate measured from an arterial blood sample, these values were used to prospectively determine subphenotypes on an individual patient basis using a validated parsimonious logistic regression model. The primary outcome was 60-day mortality. The study was registered on ClinicalTrials.gov, NCT04009330.Between Nov 22, 2019, and Sept 28, 2023, 1853 patients from 30 centres were screened for eligibility. Of these, 1328 were excluded and 525 were recruited into the study, with 512 individuals included. 308 (60%) patients were male, 204 (40%) were female, and mean age was 57·0 years (SD 15·1). 443 (87%) patients were white, 18 (4%) were Black, and 16 (3%) were Asian. 490 were subphenotyped using the near-patient assay: 89 (18%) were classified as hyperinflammatory and 401 (82%) as hypoinflammatory. The primary outcome of 60-day mortality was measured in 486 patients after four patients withdrew consent for confirmation of vital status. 60-day mortality was significantly higher in the hyperinflammatory group (45 [51%] of 88) than in the hypoinflammatory group (111 [28%] of 398; risk ratio 1·8 [95% CI 1·4-2·4], p<0·0001). After adjustment, hyperinflammatory patients had increased odds of 60-day mortality (adjusted odds ratio 2·7 [95% CI 1·6-4·4], p=0·0002).Rapid identification of ARDS inflammatory subphenotypes using a near-patient assay was feasible and associated with many clinical characteristics and outcomes consistent with those described in earlier retrospective studies, including mortality, prevalence of sepsis, and incidence of metabolic acidosis. These findings support the implementation of precision medicine approaches in ARDS and the urgent need for prospective, subphenotype-stratified interventional trials.Innovate UK, Randox Laboratories, and Belfast Health & Social Care Trust.

    View details for DOI 10.1016/S2213-2600(26)00040-8

    View details for Web of Science ID 001815648100001

    View details for PubMedID 41887245

  • Early immune events during SARS-CoV-2 infection impact memory T and B cell responses. Communications biology Woloszczuk, K., Joyner, D., Connors, J., Bernui, M., Canziani, G., Chaiken, I., Burger, J., van Gils, M. J., van Rijswijk, J., Olijhoek, W., Venkateswaren, K. V., Venkateswaran, N., Bosinger, S. E., Eckalbar, W., Altman, M. C., van Bakel, H., Steen, H., Diray-Arce, J., Levy, O., Maecker, H. T., Kim-Schulze, S., Ozonoff, A., IMPACC Network, Sekaly, R. P., Sanders, R. W., Kutzler, M. A., Cairns, C. B., Fourati, S., Haddad, E. K., Becker, P. M., Augustine, A. D., Holland, S. M., Rosen, L. B., Lee, S., Vaysman, T., Chen, J., Kho, A. T., Milliren, C. E., Hoch, A., Chang, A. C., McEnaney, K., Syphurs, C., Barton, B., Lentucci, C., Murphy, M. D., Saluvan, M., Shaheen, T., Liu, S., Albert, M., Hayati, A. N., Bryant, R., Abraham, J., Cooney, M., Karoly, M., Jayavelu, N. D., Presnell, S., Kohr, B., Jancsyk, T., Arnett, A., Peters, B., Overton, J. A., Vita, R., Westendorf, K., Overton, J. A., van Zalm, P., Fatou, B., Smolen, K. K., Viode, A., van Haren, S., Jha, M., Stevenson, D., Thomas, S., Petrova, B., Kanarek, N., Baden, L. R., Mendez, K., Lasky-Su, J., Tong, A., Rooks, R., Desjardins, M., Sherman, A. C., Walsh, S. R., Mitre, X., Cauley, J., Li, X., Evans, B., Montesano, C., Licona, J. H., Krauss, J., Issa, N. C., Chang, J. B., Izaguirre, N., Hutton, S. R., Michelotti, G., Wong, K., Tebbutt, S. J., Shannon, C. P., Sekaly, R., Fourati, S., McComsey, G. A., Harris, P., Sieg, S., Yendewa, G., Consolo, M., Tribout, H., Ribeiro, S. P., Cairns, C. B., Haddad, E. K., Kutzler, M. A., Bernui, M., Cusimano, G., Connors, J., Woloszczuk, K., Joyner, D., Edwards, C., Lee, E., Lin, E., Melnyk, N., Powell, D. L., Kim, J. N., Goonewardene, I. M., Simmons, B., Smith, C. M., Martens, M., Croen, B., Semenza, N. C., Bell, M. R., Furukawa, S., McLin, R., Tegos, G. P., Rogowski, B., Mege, N., Ulring, K., Schearer, P., Sheidy, J., Nagle, C., Seyfert-Margolis, V., Rouphael, N., Boddapati, A. K., Tharp, G. K., Pellegrini, K. L., Johnson, B., Panganiban, B., Huerta, C., Anderson, E. J., Samaha, H., Sevransky, J. E., Bristow, L., Beagle, E., Cowan, D., Hamilton, S., Hodder, T., Bechnakv, A., Cheng, A., Mehta, A., Ciric, C. R., Spainhour, C., Carter, E., Scherer, E. M., Usher, J., Hellmeister, K., Hussaini, L., Hewitt, L., Mcnair, N., Ribeiro, S. P., Wimalasena, S., Fernandez-Sesma, A., Simon, V., Krammer, F., Van Bakel, H., Gonzalez-Reiche, A. S., Qi, J., Lee, B., Carreno, J. M., Singh, G., Raskin, A., Tcheou, J., Khalil, Z., van de Guchte, A., Farrugia, K., Khan, Z., Kelly, G., Srivastava, K., Eaker, L. Q., Bermudez-Gonzalez, M. C., Mulder, L. C., Beach, K. F., Saksena, M., Altman, D., Kojic, E., Sominsky, L. A., Azad, A., Bielak, D., Kawabata, H., Yellin, T., Fried, M., Sullivan, L., Morris, S., Kleiner, G., Stadlbauer, D., Dutta, J., Xie, H., Patel, M., Nie, K., Monahan, B., Rahman, A., Messer, W. B., Hough, C. L., Siegel, S. A., Sullivan, P. E., Lu, Z., Brunton, A. E., Strand, M., Lyski, Z. L., Coulter, F. J., Micheletti, C., Maecker, H., Pulendran, B., Nadeau, K. C., Rosenberg-Hasson, Y., Leipold, M., Sigal, N., Rogers, A., Fernandes, A., Manohar, M., Do, E., Chang, I., Lee, A. S., Blish, C., Din, H. N., Roque, J., Geng, L. N., Artandi, M., Davis, M. M., Ahuja, N., Yang, S. S., Chinthrajah, S., Hagan, T., Holmes, T. H., Abe, K., Reed, E. F., Schaenman, J., Salehi-Rad, R., Rivera, A. M., Pickering, H. C., Sen, S., Elashoff, D., Ward, D. C., Brook, J., Ramires-Sanchez, E., Llamas, M., Perdomo, C., Magyar, C. E., Fulcher, J., Erle, D. J., Calfee, C. S., Hendrickson, C. M., Kangelaris, K. N., Nguyen, V., Lee, D., Chak, S., Ghale, R., Gonzalez, A., Jauregui, A., Leroux, C., Altamirano, L. T., Rashid, A. S., Willmore, A., Woodruff, P. G., Krummel, M. F., Carrillo, S., Ward, A., Langelier, C. R., Patel, R., Wilson, M., Dandekar, R., Alvarenga, B., Rajan, J., Schroeder, A. W., Fragiadakis, G. K., Tsitsiklis, A., Mick, E., Guerrero, Y. S., Love, C., Maliskova, L., Adkisson, M., Leligdowicz, A., Beagle, A., Rao, A., Sigman, A., Samad, B., Curiel, C., Shaw, C., Tietje-Ulrich, G., Milush, J., Singer, J., Vasquez, J. J., Tang, K., Betancourt, L., Santhosh, L., Pierce, L., Paz, M. T., Matthay, M., Thakur, N., Rodriguez, N., Sutter, N., Jones, N., Sinha, P., Prasad, P., Lota, R., Asthana, S., Bhide, S., Lea, T., Abe-Jones, Y., Hafler, D. A., Montgomery, R. R., Shaw, A. C., Kleinstein, S. H., Gygi, J. P., Duchen, D., Pawar, S., Konstorum, A., Chen, E., Cotsapas, C., Wang, X., Dela Cruz, C., Iwasaki, A., Mohanty, S., Nelson, A., Zhao, Y., Farhadian, S., Asashima, H., Chaudhary, O., Coppi, A., Fournier, J., Muenker, M. C., Raddassi, K., Rainone, M., Ruff, W., Salahuddin, S., Shulz, W. L., Vijayakumar, P., Wang, H., Wunder, E. J., Young, H. P., Ko, A. I., Gabernet, G., Esserman, D., Guan, L., Brito, A., Rothman, J., Grubaugh, N. D., Wang, K., Xu, L., Corry, D. B., Kheradmand, F., Song, L., Nelson, E., Metcalf, J. P., Agudelo Higuita, N. I., Sinko, L. A., Booth, J. L., Drevets, D. A., Brown, B. R., Kraft, M., Bime, C., Mosier, J., Erickson, H., Schunk, R., Kimura, H., Conway, M., Francisco, D., Molzahn, A., Wilson, C. C., Hughes, T., Sierra, B., Atkinson, M. A., Brakenridge, S. C., Ungaro, R. F., Manning, B. R., Moldawer, L., Oberhaus, J., Guirgis, F. W., Borresen, B., Anderson, M. L., Ehrlich, L. I., Melamed, E., Maguire, C., Wylie, D., Rousseau, J. F., Hurley, K. C., Geltman, J. N., Siles, N., Rogers, J. E., Tipan, P. G. 2026

    Abstract

    Immune responses elicited by natural infection of the coronavirus SARS-CoV-2 (COVID-19) show significant heterogeneity in the magnitude and quality of memory T and B cell responses. However, little is known about the contributing factors. In this study, we investigated the early immune factors that contribute to this variability using RNA-seq, targeted proteomics, and flow cytometry analyses. Specifically, we sought to investigate associations between early immune responses and SARS-CoV-2 memory immunity in a longitudinal cohort of 46 individuals hospitalized for COVID-19 from May 2020 to March 2021. These participants returned for follow-up visits up to one-year post-hospitalization where we characterized antibody titers, antibody neutralization, antibody durability, and cellular memory T and B cell responses with multiple assays. Additionally, using integration analysis of Omic measurements, we identified common genes, proteins, and cellular pathways associated with differential memory response outcomes. Our data suggests that high levels of inflammatory proteins, and co-stimulatory molecules during the early stages of COVID-19 lead to enhanced memory T and B cell responses and improved durability. Alternatively, molecules that have a negative effect on dendritic cell maturation including TNFSF11 and FLT3LG correlated with suboptimal memory immune responses. Importantly, we were able to identify early markers that are positively and negatively associated with durable antibody responses in infected participants. This study provides a unique and thorough examination of both innate and memory immunity in the same patients over time, offering valuable insights into the long-term durability of SARS-CoV-2 immunity.

    View details for DOI 10.1038/s42003-026-09927-x

    View details for PubMedID 42249109

  • What Is Sepsis, Who Gets It, How, and Why? The Keys to Unlocking Precision Medicine in Sepsis CRITICAL CARE MEDICINE Gay, E. A., Meyer, N. J., Sinha, P. 2026; 54 (4): 983-994

    Abstract

    Due to its nonspecific clinical criteria, sepsis is clinically, microbiologically, pathophysiologically and immunologically highly heterogeneous. Consequently, despite hundreds of clinical trials, no host-targeted therapy has been shown to be ubiquitously efficacious, leading investigators to pursue more precision-based approaches for enriching sepsis populations through the identification of subgroups or phenotypes. Here, we review the myriad domains in which heterogeneity is observed in sepsis and the challenges and opportunities they offer to improve outcomes. We review current strategies used by investigators leveraging novel biological measurements and/or computational algorithms to identify more homogeneous subgroups either based on pathogen or host characteristics or both. Finally, we review some of the most promising recent advances that seek to bring these complex and innovative discoveries to the bedside to facilitate precision medicine in sepsis.

    View details for DOI 10.1097/CCM.0000000000007043

    View details for Web of Science ID 001734237100029

    View details for PubMedID 41575283

  • The host response in sepsis: can it be quantified? LANCET RESPIRATORY MEDICINE Sinha, P., Meyer, N. J. 2026; 14 (4): 285-286
  • Pathogen characteristics are key determinants of distinct host response phenotypes of sepsis JOURNAL OF CLINICAL INVESTIGATION Chanderraj, R., Bartek, B., Stringer, K. A., Tiba, M. H., Sjoding, M. W., He, Y., Nuppnau, M., Bongers, K. S., Adame, M. D., Lou, S. S., Kerschberger, V., Churpek, M. M., Calfee, C. S., Tripathi, S., Foster, D. M., Kellum, J. A., Dickson, R. P., Sinha, P. 2026; 136 (6)

    Abstract

    BACKGROUNDSepsis encompasses considerable biological and clinical heterogeneity. Previously, 2 phenotypes ("hyperinflammatory" and "hypoinflammatory") have been consistently identified within sepsis via latent class analysis. These phenotypes differ in their biological features, clinical outcomes, and therapeutic responses to interventions. Prior studies of sepsis heterogeneity have focused primarily on the host response. Here, we investigate the potential influence of the causative pathogen on sepsis heterogeneity and pathobiology.METHODSWe performed a retrospective observational analysis of 8,280 critically ill patients with sepsis to identify associations between pathogen characteristics and the hyperinflammatory and hypoinflammatory patient phenotypes. We also performed controlled murine and swine modeling of sepsis and lung injury and a secondary analysis of 449 patients enrolled in the EUPHRATES randomized controlled trial.RESULTSPathogen characteristics (pathogen identity, burden, virulence, and anatomic site of infection) were strongly and independently associated with the previously reported phenotypes. In a cohort of critically ill patients with sepsis, infection with gram-negative pathogens, primarily Enterobacterales spp. (e.g., Escherichia coli, Klebsiella pneumoniae), was strongly associated with the hyperinflammatory phenotype. The hyperinflammatory phenotype was also independently associated with increased pathogen burden, virulence, and initial anatomic site of infection. In controlled murine and swine modeling, both the identity and burden of the pathogen provoked key biological features of the hyperinflammatory phenotype. Among patients with sepsis, the prognostic value of lactate clearance varied substantially by phenotype. In a secondary analysis of a randomized trial of polymyxin B hemoadsorption (which removes circulating endotoxin), hypoinflammatory patients experienced worse survival.CONCLUSIONSOur results demonstrate the central importance of pathogen features in the clinical and biological heterogeneity of sepsis. Future studies of sepsis pathobiology and heterogeneity should expand their scope beyond the host response, as understanding pathogen-host interactions will be crucial in the development of precision therapeutic strategies to improve patient outcomes.TRIAL REGISTRATIONEUPHRATES trial NCT01046669.FUNDING5P30AG024824, IK2CX002766, R01HL144599, K24HL159247, R01HL158626, R01HL173531, R35GM142992, R35GM145330, R35GM136312, K23HL166880, R35HL140026.

    View details for DOI 10.1172/JCI197346

    View details for Web of Science ID 001730360200031

    View details for PubMedID 41837287

    View details for PubMedCentralID PMC12987626

  • Empiric azithromycin alters the upper respiratory microbiome and resistome without anti-inflammatory benefit in COVID-19. Nature microbiology Glascock, A., Maguire, C., Phan, H. V., Lydon, E. C., Schaenman, J., Calfee, C. S., Melamed, E., Greenland, J., Corry, D. B., Kheradmand, F., Baden, L. R., Sekaly, R., McComsey, G. A., Haddad, E. K., Cairns, C. B., Geng, L. N., Pulendran, B., Fernandez-Sesma, A., Simon, V., Metcalf, J. P., Agudelo Higuita, N. I., Messer, W. B., Davis, M. M., Nadeau, K. C., Kraft, M., Bime, C., Erle, D. J., Atkinson, M. A., Brakenridge, S. C., Ehrlich, L. I., Montgomery, R. R., Shaw, A. C., Hough, C. L., Hafler, D. A., Augustine, A. D., Becker, P. M., Peters, B., Ozonoff, A., Hoch, A., Kim-Schulze, S., Krammer, F., Bosinger, S., Eckalbar, W., Altman, M. C., Wilson, M., Guan, L., Maecker, H., Steen, H., Diray-Arce, J., Rouphael, N., Kleinstein, S. H., Jayavelu, N. D., Reed, E. F., Levy, O., Chu, V. T., Langelier, C. R. 2026

    Abstract

    Azithromycin is a widely used antibiotic and was frequently used to treat hospitalized patients during the COVID-19 pandemic. The impact of empiric azithromycin use on the respiratory microbiome in patients with viral respiratory infections is unclear. Here we used longitudinal metatranscriptomics on nasal swabs from a prospective multicentre cohort of 1,164 patients hospitalized for COVID-19. We compared the upper respiratory microbiome, resistome and systemic immune response in patients treated with azithromycin (n = 366) with those who received no antibiotics (n = 474) or other antibiotics (n = 324). We found that azithromycin altered microbiome composition and increased the expression and relative proportion of macrolide/lincosamide/streptogramin (MLS) resistance genes. These changes occurred after 1 day of exposure and persisted for over a week. MLS resistance gene expression was associated with commensals and potential pathogens, while there were no differences in host inflammatory gene expression in blood and airways. This demonstrates that empiric azithromycin treatment impacts the upper respiratory microbiome and resistome without apparent anti-inflammatory benefit.

    View details for DOI 10.1038/s41564-026-02285-8

    View details for PubMedID 41840216

    View details for PubMedCentralID 6364667

  • Author Correction: Machine learning models predict long COVID outcomes based on baseline clinical and immunologic factors. Communications medicine Doni Jayavelu, N., Samaha, H., Wimalasena, S. T., Hoch, A., Gygi, J. P., Gabernet, G., Ozonoff, A., Liu, S., Milliren, C. E., Levy, O., Baden, L. R., Melamed, E., Ehrlich, L. I., McComsey, G. A., Sekaly, R. P., Cairns, C. B., Haddad, E. K., Schaenman, J., Shaw, A. C., Hafler, D. A., Montgomery, R. R., Corry, D. B., Kheradmand, F., Atkinson, M. A., Brakenridge, S. C., Agudelo Higuit, N. I., Metcalf, J. P., Hough, C. L., Messer, W. B., Pulendran, B., Nadeau, K. C., Davis, M. M., Geng, L. N., Fernandez Sesma, A., Simon, V., Krammer, F., Kraft, M., Bime, C., Calfee, C. S., Erle, D. J., Langelier, C. R., Guan, L., Maecker, H. T., Peters, B., Kleinstein, S. H., Reed, E. F., Augustine, A. D., Diray-Arce, J., Becker, P. M., Rouphael, N., Altman, M. C. 2026; 6 (1)

    View details for DOI 10.1038/s43856-026-01425-9

    View details for PubMedID 41730996

    View details for PubMedCentralID PMC12929789

  • Machine learning models predict long COVID outcomes based on baseline clinical and immunologic factors. Communications medicine Doni Jayavelu, N., Samaha, H., Wimalasena, S. T., Hoch, A., Gygi, J. P., Gabernet, G., Ozonoff, A., Liu, S., Milliren, C. E., Levy, O., Baden, L. R., Melamed, E., Ehrlich, L. I., McComsey, G. A., Sekaly, R. P., Cairns, C. B., Haddad, E. K., Schaenman, J., Shaw, A. C., Hafler, D. A., Montgomery, R. R., Corry, D. B., Kheradmand, F., Atkinson, M. A., Brakenridge, S. C., Agudelo Higuit, N. I., Metcalf, J. P., Hough, C. L., Messer, W. B., Pulendran, B., Nadeau, K. C., Davis, M. M., Gen, L. N., Fernandez Sesma, A., Simon, V., Krammer, F., Kraft, M., Bime, C., Calfee, C. S., Erle, D. J., Langelier, C. R., Guan, L., Maecker, H. T., Peters, B., Kleinstein, S. H., Reed, E. F., Augustine, A. D., Diray-Arce, J., Becker, P. M., Rouphael, N., Altman, M. C. 2026; 6 (1): 1

    Abstract

    The post-acute sequelae of SARS-CoV-2 (PASC), also known as long COVID, remain a significant health issue that is incompletely understood. Predicting which acutely infected individuals will develop long COVID is challenging due to the absence of established biomarkers, clear disease mechanisms, or well-defined sub-phenotypes. Machine learning (ML) models may address this gap by leveraging clinical data to enhance diagnostic precision.Clinical data, including antibody titers and viral load measurements collected at the time of hospital admission, are used to predict the likelihood of acute COVID-19 progressing to long COVID. Machine learning models are trained and evaluated for predictive performance. Feature importance analysis is performed to identify the most influential predictors.The machine learning models achieve median AUROC values ranging from 0.64 to 0.66 and AUPRC values between 0.51 and 0.54, demonstrating predictive capabilities. Low antibody titers and high viral loads at hospital admission emerge as the strongest predictors of long COVID outcomes. Comorbidities-such as chronic respiratory, cardiac, and neurologic diseases-and female sex are also identified as significant risk factors.Machine learning models identify patients at risk for developing long COVID based on baseline clinical characteristics. These models guide early interventions, improve patient outcomes, and mitigate the long-term public health impacts of SARS-CoV-2.

    View details for DOI 10.1038/s43856-025-01230-w

    View details for PubMedID 41484172

    View details for PubMedCentralID PMC12764860

  • Short stature is an independent risk factor for ventilatory inefficiency and higher mortality in acute respiratory distress syndrome AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE Monteiro, A., Bartek, B., Tripathi, S., Calfee, C. S., Matthay, M. A., Sinha, P. 2026; 212 (1): 161-164

    View details for DOI 10.1164/rccm.202502-0505RL

    View details for Web of Science ID 001686583100006

    View details for PubMedID 41026832

    View details for PubMedCentralID PMC12588821

  • Longitudinal multi-omic signatures of ARDS and sepsis inflammatory phenotypes identify pathways associated with mortality. The Journal of clinical investigation Alipanah-Lechner, N., Neyton, L., Sinha, P., Leroux, C., Bardillon, K., Carrillo, S. A., Chak, S., Chao, O., Hariharan, T., Hendrickson, C., Kangelaris, K., Langelier, C. R., Lee, D., Lin, C., Liu, K., Magee, L., Ringor, A., Sarma, A., Schmiege, E., Spottiswoode, N., Sullivan, K., Weingart, M. F., Willmore, A., Zhuo, H., Rogers, A. J., Stringer, K. A., Matthay, M. A., Calfee, C. S. 2025

    Abstract

    Critically ill patients with acute respiratory distress syndrome (ARDS) and sepsis exhibit distinct inflammatory phenotypes with divergent clinical outcomes, but the underlying molecular mechanisms remain poorly understood. These phenotypes, derived from clinical data and protein biomarkers, were associated with metabolic differences in a pilot study.We performed integrative multi-omics analysis of blood samples from 160 ARDS patients in the ROSE trial, randomly selecting 80 patients from each latent class analysis-defined inflammatory phenotype (Hyperinflammatory and Hypoinflammatory) with phenotype probability >0.9. Untargeted plasma metabolomics and whole blood transcriptomics at Day 0 and Day 2 were analyzed using multi-modal factor analysis (MEFISTO). The primary outcome was 90-day mortality, with validation in an independent critically ill sepsis cohort (EARLI).Multi-omics integration revealed four molecular signatures associated with mortality: (1) enhanced innate immune activation coupled with increased glycolysis (associated with Hyperinflammatory phenotype), (2) hepatic dysfunction and immune dysfunction paired with impaired fatty acid beta-oxidation (associated with Hyperinflammatory phenotype), (3) interferon program suppression coupled with altered mitochondrial respiration (associated with Hyperinflammatory phenotype), and (4) redox impairment and cell proliferation pathways (not associated with inflammatory phenotype). These signatures persisted through Day 2 of trial enrollment. Within-phenotype analysis revealed distinct mortality-associated pathways in each group. All molecular signatures were validated in the independent EARLI cohort.Inflammatory phenotypes of ARDS reflect distinct underlying biological processes with both phenotype-specific and phenotype-independent pathways influencing patient outcomes, all characterized by mitochondrial dysfunction. These findings suggest potential therapeutic targets for precise treatment strategies in critical illness.This work is the result of NIH funding.

    View details for DOI 10.1172/JCI196290

    View details for PubMedID 41329523

  • Prognostic Relevance of Inflammatory Subphenotypes in Immunocompromised Patients With Sepsis CRITICAL CARE MEDICINE Weingart, M. F., Willmore, A., Zhuo, H., Magee, L., Chao, O., Lin, C., Schmiege, E., Hariharan, T., Chak, S., Bardillon, K., Lee, D., Leroux, C., Obeidalla, S. N., Kerchberger, V., Sullivan, K., Langelier, C., Hendrickson, C. M., Kangelaris, K. N., Sarma, A., Evrard, B., Alipanah-Lechner, N., Sinha, P., Matthay, M. A., Ware, L. B., Calfee, C. S. 2025; 53 (12): e2429-e2439

    Abstract

    Hyperinflammatory and hypoinflammatory molecular subphenotypes in sepsis and acute respiratory distress syndrome have divergent mortality and treatment responses in secondary analyses of randomized controlled trials. However, the prevalence of immunocompromise is low in these populations, and how preexisting immunocompromise contributes to subphenotypes is unknown. We studied two observational sepsis cohorts to test associations between immunocompromise and the hyperinflammatory subphenotype and to assess whether the prognostic relevance of molecular subphenotypes is generalizable to immunocompromised populations.Observational cohort study.Prospective data from two ICU cohorts in the United States.We included 1826 patients from two combined sepsis cohorts.None.We defined immunocompromise as a history of solid organ transplant, AIDS, hematologic malignancy, solid malignancy on chemotherapy, or immunosuppressive medication use. Subphenotype was previously assigned using latent class analysis. We used logistic regression to investigate associations between type of immunocompromise and hyperinflammatory subphenotype. Models were repeated with individual covariates known or hypothesized to be associated with the hyperinflammatory subphenotype. Kaplan-Meier survival plots were used to assess mortality differences by subphenotype. Hematologic malignancy was strongly associated with the hyperinflammatory subphenotype (odds ratio [OR], 4.3; p < 0.0001), an association that persisted after adjustment for identified pathogen, presence of bacteremia, or illness severity. History of solid organ transplantation was also associated with the hyperinflammatory subphenotype (OR, 1.6; p = 0.02) but was no longer significant after accounting for bacteremia. Hyperinflammatory classification was associated with a decreased likelihood of survival in hematologic malignancy, but not in organ transplant or solid malignancy populations.Preexisting immune status is associated with subphenotype assignment and may influence its prognostic utility.

    View details for DOI 10.1097/CCM.0000000000006920

    View details for Web of Science ID 001630974900022

    View details for PubMedID 41150892

    View details for PubMedCentralID PMC12912362

  • Individualised treatment effects of enhanced early mobilisation in mechanically ventilated patients: a secondary analysis of the TEAM trial INTENSIVE CARE MEDICINE Hodgson, C. L., Spicer, A. B., Broadley, T., Bailey, M., Bellomo, R., Brickell, K., Buhr, H., Gabbe, B. J., Gould, D. W., Harrold, M., Higgins, A. M., Hurford, S., Iwashyna, T. J., Serpa Neto, A., Nichol, A. D., Presneill, J. J., Schaller, S. J., Sivasuthan, J., Tipping, C. J., Webb, S., Graham Linck, E. J., Sinha, P., Semler, M. W., Young, P. J., Churpek, M. M. 2026; 52 (1): 11-21

    Abstract

    Benefit or harm from early mobilisation (EM) in mechanically ventilated patients may vary by individual patient characteristics. We used machine learning to predict individualised treatment effects (ITEs) in the "Early Active Mobilization during Mechanical Ventilation in the ICU" (TEAM) trial.This was a secondary analysis of the TEAM trial using a causal inference approach to estimate ITEs, which compared enhanced EM to usual care EM. Baseline variables in the original publication were used as predictor variables. The primary outcome was death by day 180. The dataset was randomly split into two halves (train and test) by site. In the training data, fivefold cross-validation was used to compare six candidate machine learning algorithms. The best-performing model was evaluated in the test dataset. Patients were stratified into tertiles based on predicted ITEs, reflecting estimated benefit, no effect or harm.We included 687 patients from 40 sites, and 141 (20.5%) patients died by day 180. Predicted ITEs in the test cohort ranged from an absolute 34.0% reduction to a 39.3% increase in mortality with enhanced EM. The interaction term between the model predictions and treatment assignment demonstrated significant heterogeneity of treatment effect (p = 0.006). Patients predicted to respond poorly to enhanced EM therapy were more likely to receive vasopressors, have diabetes and have lower RASS scores at baseline, compared to patients predicted to have benefit.Using baseline characteristics, a machine learning model identified patients with estimated benefit or harm with enhanced EM. Future testing of a personalised approach to mobilisation in the ICU is warranted.

    View details for DOI 10.1007/s00134-025-08217-0

    View details for Web of Science ID 001621383100001

    View details for PubMedID 41284015

    View details for PubMedCentralID PMC12852203

  • Type 2 immune responses are associated with less severe COVID-19 in a hospitalized cohort. The journal of allergy and clinical immunology. Global Jayavelu, N. D., Qi, J., Milliren, C. E., Ozonoff, A., Liu, S., Levy, O., Baden, L. R., Melamed, E., McComsey, G. A., Cairns, C. B., Schaenman, J., Shaw, A. C., Hafler, D. A., Corry, D. B., Kheradmand, F., Atkinson, M. A., Brakenridge, S. C., Agudelo Higuita, N. I., Metcalf, J. P., Hough, C. L., Messer, W. B., Pulendran, B., Nadeau, K. C., Davis, M. M., Geng, L. N., Sesma, A. F., Simon, V., Krammer, F., Bime, C., Calfee, C. S., Bosinger, S. E., Eckalbar, W., Steen, H., Maecker, H. T., Augustine, A. D., Diray-Arce, J., Haddad, E. K., Sekaly, R. P., Kraft, M., Woodruff, P. G., Erle, D. J., Ehrlich, L. I., Montgomery, R. R., Becker, P. M., Altman, M. C., Fourati, S. 2025; 4 (4): 100515

    Abstract

    The novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread rapidly after its identification in December 2019 to cause a global pandemic. The respiratory tract is the primary site of infection, and there is a large range in the severity of respiratory illnesses caused by the virus. Defining molecular and cellular factors for protection from severe disease and death has been a goal to better understand and to predict and mitigate the effects of SARS-CoV-2 and future coronaviruses.Despite well-known susceptibilities to respiratory viral infections, respiratory allergy and allergic asthma have not been identified as risk factors for severe coronavirus disease 2019 (COVID-19) in most epidemiologic studies and may be protective. We sought to investigate associations between markers of type 2 (T2) immune responses with SARS-CoV-2 clinical outcomes and virus loads in a cohort of 1164 individuals hospitalized for COVID-19 from May 2020 to March 2021 as part of the IMPACC study.We characterized the clinical outcomes, as defined by severity trajectory groups reflecting the degree of respiratory support required, virus loads, and antibody titers of COVID-19 infections in IMPACC participants in relation to molecular and cellular markers of T2 immune responses through multiple assays, including, (1) IL-4, IL-5, and IL-13 levels in serum Olink data, (2) T2 cellular signatures in blood cytometry by time of flight data, (3) relative quantification of T2 signaling gene pathways in airway RNA sequencing data, and/or (4) T2 pathways in peripheral blood mononuclear cell RNA sequencing data. We also investigated the outcomes of individuals with self-reported asthma and evidence of T2 immune responses.The diagnosis of asthma (odd ratio = 1.27), elevated serum T2 cytokine levels (median fold change = 1.06), and a higher frequency of TH2 cells (difference = +2%) were associated with less severe clinical disease during hospitalization. Distinct T2-related transcriptomic changes in nasal and blood samples were associated with reduced virus loads. This included the expression of T2-regulated genes implicated in T-/B-cell activation and apoptosis in nasal samples and the expression of T2-regulated genes implicated in myeloid differentiation and reactive oxygen species signaling in blood. Among these, several canonical T2-regulated genes that were increased in less severe disease were identified to have antiviral properties in large high-throughput screens.T2 immune responses were associated with lower virus loads and more favorable clinical outcomes, suggesting that T2 inflammation related to asthma and allergic diseases may have a direct protective effect against SARS-CoV-2.

    View details for DOI 10.1016/j.jacig.2025.100515

    View details for PubMedID 40709330

    View details for PubMedCentralID PMC12284355

  • Circulating endothelial signatures correlate with worse outcomes in COVID-19, respiratory failure and ARDS. Critical care (London, England) Costa Monteiro, A. C., Pickering, H., Sarma, A., Taylor, C. S., Jenkins, M. M., Hsu, F. M., Nadel, B., Levy, O., Baden, L. R., Melamed, E., Ehrlich, L. I., McComsey, G. A., Sekaly, R. P., Cairns, C. B., Haddad, E. K., Shaw, A. C., Hafler, D. A., Montgomery, R. R., Corry, D. B., Kheradmand, F., Atkinson, M. A., Brakenridge, S. C., Higuita, N. I., Metcalf, J. P., Hough, C. L., Messer, W. B., Pulendran, B., Nadeau, K. C., Davis, M. M., Geng, L. N., Fernandez-Sesma, A., Simon, V., Krammer, F., Kraft, M., Bime, C., Calfee, C. S., Erle, D. J., Bosinger, S., Eckalbar, W., Maecker, H., Rahman, A., Guan, L., Peters, B., Kleinstein, S. H., Augustine, A. D., Diray-Arce, J., Becker, P. M., Rouphael, N., Agus, M., Kulkarni, H., Schaenmann, J. M., Salehi-Rad, R., Matthay, M. A., Reed, E. F., Sapru, A. 2025; 29 (1): 432

    Abstract

    Elevated circulating endothelial cells (CECs), released from monolayers after insult, have been implicated in worse outcomes in ARDS and COVID-19, however there is no consensus proteomic phenotype that define CECs. We queried whether a transcriptomic approach would alternatively support the presence of endothelial cells in circulation and correlate with worsening respiratory failure.To test whether elevated endothelial cell signatures (ECS) in circulation plays a role in worse respiratory outcomes, we used unsupervised bulk-transcriptome deconvolution to quantify ECS% in two cohorts. Our pilot analysis included pediatric patients requiring invasive mechanical ventilation (CAF-PINT, NCT01892969). Our validation cohort included adult hospitalized patients with COVID-19 (IMPACC, NCT04378777), testing the association of ECS% to outcomes in patients at risk of acute respiratory failure/ARDS. Primary outcome was 28-day mortality.In CAF-PINT, day 0 ECS% was higher in non-survivors compared to survivors of respiratory failure (2.8%, IQR 2.4-3.4% versus 2.6%, IQR 2.2-3.0% n = 244, p < 0.05, Wilcoxon rank-sum). In IMPACC, baseline ECS% (< 72 h of hospitalization) was higher in COVID-19 non-survivors versus survivors (2.9%, IQR 2.6-3.4%, versus 2.7%, IQR 2.3-3.1%, n = 932, p < 0.001, Wilcoxon rank-sum). Each 1% increase in baseline ECS% was significantly associated with mortality (adjusted OR 1.36, CI 1.03-1.79) by multivariable logistic regression. Increased baseline ECS% was associated with worse respiratory trajectories (2.5%, IQR 2.2-2.8% for trajectory with no oxygen requirements, 2.9%, IQR 2.6-3.4% for the trajectory with fatal outcome by day 28, n = 932, p < 0.001, one-way ANOVA).Quantifying ECS by deconvolution supports a transcriptomics-driven approach towards the non-invasive evaluation of endothelial damage in respiratory outcomes. This is a first step towards elucidating mechanistic components linking endothelial damage to ARDS utilizing non-invasive, circulating transcriptomic data by leveraging a novel deconvolution approach.

    View details for DOI 10.1186/s13054-025-05596-0

    View details for PubMedID 41088445

    View details for PubMedCentralID PMC12522733

  • Premorbid Metabolic Syndrome Is Associated with the Hypoinflammatory Phenotype in Acute Respiratory Distress Syndrome and Sepsis AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE Bogart, A. M., Obeidalla, S. N., Van Amstel, R. B. E., Cremer, O., Bos, L. D. J., Bartek, B., Sinha, P. S., Calfee, C. S., Kerchberger, V., Ware, L. B., MARS Consortium 2025; 211 (12): 2399-2401

    View details for DOI 10.1164/rccm.202503-0596RL

    View details for Web of Science ID 001632603700001

    View details for PubMedID 41072401

    View details for PubMedCentralID PMC12700243

  • ARDS Molecular Phenotypes Have Distinct Lower Respiratory Tract Transcriptomes. American journal of respiratory and critical care medicine Sarma, A., Christenson, S. A., Zha, B. S., Pisco, A. O., Neyton, L. P., Mick, E., Sinha, P. S., Wilson, J. G., Moazed, F., Leligdowicz, A., Maddali, M. V., Siegel, E. R., Lyon, Z. M., Carillo Haller, S., Zhuo, H., Jauregui, A., Ghale, R., Caldera, S., Serpa, P. H., Deiss, T., Love, C., Byrne, A., Kalantar, K. L., DeRisi, J. L., Erle, D. J., Krummel, M. F., Kangelaris, K. N., Hendrickson, C. M., Woodruff, P. G., Matthay, M. A., Bos, L. D., Langelier, C. R., Calfee, C. S. 2025

    Abstract

    Two molecular phenotypes of the acute respiratory distress syndrome (ARDS) with divergent clinical trajectories and responses to therapy have been identified. Classification as "hyperinflammatory" or "hypoinflammatory" depends on plasma biomarker profiling. Limited data are available about the differences in the pulmonary biology of the molecular phenotypes.To identify differences in the pulmonary biology of ARDS molecular phenotypes.We compared tracheal aspirate gene expression between hyperinflammatory and hypoinflammatory phenotypes in bulk RNASeq from COVID and non-COVID ARDS, and single cell RNASeq from non-COVID ARDS. In a subset of subjects, we also compared plasma proteomic data.In bulk RNASeq analyses, 1157 genes were differentially expressed (FDR < 0.1) between phenotypes in non-COVID ARDS, and 85 genes were differentially expressed between phenotypes in COVID ARDS. 18 genes were reproducibly differentially expressed between phenotypes in both cohorts, including greater expression of IL32, HSPA8, and PPP3CC in hyperinflammatory ARDS. Gene set enrichment analysis identified greater expression of granulopoiesis, T cell and interferon signaling, and integrated stress response pathways in hyperinflammatory ARDS. Network analysis of scRNASeq in a third group of patients identified greater T cell signaling to other immune cells in hyperinflammatory ARDS.Hyperinflammatory and hypoinflammatory ARDS molecular phenotypes have distinct air space biology. Hyperinflammatory ARDS is characterized by an increased interferon-stimulated gene expression and T cell activation in the lungs. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/).

    View details for DOI 10.1164/rccm.202407-1454OC

    View details for PubMedID 40997225

  • Longitudinal multi-omic signatures of ARDS and sepsis inflammatory phenotypes identify key pathways associated with mortality. medRxiv : the preprint server for health sciences Alipanah-Lechner, N., Neyton, L., Sinha, P., Leroux, C., Bardillon, K., Carrillo, S. A., Chak, S., Chao, O., Hariharan, T., Henrickson, C., Kangelaris, K., Langelier, C. R., Lee, D., Lin, C., Liu, K., Magee, L., Ringor, A., Sarma, A., Schmiege, E., Spottiswoode, N., Sullivan, K., Weingart, M. F., Willmore, A., Zhuo, H., Rogers, A. J., Stringer, K. A., Matthay, M. A., Calfee, C. S. 2025

    Abstract

    Critically ill patients with acute respiratory distress syndrome (ARDS) and sepsis exhibit distinct inflammatory phenotypes with divergent clinical outcomes and apparent heterogeneity of treatment effects, but the underlying molecular mechanisms remain poorly understood. These phenotypes, derived from clinical data and protein biomarkers, were associated with metabolic differences in a prior pilot study. This study investigated the metabolomic and transcriptomic differences between Hyperinflammatory and Hypoinflammatory phenotypes through integrative multi-omics analysis of blood samples from ARDS patients in the ROSE trial. Multi-omics integration revealed three molecular signatures strongly associated with the Hyperinflammatory phenotype and with mortality: enhanced innate immune activation coupled with increased glycolysis, hepatic dysfunction and immune dysfunction paired with impaired fatty acid beta-oxidation, and interferon program suppression coupled with altered mitochondrial respiration. A fourth molecular signature, not associated with inflammatory phenotype, identified redox impairment and cell proliferation pathways associated with mortality. Integrated multi-omics analysis within each inflammatory phenotype revealed distinct pathways associated with mortality. All mortality-associated molecular signatures including those within phenotypes were validated in an independent cohort of critically ill patients with sepsis (EARLI). These findings reveal distinct molecular mechanisms underlying ARDS/sepsis phenotypes and suggest potential therapeutic targets for precise treatment strategies in critical illness.

    View details for DOI 10.1101/2025.05.07.25327117

    View details for PubMedID 40963763

  • Bedside prospective identification of ARDS subphenotypes: a multicentre study - an ERS Clinical Research Collaboration Reddy, K., O'Kane, C., Antcliffe, D., Mcdowell, C., Bradley, P., Black, L., Murphy, L., Shankar-Hari, M., Gordon, A., Shyamsundar, M., Delucchi, K., Sinha, P., Calfee, C., Mcauley, D. EUROPEAN RESPIRATORY SOC JOURNALS LTD. 2025
  • Multivariate protein landscape of host response in hospitalised patients with suspected infection in the emergency department NATURE COMMUNICATIONS Sinha, P., Spicer, A. B., Bhavani, S., Lopez-Espina, C., Watson, G. L., Bhargava, A., Schmalz, L., Khan, S., Sims, M. D., Palagiri, A. V., Dagan, A., Iyer, K. V., Crisp, M. J., Demarco, C., Halalau, A., Maddens, N., Kurtzman, N., Sarma, D., Gosai, F., Syed, A., Azad, S., Espinosa, A., Davila, F., Davila, H., Evans, N., Smith, S., Reddy Jr, B., Verhoef, P. A., Churpek, M. M. 2025; 16 (1): 7848

    Abstract

    Suspected infection requiring hospitalisation has highly heterogenous presentation. Yet, variances in host response and its implications are largely unknown. In this multicentre cohort of 3802 individual patients presenting to the Emergency Department (ED) with suspected infection requiring hospitalisation, we apply uniform manifold approximation and projections and K-means clustering to 29 plasma proteins to identify biologically discrete host response clusters. In this work, we first describe two large clusters, called "Dysregulated" and "Undifferentiated", with abnormal protein concentrations and adverse outcomes in the former. Through further clustering, we identify 4 sub-clusters in the Dysregulated cluster, each with discrete biological signatures, clinical correlates, and outcomes. Clusters 3 and 4 are characterised by renal impairment and viral infections respectively. Clusters 5 and 6 are associated with bacterial culture positivity, with the former consistent with an immunosuppressed signature and worse outcomes, and the latter with gram-negative bacteria, higher IL-6 and IL-8, and better outcomes despite higher vasopressor use. These clusters are a biologically driven approach to characterising acute suspected infection and may lead to more targeted therapeutics.

    View details for DOI 10.1038/s41467-025-62848-x

    View details for Web of Science ID 001559383200027

    View details for PubMedID 40846700

    View details for PubMedCentralID PMC12373923

  • Host-Microbe Multiomic Profiling Predicts Mortality in Sepsis. American journal of respiratory and critical care medicine Spottiswoode, N., Neyton, L. P., Mick, E., Kalantar, K. L., Hao, S., Lydon, E. C., Narendra, R., Serpa, P. H., Caldera, S., Gomez, A., Hendrickson, C., Kangelaris, K., Liu, K. D., Sinha, P., DeRisi, J. L., Matthay, M. A., Calfee, C. S., Langelier, C. R. 2025

    Abstract

    Sepsis is a leading cause of mortality and involves a dysregulated host response to infection. Host and microbe have historically been considered independently in studies of sepsis, limiting our understanding of key relationships driving mortality.We sought to identify host and microbial factors associated with sepsis mortality and build prognostic classifiers.We studied 321 critically ill adults and adjudicated sepsis status. From whole blood collected within 24 hours of admission we performed transcriptional profiling, and from plasma we carried out proteomics and metagenomics. We evaluated associations between in-hospital mortality and gene expression, protein levels and microbial metagenomic data, and built support vector machine-based prognostic classifiers.In patients with sepsis, mortality associated with increased expression of genes related to neutrophil degranulation, lower expression of genes related to T cell signaling, and higher interleukin-8. Mortality also associated with higher microbial mass and greater bacterial relative dominance. Similar findings were observed in a broader group that also included patients with culture-negative sepsis or indeterminate sepsis status. An integrated host-microbe metagenomic classifier predicted sepsis mortality with an area under the curve (AUC) of 0.79, and a host transcriptomic classifier performed comparably with an AUC of 0.75. Both performed better (p<0.05 by paired DeLong tests) that the APACHE-III score (AUC of 0.69).Taken together, our findings provide a conceptual advance in the understanding of host and microbial factors associated with mortality in critical illness and demonstrate a new approach to mortality prediction in sepsis.

    View details for DOI 10.1164/rccm.202410-1996OC

    View details for PubMedID 40788839

  • Biologic Mechanisms Underlying the Heterogeneous Response to Tight Glycemic Control among Differentially Inflamed Patients in the HALF-PINT Trial AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE Zinter, M. S., Taylor, C. S., Markovic, D., Pellegrini, M., Wong, K., Balliu, B., Gala, K. P., Asaro, L. A., Nadkarni, V. M., McQuillen, P. S., Vangala, S. S., Sinha, P., Matthay, M. A., Agus, M. S. D., Sapru, A., CAF PINT Investigators PALISI Network 2025; 211 (8): 1463-1473

    Abstract

    Rationale: Tight glycemic control (TGC) with insulin has not consistently shown benefit in critically ill patients. We previously reported that the subset of children with a hyperinflammatory subphenotype benefited from TGC in the HALF-PINT (Heart and Lung Failure - Pediatric Insulin Titration) study of hyperglycemic children with heart and lung failure and the IIT-SBPP (Intensive Insulin Treatment - Severely Burned Pediatric Patients) study in severely burned pediatric patients. However, whether this effect was mediated through a reduction in inflammation or some other biologic process is not fully understood. Objectives: To deepen the understanding of inflammatory subphenotypes and explore the biologic mechanisms underlying heterogeneous response to TGC. Methods: Plasma cytokine measurements and whole-blood transcriptomics from 740 blood samples collected on Pre- and Post-treatment Study Days 0, 2, and 4 from 293 HALF-PINT participants (n = 250 hypoinflammatory and n = 43 hyperinflammatory) were used to identify cytokine and gene expression signatures of differential responses to TGC. Measurements and Results: Patients with the hyperinflammatory subphenotype had greater baseline expression of genes relating to inflammation, cell-cycle activity, and immunometabolism. Hyperinflammatory patients treated to a target glucose range of 80-110 mg/dl experienced greater reductions in inflammatory cytokines, innate immune gene expression, and heme metabolism gene expression, as well as an increase in lymphocyte gene expression, compared with those treated to a target range of 150-180 mg/dl. Causal mediation testing indicated that these changes partly explained the observed mortality benefit of TGC in the hyperinflammatory subgroup of patients. Conclusions: These findings expand our understanding of the biology underlying inflammatory subphenotypes and provide biologic insight into the mortality benefit of TGC in hyperinflammatory children.

    View details for DOI 10.1164/rccm.202409-1719OC

    View details for Web of Science ID 001578061300023

    View details for PubMedID 40493436

    View details for PubMedCentralID PMC12318495

  • Plasma Soluble Intercellular Adhesion Molecule-1 Has a Central Role in Biomarker Network Analysis and Is Associated With Poor Outcomes in Two Distinct Pediatric Cohorts of Acute Respiratory Distress Syndrome and Acute Respiratory Failure CRITICAL CARE MEDICINE Lim, M. J., Whitney, J. E., Sallee, C. J., Markovic, D., Bera, A., Sinha, P., Zeigler, A., Chen, L., Zinter, M. S., Ali, A., Matthay, M. A., Schwingshackl, A., Agus, M. S. D., Sapru, A. 2025; 53 (7): e1457-e1469

    Abstract

    Intercellular adhesion molecule-1 (ICAM-1) is a glycoprotein expressed on immune, endothelial, and epithelial cells. In the setting of inflammation, it becomes upregulated and spliced into a soluble form (soluble ICAM-1 [sICAM-1]). This study examined the association of sICAM-1 with clinical outcomes in two large pediatric cohorts with acute respiratory distress syndrome (ARDS) and acute respiratory failure (ARF) and examined the relationships between sICAM-1 and other protein biomarkers utilizing network analysis to contextualize its role in ARDS pathophysiology.Secondary analysis of prospective cohort studies.Multicenter PICUs.Critically ill children with ARDS (Pediatric Acute Lung Injury [PALI], 2008-2014) and ARF (Coagulation and Fibrinolysis in Pediatric Insulin Titration Trial [CAF-PINT], 2012-2016).None.sICAM-1 levels were measured from plasma collected within 72 hours of diagnosis. The primary outcome was in-hospital mortality, and secondary outcomes included multiple organ dysfunction and ventilator-free days. We constructed a biomarker correlation-based network that included sICAM-1 and 32 plasma biomarkers reflective of inflammation, endothelial and epithelial injury, and extracellular matrix degradation. Key biomarkers with centrality metrics in the top 10% (≥ 90th percentile) were defined as critical hubs within the network. The study included 214 children from PALI and 251 from CAF-PINT. In-hospital mortality was 18% and 14%, respectively. Baseline median oxygenation index ratios were 10 (interquartile range [IQR], 5.6-19.7) and 8.5 (IQR, 3.5-17.7). Higher plasma sICAM-1 was associated with in-hospital mortality, multiple organ dysfunction, and fewer ventilator-free days in each of the two cohorts (all p < 0.05). Tissue inhibitor of metalloproteinase-1 (composite centrality, 0.99), tumor necrosis factor receptor-1 (0.83), sICAM-1 (0.74), and interleukin-8 (0.74) were identified as network hubs.Elevated sICAM-1 levels were associated with poor outcomes in two separate cohorts of ARDS and ARF patients. Network analysis revealed sICAM-1 as a central hub, characterized by high centrality metrics. These findings underscore the multifaceted role of sICAM-1 in leukocyte transmigration, inflammation, and endothelial dysfunction and highlight its critical role in ARDS pathophysiology.

    View details for DOI 10.1097/CCM.0000000000006719

    View details for Web of Science ID 001521414000021

    View details for PubMedID 40459371

    View details for PubMedCentralID PMC12323721

  • Elastance May Determine the Neuromuscular Blockade Effect on Mortality in Acute Respiratory Distress Syndrome AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE Zalucky, A. A., Dianti, J., Neyton, L. P. A., Sinha, P., Liu, K. D., Matthay, M. A., Thompson, B., Goligher, E. C., Calfee, C. S. 2025; 211 (6): 966-974

    Abstract

    Rationale: Patients with acute respiratory distress syndrome (ARDS) have a reduction in functional lung volume that results in increased respiratory system elastance (Ers); however, the extent of this increase varies by patient. Patients with high Ers are at risk of excess lung-distending pressures and may derive greater clinical benefit from neuromuscular blockade (NMB). Objectives: We sought to evaluate whether the effect of early NMB administration on mortality varies according to baseline physiological and biological biomarkers of lung injury, including Ers. Methods: We conducted a secondary analysis of the Reevaluation of Systemic Early Neuromuscular Blockade, or ROSE, trial. Bayesian logistic regression modeling was used to estimate the posterior probability of NMB effect moderation by baseline Ers, ventilatory ratio, and select ARDS plasma biomarkers on 90-day mortality. Measurements and Main Results: The probability of mortality benefit with NMB increased substantially with higher baseline Ers (posterior probability of interaction, 92%; interaction odds ratio = 0.76; 90% credible interval = 0.59-0.99). In patients with an Ers ⩾2 cm H2O/(ml/kg), the posterior probability of benefit was 96% (median absolute risk reduction, 9%; 90% credible interval = 0.5-17.9). The effect of NMB did not vary meaningfully according to ventilatory ratio (posterior probability of interaction, 62%) or baseline plasma levels of receptor for advanced glycation end-products, tumor necrosis factor receptor-1, IL-6, or IL-8 (posterior probabilities of interaction: 12%, 18%, 44%, and 22% respectively). Conclusions: These findings suggest that the mortality benefit of NMB varies with baseline Ers. High Ers may represent a physiological phenotype of acute respiratory distress syndrome. Future prospective testing to confirm benefit in this potentially treatment-responsive group is needed.

    View details for DOI 10.1164/rccm.202406-1231OC

    View details for Web of Science ID 001530451600023

    View details for PubMedID 39998496

    View details for PubMedCentralID PMC12175940

  • Evidence-based personalised medicine in critical care: a framework for quantifying and applying individualised treatment effects in patients who are critically ill LANCET RESPIRATORY MEDICINE Munroe, E. S., Spicer, A., Castellvi-Font, A., Zalucky, A., Dianti, J., Linck, E., Talisa, V., Urner, M., Angus, D. C., Baedorf-Kassis, E., Blette, B., Bos, L. D., Buell, K. G., Casey, J. D., Calfee, C. S., Del Sorbo, L., Estenssoro, E., Ferguson, N. D., Giblon, R., Granholm, A., Harhay, M. O., Heath, A., Hodgson, C., Houle, T., Jiang, C., Kramer, L., Lawler, P. R., Leligdowicz, A., Li, F., Liu, K., Maiga, A., Maslove, D., McArthur, C., McAuley, D. F., Neto, A., Oosthuysen, C., Perner, A., Prescott, H. C., Rochwerg, B., Sahetya, S., Samoilenko, M., Schnitzer, M. E., Seitz, K. P., Shah, F., Shankar-Hari, M., Sinha, P., Slutsky, A. S., Qian, E. T., Webb, S. A., Young, P. J., Zampieri, F. G., Zarychanski, R., Fan, E., Semler, M. W., Churpek, M., Goligher, E. C., Platform Randomized Adaptive Clin Trials Critical Illness, Evidence Based Individualized Treatment Effects EviTE Grp 2025; 13 (6): 556-568

    Abstract

    Clinicians aim to provide treatments that will result in the best outcome for each patient. Ideally, treatment decisions are based on evidence from randomised clinical trials. Randomised trials conventionally report an aggregated difference in outcomes between patients in each group, known as an average treatment effect. However, the actual effect of treatment on outcomes (treatment response) can vary considerably between individuals, and can differ substantially from the average treatment effect. This variation in response to treatment between patients-heterogeneity of treatment effect-is particularly important in critical care because common critical care syndromes (eg, sepsis and acute respiratory distress syndrome) are clinically and biologically heterogeneous. Statistical approaches have been developed to analyse heterogeneity of treatment effect and predict individualised treatment effects for each patient. In this Review, we outline a framework for deriving and validating individualised treatment effects and identify challenges to applying individualised treatment effect estimates to inform treatment decisions in clinical care.

    View details for DOI 10.1016/S2213-2600(25)00054-2

    View details for Web of Science ID 001511800700009

    View details for PubMedID 40250459

    View details for PubMedCentralID PMC12362495

  • Temporal Transitions of the Hyperinflammatory and Hypoinflammatory Phenotypes in Critical Illness AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE van Amstel, R. B. E., Bartek, B., Vlaar, A. P. J., Gay, E., van Vught, L. A., Cremer, O. L., van der Poll, T., Shapiro, N. I., Matthay, M. A., Calfee, C. S., Sinha, P., Bos, L. D. J., NHLBI PETAL Network, MARS Consortium 2025; 211 (3): 347-356

    Abstract

    Rationale: Systemic molecular phenotypes of critical illness are prognostically informative, yet their temporal kinetics and implications of changing phenotypes remain incompletely understood. Objectives: To determine the temporal nature of the Hyperinflammatory and Hypoinflammatory phenotypes and assess the impact of transition between the phenotypes on mortality. Methods: We used data from one prospective observational cohort (MARS [Molecular Diagnosis and Risk Stratification of Sepsis]) and two randomized controlled trials in acute respiratory distress syndrome (ALVEOLI [Assessment of Low Tidal Volume and Elevated End-Expiratory Pressure to Obviate Lung Injury]) and sepsis (CLOVERS [Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis]). Critically ill patients with biomarkers available at multiple time points (Days 0-4) were included. We used a validated classifier model incorporating plasma IL-8, protein C, and serum bicarbonate to assign phenotypes on each day. We determined the association of longitudinal phenotype transition and 90-day all-cause mortality. Measurements and Main Results: Data from 2,407, 527, and 868 patients were included in MARS, ALVEOLI, and CLOVERS, respectively. In MARS, 36.0% were classified by the parsimonious model as Hyperinflammatory at Day 0, decreasing to 15.6% by Day 2 and 6.3% by Day 4. In ALVEOLI and CLOVERS, 26.4% and 24.8% of patients were Hyperinflammatory at Day 0, decreasing to 13.4% and 5.7% at Day 3, respectively. In all three cohorts, switching classification from Hyperinflammatory (Day 0) to Hypoinflammatory over time was associated with significantly improved mortality compared with persistently Hyperinflammatory patients. Mediation analysis indicated that only a minor proportion of this improvement could be attributed to ameliorating organ failure. Conclusions: The prevalence of the Hyperinflammatory phenotype, as assigned using a parsimonious biomarker classifier model, decreases over the first several days of critical illness, irrespective of acute respiratory distress syndrome diagnosis. The transition from Hyperinflammatory to Hypoinflammatory mediates a trajectory toward recovery beyond the resolution of organ failure.

    View details for DOI 10.1164/rccm.202406-1241OC

    View details for Web of Science ID 001440726000015

    View details for PubMedID 39642348

    View details for PubMedCentralID PMC11936145

  • Host-microbe multiomic profiling identifies distinct COVID-19 immune dysregulation in solid organ transplant recipients. Nature communications Pickering, H., Schaenman, J., Phan, H. V., Maguire, C., Tsitsiklis, A., Rouphael, N., Higuita, N. I., Atkinson, M. A., Brakenridge, S., Fung, M., Messer, W., Salehi-Rad, R., Altman, M. C., Becker, P. M., Bosinger, S. E., Eckalbar, W., Hoch, A., Doni Jayavelu, N., Kim-Schulze, S., Jenkins, M., Kleinstein, S. H., Krammer, F., Maecker, H. T., Ozonoff, A., Diray-Arce, J., Shaw, A., Baden, L., Levy, O., Reed, E. F., Langelier, C. R. 2025; 16 (1): 586

    Abstract

    Coronavirus disease 2019 (COVID-19) poses significant risks for solid organ transplant recipients, who have atypical but poorly characterized immune responses to infection. We aim to understand the host immunologic and microbial features of COVID-19 in transplant recipients by leveraging a prospective multicenter cohort of 86 transplant recipients age- and sex-matched with 172 non-transplant controls. We find that transplant recipients have higher nasal SARS-CoV-2 viral abundance and impaired viral clearance, and lower anti-spike IgG levels. In addition, transplant recipients exhibit decreased plasmablasts and transitional B cells, and increased senescent T cells. Blood and nasal transcriptional profiling demonstrate unexpected upregulation of innate immune signaling pathways and increased levels of several proinflammatory serum chemokines. Severe disease in transplant recipients, however, is characterized by a less robust induction of pro-inflammatory genes and chemokines. Together, our study reveals distinct immune features and altered viral dynamics in solid organ transplant recipients.

    View details for DOI 10.1038/s41467-025-55823-z

    View details for PubMedID 39794319

    View details for PubMedCentralID PMC11723965

  • Precision Medicine in Acute Respiratory Distress Syndrome Progress, Challenges, and the Road ahead CLINICS IN CHEST MEDICINE Leonard, J., Sinha, P. 2024; 45 (4): 835-848

    Abstract

    Several novel high-dimensional biologic measurements are increasingly being applied to biomedical sciences. Acute respiratory distress syndrome (ARDS) is a theoretically fertile ground for such approaches. Not only are these biologic and analytic tools available to better understand ARDS but also arguably, simpler approaches such as respiratory physiology has been vastly underutilized as a means of delivering precision-based care in the field. Here we review the progress made in ARDS toward discovering biologically homogeneous phenotypes, treatment responsive subgroups, the challenges to implement these discoveries at the bedside, and the road ahead that will enable precision medicine in ARDS.

    View details for DOI 10.1016/j.ccm.2024.08.005

    View details for Web of Science ID 001343318100001

    View details for PubMedID 39443001

    View details for PubMedCentralID PMC11507056

  • Distinct immune profiles and clinical outcomes in sepsis subphenotypes based on temperature trajectories INTENSIVE CARE MEDICINE Bhavani, S. V., Spicer, A., Sinha, P., Malik, A., Lopez-Espina, C., Schmalz, L., Watson, G. L., Bhargava, A., Khan, S., Urdiales, D., Updike, L., Dagan, A., Davila, H., Demarco, C., Evans, N., Gosai, F., Iyer, K., Kurtzman, N., Palagiri, A. V., Sims, M., Smith, S., Syed, A., Sarma, D., Reddy Jr, B., Verhoef, P. A., Churpek, M. M. 2024; 50 (12): 2094-2104

    Abstract

    Sepsis is a heterogeneous syndrome. Identification of sepsis subphenotypes with distinct immune profiles could lead to targeted therapies. This study investigates the immune profiles of patients with sepsis following distinct body temperature patterns (i.e., temperature trajectory subphenotypes).Hospitalized patients from four hospitals between 2018 and 2022 with suspicion of infection were included. A previously validated temperature trajectory algorithm was used to classify study patients into temperature trajectory subphenotypes. Microbiological profiles, clinical outcomes, and levels of 31 biomarkers were compared between these subphenotypes.The 3576 study patients were classified into four temperature trajectory subphenotypes: hyperthermic slow resolvers (N = 563, 16%), hyperthermic fast resolvers (N = 805, 23%), normothermic (N = 1693, 47%), hypothermic (N = 515, 14%). The mortality rate was significantly different between subphenotypes, with the highest rate in hypothermics (14.2%), followed by hyperthermic slow resolvers 6%, normothermic 5.5%, and lowest in hyperthermic fast resolvers 3.6% (p < 0.001). After multiple testing correction for the 31 biomarkers tested, 20 biomarkers remained significantly different between temperature trajectories: angiopoietin-1 (Ang-1), C-reactive protein (CRP), feline McDonough sarcoma-like tyrosine kinase 3 ligand (Flt-3l), granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin (IL)-15, IL-1 receptor antagonist (RA), IL-2, IL-6, IL-7, interferon gamma-induced protein 10 (IP-10), monocyte chemoattractant protein-1 (MCP-1), human macrophage inflammatory protein 3 alpha (MIP-3a), neutrophil gelatinase-associated lipocalin (NGAL), pentraxin-3, thrombomodulin, tissue factor, soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), and vascular cellular adhesion molecule-1 (vCAM-1).The hyperthermic fast and slow resolvers had the highest levels of most pro- and anti-inflammatory cytokines. Hypothermics had suppressed levels of most cytokines but the highest levels of several coagulation markers (Ang-1, thrombomodulin, tissue factor).Sepsis subphenotypes identified using the universally available measurement of body temperature had distinct immune profiles. Hypothermic patients, who had the highest mortality rate, also had the lowest levels of most pro- and anti-inflammatory cytokines.

    View details for DOI 10.1007/s00134-024-07669-0

    View details for Web of Science ID 001335694600003

    View details for PubMedID 39382693

    View details for PubMedCentralID PMC12674214

  • Machine Learning-Driven Analysis of Individualized Treatment Effects Comparing Buprenorphine and Naltrexone in Opioid Use Disorder Relapse Prevention JOURNAL OF ADDICTION MEDICINE Afshar, M., Linck, E., Spicer, A. B., Rotrosen, J., Salisbury-Afshar, E. M., Sinha, P., Semler, M. W., Churpek, M. M. 2024; 18 (5): 511-519

    Abstract

    A trial comparing extended-release naltrexone and sublingual buprenorphine-naloxone demonstrated higher relapse rates in individuals randomized to extended-release naltrexone. The effectiveness of treatment might vary based on patient characteristics. We hypothesized that causal machine learning would identify individualized treatment effects for each medication.This is a secondary analysis of a multicenter randomized trial that compared the effectiveness of extended-release naltrexone versus buprenorphine-naloxone for preventing relapse of opioid misuse. Three machine learning models were derived using all trial participants with 50% randomly selected for training (n = 285) and the remaining 50% for validation. Individualized treatment effect was measured by the Qini value and c-for-benefit, with the absence of relapse denoting treatment success. Patients were grouped into quartiles by predicted individualized treatment effect to examine differences in characteristics and the observed treatment effects.The best-performing model had a Qini value of 4.45 (95% confidence interval, 1.02-7.83) and a c-for-benefit of 0.63 (95% confidence interval, 0.53-0.68). The quartile most likely to benefit from buprenorphine-naloxone had a 35% absolute benefit from this treatment, and at study entry, they had a high median opioid withdrawal score ( P < 0.001), used cocaine on more days over the prior 30 days than other quartiles ( P < 0.001), and had highest proportions with alcohol and cocaine use disorder ( P ≤ 0.02). Quartile 4 individuals were predicted to be most likely to benefit from extended-release naltrexone, with the greatest proportion having heroin drug preference ( P = 0.02) and all experiencing homelessness ( P < 0.001).Causal machine learning identified differing individualized treatment effects between medications based on characteristics associated with preventing relapse.

    View details for DOI 10.1097/ADM.0000000000001313

    View details for Web of Science ID 001326783800014

    View details for PubMedID 38776423

    View details for PubMedCentralID PMC11446670

  • Molecular Endotypes of Idiopathic Pulmonary Fibrosis: A Latent Class Analysis of Two Multicenter Observational Cohorts. American journal of respiratory and critical care medicine Maddali, M. V., Moore, A. R., Sinha, P., Newton, C. A., Kim, J. S., Adegunsoye, A., Ma, S. F., Strek, M. E., Chen, C. H., Linderholm, A. L., Zemans, R. L., Moore, B. B., Wolters, P. J., Martinez, F. J., Rogers, A. J., Raj, R., Noth, I., Oldham, J. M. 2024

    Abstract

    Rationale: Idiopathic pulmonary fibrosis (IPF) causes irreversible fibrosis of the lung parenchyma. While antifibrotic therapy can slow IPF progression, treatment response is variable. There exists a critical need to develop a precision medicine approach to IPF. Objective: To identify and validate biologically driven molecular endotypes of IPF. Methods: Latent class analysis (LCA) was independently performed in prospectively recruited discovery (n=875) and validation (n=347) cohorts. Twenty-five plasma biomarkers associated with fibrogenesis served as class-defining variables. The association between molecular endotype and 4-year transplant-free survival was tested using multivariable Cox regression adjusted for baseline confounders. Endotype-dependent differential treatment response to future antifibrotic exposure was then assessed in a pooled cohort of patients naïve to antifibrotic therapy at time of biomarker measurement (n=555). Results: LCA independently identified two latent classes in both cohorts (p<0.0001). WAP four-disulfide core domain protein 2 (WFDC2) was the most important determinant of class membership across cohorts. Membership in Class 2 was characterized by higher biomarker concentrations and higher risk of death or transplantation (discovery: HR 2.02 [95% CI 1.64-2.48]; p<0.001; validation: HR 1.95 [1.34-2.82]; p<0.001). In pooled analysis, significant heterogeneity in treatment effect was observed between endotypes (pinteraction=0.030), with a favorable antifibrotic response in Class 2 (HR 0.64 [0.45-0.93]; p=0.018) but not in Class 1 (HR 1.19 [0.77-1.84]; p=0.422). Conclusions: In this multicohort study, we identified two novel molecular endotypes of IPF with divergent clinical outcomes and response to antifibrotics. Pending further validation, these endotypes could enable a precision medicine approach for future IPF clinical trials.

    View details for DOI 10.1164/rccm.202402-0339OC

    View details for PubMedID 38913573

  • Causes and attributable fraction of death from ARDS in inflammatory phenotypes of sepsis CRITICAL CARE Evrard, B., Sinha, P., Delucchi, K., Hendrickson, C. M., Kangelaris, K. N., Liu, K. D., Willmore, A., Wu, N., Neyton, L., Schmiege, E., Gomez, A., Kerchberger, V., Zalucky, A., Matthay, M. A., Ware, L. B., Calfee, C. S. 2024; 28 (1): 164

    Abstract

    Hypoinflammatory and hyperinflammatory phenotypes have been identified in both Acute Respiratory Distress Syndrome (ARDS) and sepsis. Attributable mortality of ARDS in each phenotype of sepsis is yet to be determined. We aimed to estimate the population attributable fraction of death from ARDS (PAFARDS) in hypoinflammatory and hyperinflammatory sepsis, and to determine the primary cause of death within each phenotype.We studied 1737 patients with sepsis from two prospective cohorts. Patients were previously assigned to the hyperinflammatory or hypoinflammatory phenotype using latent class analysis. The PAFARDS in patients with sepsis was estimated separately in the hypo and hyperinflammatory phenotypes. Organ dysfunction, severe comorbidities, and withdrawal of life support were abstracted from the medical record in a subset of patients from the EARLI cohort who died (n = 130/179). Primary cause of death was defined as the organ system that most directly contributed to death or withdrawal of life support.The PAFARDS was 19% (95%CI 10,28%) in hypoinflammatory sepsis and, 14% (95%CI 6,20%) in hyperinflammatory sepsis. Cause of death differed between the two phenotypes (p < 0.001). Respiratory failure was the most common cause of death in hypoinflammatory sepsis, whereas circulatory shock was the most common cause in hyperinflammatory sepsis. Death with severe underlying comorbidities was more frequent in hypoinflammatory sepsis (81% vs. 67%, p = 0.004).The PAFARDS is modest in both phenotypes whereas primary cause of death among patients with sepsis differed substantially by phenotype. This study identifies challenges in powering future clinical trials to detect changes in mortality outcomes among patients with sepsis and ARDS.

    View details for DOI 10.1186/s13054-024-04943-x

    View details for Web of Science ID 001222706800002

    View details for PubMedID 38745253

    View details for PubMedCentralID PMC11092165

  • Rapidly improving ARDS differs clinically and biologically from persistent ARDS CRITICAL CARE Valda Toro, P. L., Willmore, A., Wu, N. E., Delucchi, K. L., Jauregui, A., Sinha, P., Liu, K. D., Hendrickson, C. M., Sarma, A., Neyton, L. P. A., Leligdowicz, A., Langelier, C. R., Zhuo, H., Jones, C., Kangelaris, K. N., Gomez, A. D., Matthay, M. A., Calfee, C. S. 2024; 28 (1): 132

    Abstract

    Rapidly improving acute respiratory distress syndrome (RIARDS) is an increasingly appreciated subgroup of ARDS in which hypoxemia improves within 24 h after initiation of mechanical ventilation. Detailed clinical and biological features of RIARDS have not been clearly defined, and it is unknown whether RIARDS is associated with the hypoinflammatory or hyperinflammatory phenotype of ARDS. The purpose of this study was to define the clinical and biological features of RIARDS and its association with inflammatory subphenotypes.We analyzed data from 215 patients who met Berlin criteria for ARDS (endotracheally intubated) and were enrolled in a prospective observational cohort conducted at two sites, one tertiary care center and one urban safety net hospital. RIARDS was defined according to previous studies as improvement of hypoxemia defined as (i) PaO2:FiO2 > 300 or (ii) SpO2: FiO2 > 315 on the day following diagnosis of ARDS (day 2) or (iii) unassisted breathing by day 2 and for the next 48 h (defined as absence of endotracheal intubation on day 2 through day 4). Plasma biomarkers were measured on samples collected on the day of study enrollment, and ARDS phenotypes were allocated as previously described.RIARDS accounted for 21% of all ARDS participants. Patients with RIARDS had better clinical outcomes compared to those with persistent ARDS, with lower hospital mortality (13% vs. 57%; p value < 0.001) and more ICU-free days (median 24 vs. 0; p value < 0.001). Plasma levels of interleukin-6, interleukin-8, and plasminogen activator inhibitor-1 were significantly lower among patients with RIARDS. The hypoinflammatory phenotype of ARDS was more common among patients with RIARDS (78% vs. 51% in persistent ARDS; p value = 0.001).This study identifies a high prevalence of RIARDS in a multicenter observational cohort and confirms the more benign clinical course of these patients. We report the novel finding that RIARDS is characterized by lower concentrations of plasma biomarkers of inflammation compared to persistent ARDS, and that hypoinflammatory ARDS is more prevalent among patients with RIARDS. Identification and exclusion of RIARDS could potentially improve prognostic and predictive enrichment in clinical trials.

    View details for DOI 10.1186/s13054-024-04883-6

    View details for Web of Science ID 001206332300002

    View details for PubMedID 38649920

    View details for PubMedCentralID PMC11034037

  • Host and Microbe Blood Metagenomics Reveals Key Pathways Characterizing Critical Illness Phenotypes AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE Neyton, L. P. A., Sinha, P., Sarma, A., Mick, E., Kalantar, K., Chen, S., Wu, N., Delucchi, K., Zhuo, H., Bos, L. D. J., Jauregui, A., Gomez, A., Hendrickson, C. M., Kangelaris, K. N., Leligdowicz, A., Liu, K. D., Matthay, M. A., Langelier, C. R., Calfee, C. S. 2024; 209 (7): 805-815

    Abstract

    Rationale: Two molecular phenotypes of sepsis and acute respiratory distress syndrome, termed hyperinflammatory and hypoinflammatory, have been consistently identified by latent class analysis in numerous cohorts, with widely divergent clinical outcomes and differential responses to some treatments; however, the key biological differences between these phenotypes remain poorly understood.Objectives: We used host and microbe metagenomic sequencing data from blood to deepen our understanding of biological differences between latent class analysis-derived phenotypes and to assess concordance between the latent class analysis-derived phenotypes and phenotypes reported by other investigative groups (e.g., Sepsis Response Signature [SRS1-2], molecular diagnosis and risk stratification of sepsis [MARS1-4], reactive and uninflamed).Methods: We analyzed data from 113 patients with hypoinflammatory sepsis and 76 patients with hyperinflammatory sepsis enrolled in a two-hospital prospective cohort study. Molecular phenotypes had been previously assigned using latent class analysis.Measurements and Main Results: The hyperinflammatory and hypoinflammatory phenotypes of sepsis had distinct gene expression signatures, with 5,755 genes (31%) differentially expressed. The hyperinflammatory phenotype was associated with elevated expression of innate immune response genes, whereas the hypoinflammatory phenotype was associated with elevated expression of adaptive immune response genes and, notably, T cell response genes. Plasma metagenomic analysis identified differences in prevalence of bacteremia, bacterial DNA abundance, and composition between the phenotypes, with an increased presence and abundance of Enterobacteriaceae in the hyperinflammatory phenotype. Significant overlap was observed between these phenotypes and previously identified transcriptional subtypes of acute respiratory distress syndrome (reactive and uninflamed) and sepsis (SRS1-2). Analysis of data from the VANISH trial indicated that corticosteroids might have a detrimental effect in patients with the hypoinflammatory phenotype.Conclusions: The hyperinflammatory and hypoinflammatory phenotypes have distinct transcriptional and metagenomic features that could be leveraged for precision treatment strategies.

    View details for DOI 10.1164/rccm.202308-1328OC

    View details for Web of Science ID 001208693400012

    View details for PubMedID 38190719

    View details for PubMedCentralID PMC10995577

  • Molecular Phenotypes of Acute Respiratory Distress Syndrome in the ROSE Trial Have Differential Outcomes and Gene Expression Patterns That Differ at Baseline and Longitudinally over Time AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE Sinha, P., Neyton, L., Sarma, A., Wu, N., Jones, C., Zhuo, H., Liu, K. D., Guerrero, E., Ghale, R., Love, C., Mick, E., Delucchi, K. L., Langelier, C. R., Thompson, B., Matthay, M. A., Calfee, C. S., NHLBI PETAL Network 2024; 209 (7): 816-828

    Abstract

    Rationale: Two molecular phenotypes have been identified in acute respiratory distress syndrome (ARDS). In the ROSE (Reevaluation of Systemic Early Neuromuscular Blockade) trial of cisatracurium in moderate to severe ARDS, we addressed three unanswered questions: 1) Do the same phenotypes emerge in a more severe ARDS cohort with earlier recruitment; 2) Do phenotypes respond differently to neuromuscular blockade? and 3) What biological pathways most differentiate inflammatory phenotypes?Methods: We performed latent class analysis in ROSE using preenrollment clinical and protein biomarkers. In a subset of patients (n = 134), we sequenced whole-blood RNA using enrollment and Day 2 samples and performed differential gene expression and pathway analyses. Informed by the differential gene expression analysis, we measured additional plasma proteins and evaluated their abundance relative to gene expression amounts.Measurements and Main Results: In ROSE, we identified the hypoinflammatory (60.4%) and hyperinflammatory (39.6%) phenotypes with similar biological and clinical characteristics as prior studies, including higher mortality at Day 90 for the hyperinflammatory phenotype (30.3% vs. 61.6%; P < 0.0001). We observed no treatment interaction between the phenotypes and randomized groups for mortality. The hyperinflammatory phenotype was enriched for genes associated with innate immune response, tissue remodeling, and zinc metabolism at Day 0 and collagen synthesis and neutrophil degranulation at Day 2. Longitudinal changes in gene expression patterns differed dependent on survivorship. For most highly expressed genes, we observed correlations with their corresponding plasma proteins' abundance. However, for the class-defining plasma proteins in the latent class analysis, no correlation was observed with their corresponding genes' expression.Conclusions: The hyperinflammatory and hypoinflammatory phenotypes have different clinical, protein, and dynamic transcriptional characteristics. These findings support the clinical and biological potential of molecular phenotypes to advance precision care in ARDS.

    View details for DOI 10.1164/rccm.202308-1490OC

    View details for Web of Science ID 001208693400013

    View details for PubMedID 38345571

    View details for PubMedCentralID PMC10995566

  • Individualized Treatment Effects of Oxygen Targets in Mechanically Ventilated Critically Ill Adults JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION Buell, K. G., Spicer, A. B., Casey, J. D., Seitz, K. P., Qian, E. T., Graham Linck, E. J., Self, W. H., Rice, T. W., Sinha, P., Young, P. J., Semler, M. W., Churpek, M. M. 2024; 331 (14): 1195-1204

    Abstract

    Among critically ill adults, randomized trials have not found oxygenation targets to affect outcomes overall. Whether the effects of oxygenation targets differ based on an individual's characteristics is unknown.To determine whether an individual's characteristics modify the effect of lower vs higher peripheral oxygenation-saturation (Spo2) targets on mortality.A machine learning model to predict the effect of treatment with a lower vs higher Spo2 target on mortality for individual patients was derived in the Pragmatic Investigation of Optimal Oxygen Targets (PILOT) trial and externally validated in the Intensive Care Unit Randomized Trial Comparing Two Approaches to Oxygen Therapy (ICU-ROX) trial. Critically ill adults received invasive mechanical ventilation in an intensive care unit (ICU) in the United States between July 2018 and August 2021 for PILOT (n = 1682) and in 21 ICUs in Australia and New Zealand between September 2015 and May 2018 for ICU-ROX (n = 965).Randomization to a lower vs higher Spo2 target group.28-Day mortality.In the ICU-ROX validation cohort, the predicted effect of treatment with a lower vs higher Spo2 target for individual patients ranged from a 27.2% absolute reduction to a 34.4% absolute increase in 28-day mortality. For example, patients predicted to benefit from a lower Spo2 target had a higher prevalence of acute brain injury, whereas patients predicted to benefit from a higher Spo2 target had a higher prevalence of sepsis and abnormally elevated vital signs. Patients predicted to benefit from a lower Spo2 target experienced lower mortality when randomized to the lower Spo2 group, whereas patients predicted to benefit from a higher Spo2 target experienced lower mortality when randomized to the higher Spo2 group (likelihood ratio test for effect modification P = .02). The use of a Spo2 target predicted to be best for each patient, instead of the randomized Spo2 target, would have reduced the absolute overall mortality by 6.4% (95% CI, 1.9%-10.9%).Oxygenation targets that are individualized using machine learning analyses of randomized trials may reduce mortality for critically ill adults. A prospective trial evaluating the use of individualized oxygenation targets is needed.

    View details for DOI 10.1001/jama.2024.2933

    View details for Web of Science ID 001189209900002

    View details for PubMedID 38501205

    View details for PubMedCentralID PMC10951851

  • IgM N-glycosylation correlates with COVID-19 severity and rate of complement deposition. Nature communications Haslund-Gourley, B. S., Woloszczuk, K., Hou, J., Connors, J., Cusimano, G., Bell, M., Taramangalam, B., Fourati, S., Mege, N., Bernui, M., Altman, M. C., Krammer, F., van Bakel, H., IMPACC Network, Maecker, H. T., Rouphael, N., Diray-Arce, J., Wigdahl, B., Kutzler, M. A., Cairns, C. B., Haddad, E. K., Comunale, M. A., Ozonoff, A., Ehrlich, L. I., Melamed, E., Sesma, A. F., Simon, V., Pulendran, B., Nadeau, K. C., Davis, M. M., McCoey, G. A., Sekaly, R., Baden, L. R., Levy, O., Schaenman, J., Reed, E. F., Shaw, A. C., Hafler, D. A., Montgomery, R. R., Kleinstein, S. H., Becker, P. M., Augustine, A. D., Calfee, C. S., Erle, D. J., DeBakey, M. E., Corry, D. B., Kheradmand, F., Atkinson, M. A., Brakenridge, S. C., Higuita, N. I., Metcalf, J. P., Hough, C. L., Messer, W. B., Kraft, M., Bime, C., Peters, B., Milliren, C. E., Syphurs, C., McEnaney, K., Barton, B., Lentucci, C., Saluvan, M., Chang, A. C., Hoch, A., Albert, M., Shaheen, T., Kho, A. T., Liu, S., Thomas, S., Chen, J., Murphy, M. D., Cooney, M., Hayati, A. N., Bryant, R., Abraham, J., Jayavelu, N. D., Presnell, S., Jancsyk, T., Maguire, C., Qi, J., Lee, B., Fourati, S., Esserman, D. A., Guan, L., Gygi, J., Pawar, S., Brito, A., Fragiadakis, G. K., Patel, R., Overton, J. A., Vita, R., Westendorf, K., Shannon, C. P., Tebbutt, S. J., Thyagarajan, R. V., Rousseau, J. F., Wylie, D., Triplett, T. A., Kojic, E., Chinthrajah, S., Ahuja, N., Rogers, A. J., Artandi, M., Geng, L., Yendewa, G., Powell, D. L., Kim, J. N., Simmons, B., Goonewardene, I. M., Smith, C. M., Martens, M., Sherman, A. C., Walsh, S. R., Issa, N. C., Salehi-Rad, R., Dela Cruz, C., Farhadian, S., Iwasaki, A., Ko, A. I., Anderson, E. J., Mehta, A. K., Sevransky, J. E., Seyfert-Margolis, V., Leligdowicz, A., Matthay, M. A., Singer, J. P., Kangelaris, K. N., Hendrickson, C. M., Krummel, M. F., Langelier, C. R., Woodruff, P. G., Corry, D. B., Kheradmand, F., Anderson, M. L., Guirgis, F. W., Drevets, D. A., Brown, B. R., Siegel, S. A., Lu, Z., Mosier, J., Kimura, H., Khor, B., van Bakel, H., Rahman, A., Stadlbauer, D., Dutta, J., Xie, H., Kim-Schulze, S., Gonzalez-Reiche, A. S., van de Guchte, A., Carreno, J. M., Singh, G., Raskin, A., Tcheou, J., Bielak, D., Kawabata, H., Kelly, G., Patel, M., Nie, K., Yellin, T., Fried, M., Sullivan, L., Morris, S., Sieg, S., Steen, H., van Zalm, P., Fatou, B., Mendez, K., Lasky-Su, J., Hutton, S. R., Michelotti, G., Wong, K., Jha, M., Viode, A., Kanarek, N., Petrova, B., Zhao, Y., Bosinger, S. E., Boddapati, A. K., Tharp, G. K., Pellegrini, K. L., Beagle, E., Cowan, D., Hamilton, S., Ribeiro, S. P., Hodder, T., Rosen, L. B., Lee, S., Wilson, M. R., Dandekar, R., Alvarenga, B., Rajan, J., Eckalbar, W., Schroeder, A. W., Tsitsiklis, A., Mick, E., Guerrero, Y. S., Love, C., Maliskova, L., Adkisson, M., Siles, N., Geltman, J., Hurley, K., Saksena, M., Altman, D., Srivastava, K., Eaker, L. Q., Bermudez-Gonzalez, M. C., Beach, K. F., Sominsky, L. A., Azad, A. R., Mulder, L. C., Kleiner, G., Lee, A. S., Do, E., Fernandes, A., Manohar, M., Hagan, T., Blish, C. A., Din, H. N., Roque, J., Yang, S., Sigal, N., Chang, I., Tribout, H., Harris, P., Consolo, M., Edwards, C., Lee, E., Lin, E., Croen, B., Semenza, N. C., Rogowski, B., Melnyk, N., Bell, M. R., Furukawa, S., McLin, R., Schearer, P., Sheidy, J., Tegos, G. P., Nagle, C., Smolen, K., Desjardins, M., van Haren, S., Mitre, X., Cauley, J., Li, X., Tong, A., Evans, B., Montesano, C., Licona, J. H., Krauss, J., Chang, J. B., Izaguirre, N., Rooks, R., Elashoff, D., Brook, J., Ramires-Sanchez, E., Llamas, M., Rivera, A., Perdomo, C., Ward, D. C., Magyar, C. E., Fulcher, J. A., Pickering, H. C., Sen, S., Chaudhary, O., Coppi, A., Fournier, J., Mohanty, S., Muenker, C., Nelson, A., Raddassi, K., Rainone, M., Ruff, W. E., Salahuddin, S., Schulz, W. L., Vijayakumar, P., Wang, H., Wunder, E. J., Young, H. P., Rothman, J., Konstorum, A., Chen, E., Cotsapas, C., Grubaugh, N. D., Wang, X., Xu, L., Asashima, H., Bristow, L., Hussaini, L., Hellmeister, K., Samaha, H., Wimalasena, S. T., Cheng, A., Spainhour, C., Scherer, E. M., Johnson, B., Bechnak, A., Ciric, C. R., Hewitt, L., Carter, E., Mcnair, N., Panganiban, B., Huerta, C., Usher, J., Vaysman, T., Holland, S. M., Abe-Jones, Y., Asthana, S., Beagle, A., Bhide, S., Carrillo, S. A., Chak, S., Ghale, R., Gonzalez, A., Jauregui, A., Jones, N., Lea, T., Lee, D., Lota, R., Milush, J., Nguyen, V., Pierce, L., Prasad, P. A., Rao, A., Samad, B., Shaw, C., Sigman, A., Sinha, P., Ward, A., Willmore, A., Zhan, J., Rashid, S., Rodriguez, N., Tang, K., Altamirano, L. T., Betancourt, L., Curiel, C., Sutter, N., Paz, M. T., Tietje-Ulrich, G., Leroux, C., Thakur, N., Vasquez, J. J., Santhosh, L., Song, L., Nelson, E., Moldawer, L. L., Borresen, B., Roth-Manning, B., Ungaro, R. F., Oberhaus, J., Booth, J. L., Sinko, L. A., Brunton, A., Sullivan, P. E., Strnad, M., Lyski, Z. L., Coulter, F. J., Micheleti, C., Conway, M., Francisco, D., Molzahn, A., Erickson, H., Wilson, C. C., Schunk, R., Sierra, B., Hughes, T. 2024; 15 (1): 404

    Abstract

    The glycosylation of IgG plays a critical role during human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, activating immune cells and inducing cytokine production. However, the role of IgM N-glycosylation has not been studied during human acute viral infection. The analysis of IgM N-glycosylation from healthy controls and hospitalized coronavirus disease 2019 (COVID-19) patients reveals increased high-mannose and sialylation that correlates with COVID-19 severity. These trends are confirmed within SARS-CoV-2-specific immunoglobulin N-glycan profiles. Moreover, the degree of total IgM mannosylation and sialylation correlate significantly with markers of disease severity. We link the changes of IgM N-glycosylation with the expression of Golgi glycosyltransferases. Lastly, we observe antigen-specific IgM antibody-dependent complement deposition is elevated in severe COVID-19 patients and modulated by exoglycosidase digestion. Taken together, this work links the IgM N-glycosylation with COVID-19 severity and highlights the need to understand IgM glycosylation and downstream immune function during human disease.

    View details for DOI 10.1038/s41467-023-44211-0

    View details for PubMedID 38195739

  • Features of acute COVID-19 associated with post-acute sequelae of SARS-CoV-2 phenotypes: results from the IMPACC study. Nature communications Ozonoff, A., Jayavelu, N. D., Liu, S., Melamed, E., Milliren, C. E., Qi, J., Geng, L. N., McComsey, G. A., Cairns, C. B., Baden, L. R., Schaenman, J., Shaw, A. C., Samaha, H., Seyfert-Margolis, V., Krammer, F., Rosen, L. B., Steen, H., Syphurs, C., Dandekar, R., Shannon, C. P., Sekaly, R. P., Ehrlich, L. I., Corry, D. B., Kheradmand, F., Atkinson, M. A., Brakenridge, S. C., Higuita, N. I., Metcalf, J. P., Hough, C. L., Messer, W. B., Pulendran, B., Nadeau, K. C., Davis, M. M., Sesma, A. F., Simon, V., van Bakel, H., Kim-Schulze, S., Hafler, D. A., Levy, O., Kraft, M., Bime, C., Haddad, E. K., Calfee, C. S., Erle, D. J., Langelier, C. R., Eckalbar, W., Bosinger, S. E., Peters, B., Kleinstein, S. H., Reed, E. F., Augustine, A. D., Diray-Arce, J., Maecker, H. T., Altman, M. C., Montgomery, R. R., Becker, P. M., Rouphael, N. 2024; 15 (1): 216

    Abstract

    Post-acute sequelae of SARS-CoV-2 (PASC) is a significant public health concern. We describe Patient Reported Outcomes (PROs) on 590 participants prospectively assessed from hospital admission for COVID-19 through one year after discharge. Modeling identified 4 PRO clusters based on reported deficits (minimal, physical, mental/cognitive, and multidomain), supporting heterogenous clinical presentations in PASC, with sub-phenotypes associated with female sex and distinctive comorbidities. During the acute phase of disease, a higher respiratory SARS-CoV-2 viral burden and lower Receptor Binding Domain and Spike antibody titers were associated with both the physical predominant and the multidomain deficit clusters. A lower frequency of circulating B lymphocytes by mass cytometry (CyTOF) was observed in the multidomain deficit cluster. Circulating fibroblast growth factor 21 (FGF21) was significantly elevated in the mental/cognitive predominant and the multidomain clusters. Future efforts to link PASC to acute anti-viral host responses may help to better target treatment and prevention of PASC.

    View details for DOI 10.1038/s41467-023-44090-5

    View details for PubMedID 38172101

    View details for PubMedCentralID PMC10764789

  • Analysis of Protein Biomarkers From Hospitalized COVID-19 Patients Reveals Severity-Specific Signatures and Two Distinct Latent Profiles With Differential Responses to Corticosteroids CRITICAL CARE MEDICINE Verhoef, P. A., Spicer, A. B., Lopez-Espina, C., Bhargava, A., Schmalz, L., Sims, M. D., Palagiri, A. V., Iyer, K. V., Crisp, M. J., Halalau, A., Maddens, N., Gosai, F., Syed, A., Azad, S., Espinosa, A., Davila, F., Davila, H., Evans, N. R., Smith, S., Reddy, B., Sinha, P., Churpek, M. M. 2023; 51 (12): 1697-1705

    Abstract

    To identify and validate novel COVID-19 subphenotypes with potential heterogenous treatment effects (HTEs) using electronic health record (EHR) data and 33 unique biomarkers.Retrospective cohort study of adults presenting for acute care, with analysis of biomarkers from residual blood collected during routine clinical care. Latent profile analysis (LPA) of biomarker and EHR data identified subphenotypes of COVID-19 inpatients, which were validated using a separate cohort of patients. HTE for glucocorticoid use among subphenotypes was evaluated using both an adjusted logistic regression model and propensity matching analysis for in-hospital mortality.Emergency departments from four medical centers.Patients diagnosed with COVID-19 based on International Classification of Diseases , 10th Revision codes and laboratory test results.None.Biomarker levels generally paralleled illness severity, with higher levels among more severely ill patients. LPA of 522 COVID-19 inpatients from three sites identified two profiles: profile 1 ( n = 332), with higher levels of albumin and bicarbonate, and profile 2 ( n = 190), with higher inflammatory markers. Profile 2 patients had higher median length of stay (7.4 vs 4.1 d; p < 0.001) and in-hospital mortality compared with profile 1 patients (25.8% vs 4.8%; p < 0.001). These were validated in a separate, single-site cohort ( n = 192), which demonstrated similar outcome differences. HTE was observed ( p = 0.03), with glucocorticoid treatment associated with increased mortality for profile 1 patients (odds ratio = 4.54).In this multicenter study combining EHR data with research biomarker analysis of patients with COVID-19, we identified novel profiles with divergent clinical outcomes and differential treatment responses.

    View details for DOI 10.1097/CCM.0000000000005983

    View details for Web of Science ID 001124481500004

    View details for PubMedID 37378460

    View details for PubMedCentralID PMC11796285

  • Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlledtrials LANCET RESPIRATORY MEDICINE Sinha, P., Kerchberger, V., Willmore, A., Chambers, J., Zhuo, H., Abbott, J., Jones, C., Wickersham, N., Wu, N., Neyton, L., Langelier, C. R., Mick, E., He, J., Jauregui, A., Churpek, M. M., Gomez, A. D., Hendrickson, C. M., Kangelaris, K. N., Sarma, A., Leligdowicz, A., Delucchi, K. L., Liu, K. D., Russell, J. A., Matthay, M. A., Walley, K. R., Ware, L. B., Calfee, C. S. 2023; 11 (11): 965-974

    Abstract

    In sepsis and acute respiratory distress syndrome (ARDS), heterogeneity has contributed to difficulty identifying effective pharmacotherapies. In ARDS, two molecular phenotypes (hypoinflammatory and hyperinflammatory) have consistently been identified, with divergent outcomes and treatment responses. In this study, we sought to derive molecular phenotypes in critically ill adults with sepsis, determine their overlap with previous ARDS phenotypes, and evaluate whether they respond differently to treatment in completed sepsis trials.We used clinical data and plasma biomarkers from two prospective sepsis cohorts, the Validating Acute Lung Injury biomarkers for Diagnosis (VALID) study (N=1140) and the Early Assessment of Renal and Lung Injury (EARLI) study (N=818), in latent class analysis (LCA) to identify the optimal number of classes in each cohort independently. We used validated models trained to classify ARDS phenotypes to evaluate concordance of sepsis and ARDS phenotypes. We applied these models retrospectively to the previously published Prospective Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis and Septic Shock (PROWESS-SHOCK) trial and Vasopressin and Septic Shock Trial (VASST) to assign phenotypes and evaluate heterogeneity of treatment effect.A two-class model best fit both VALID and EARLI (p<0·0001). In VALID, 804 (70·5%) of the 1140 patients were classified as hypoinflammatory and 336 (29·5%) as hyperinflammatory; in EARLI, 530 (64·8%) of 818 were hypoinflammatory and 288 (35·2%) hyperinflammatory. We observed higher plasma pro-inflammatory cytokines, more vasopressor use, more bacteraemia, lower protein C, and higher mortality in the hyperinflammatory than in the hypoinflammatory phenotype (p<0·0001 for all). Classifier models indicated strong concordance between sepsis phenotypes and previously identified ARDS phenotypes (area under the curve 0·87-0·96, depending on the model). Findings were similar excluding participants with both sepsis and ARDS. In PROWESS-SHOCK, 1142 (68·0%) of 1680 patients had the hypoinflammatory phenotype and 538 (32·0%) had the hyperinflammatory phenotype, and response to activated protein C differed by phenotype (p=0·0043). In VASST, phenotype proportions were similar to other cohorts; however, no treatment interaction with the type of vasopressor was observed (p=0·72).Molecular phenotypes previously identified in ARDS are also identifiable in multiple sepsis cohorts and respond differently to activated protein C. Molecular phenotypes could represent a treatable trait in critical illness beyond the patient's syndromic diagnosis.US National Institutes of Health.

    View details for DOI 10.1016/S2213-2600(23)00237-0

    View details for Web of Science ID 001109650000001

    View details for PubMedID 37633303

    View details for PubMedCentralID PMC10841178

  • Simvastatin in Critically Ill Patients with Covid-19 NEW ENGLAND JOURNAL OF MEDICINE Hills, T. E., Lorenzi, E., Berry, L. R., Shyamsundar, M., Al-Beidh, F., Annane, D., Arabi, Y., Aryal, D., Au, C., Beane, A., Bhimani, Z., Bonten, M., Bradbury, C. A., Brunkhorst, F. M., Burrell, A., Buxton, M., Calfee, C. S., Cecconi, M., Cheng, A. C., Cove, M. E., Detry, M. A., Estcourt, L. J., Fitzgerald, M., Goligher, E. C., Goossens, H., Green, C., Haniffa, R., Harrison, D. A., Hashmi, M., Higgins, A. M., Huang, D. T., Ichihara, N., Jayakumar, D., Kruger, P. S., Lamontagne, F., Lampro, L., Lawler, P. R., Marshall, J. C., Mason, A. J., McGlothlin, A., McGuinness, S., McQuilten, Z. K., McVerry, B. J., Mouncey, P. R., Murthy, S., Neal, M. D., Nichol, A. D., O'Kane, C. M., Parke, R. L., Parker, J. C., Rabindrarajan, E., Reyes, L. F., Rowan, K. M., Saito, H., Santos, M., Saunders, C. T., Seymour, C. W., Shankar-Hari, M., Sinha, P., Thompson, B., Turgeon, A. F., Turner, A. M., van van de Veerdonk, F., Weis, S., Young, I. S., Zarychanski, R., Lewis, R. J., McArthur, C. J., Angus, D. C., Berry, S. M., Derde, L. P. G., Webb, S. A., Gordon, A. C., McAuley, D. F., REMAP-CAP Investigators 2023: 2341-2354

    Abstract

    The efficacy of simvastatin in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear.In an ongoing international, multifactorial, adaptive platform, randomized, controlled trial, we evaluated simvastatin (80 mg daily) as compared with no statin (control) in critically ill patients with Covid-19 who were not receiving statins at baseline. The primary outcome was respiratory and cardiovascular organ support-free days, assessed on an ordinal scale combining in-hospital death (assigned a value of -1) and days free of organ support through day 21 in survivors; the analyis used a Bayesian hierarchical ordinal model. The adaptive design included prespecified statistical stopping criteria for superiority (>99% posterior probability that the odds ratio was >1) and futility (>95% posterior probability that the odds ratio was <1.2).Enrollment began on October 28, 2020. On January 8, 2023, enrollment was closed on the basis of a low anticipated likelihood that prespecified stopping criteria would be met as Covid-19 cases decreased. The final analysis included 2684 critically ill patients. The median number of organ support-free days was 11 (interquartile range, -1 to 17) in the simvastatin group and 7 (interquartile range, -1 to 16) in the control group; the posterior median adjusted odds ratio was 1.15 (95% credible interval, 0.98 to 1.34) for simvastatin as compared with control, yielding a 95.9% posterior probability of superiority. At 90 days, the hazard ratio for survival was 1.12 (95% credible interval, 0.95 to 1.32), yielding a 91.9% posterior probability of superiority of simvastatin. The results of secondary analyses were consistent with those of the primary analysis. Serious adverse events, such as elevated levels of liver enzymes and creatine kinase, were reported more frequently with simvastatin than with control.Although recruitment was stopped because cases had decreased, among critically ill patients with Covid-19, simvastatin did not meet the prespecified criteria for superiority to control. (REMAP-CAP ClinicalTrials.gov number, NCT02735707.).

    View details for DOI 10.1056/NEJMoa2309995

    View details for Web of Science ID 001094542300001

    View details for PubMedID 37888913

    View details for PubMedCentralID PMC10755839

  • Identification of molecular subphenotypes in two cohorts of paediatric ARDS THORAX Yehya, N., Zinter, M. S., Thompson, J. M., Lim, M. J., Hanudel, M. R., Alkhouli, M. F., Wong, H., Alder, M. N., Mckeone, D. J., Halstead, E., Sinha, P., Sapru, A. 2024; 79 (2): 128-134

    Abstract

    Two subphenotypes of acute respiratory distress syndrome (ARDS), hypoinflammatory and hyperinflammatory, have been reported in adults and in a single paediatric cohort. The relevance of these subphenotypes in paediatrics requires further investigation. We aimed to identify subphenotypes in two large observational cohorts of paediatric ARDS and assess their congruence with prior descriptions.We performed latent class analysis (LCA) separately on two cohorts using biomarkers as inputs. Subphenotypes were compared on clinical characteristics and outcomes. Finally, we assessed overlap with adult cohorts using parsimonious classifiers.In two cohorts from the Children's Hospital of Philadelphia (n=333) and from a multicentre study based at the University of California San Francisco (n=293), LCA identified two subphenotypes defined by differential elevation of biomarkers reflecting inflammation and endotheliopathy. In both cohorts, hyperinflammatory subjects had greater illness severity, more sepsis and higher mortality (41% and 28% in hyperinflammatory vs 11% and 7% in hypoinflammatory). Both cohorts demonstrated overlap with adult subphenotypes when assessed using parsimonious classifiers.We identified hypoinflammatory and hyperinflammatory subphenotypes of paediatric ARDS from two separate cohorts with utility for prognostic and potentially predictive, enrichment. Future paediatric ARDS trials should identify and leverage biomarker-defined subphenotypes in their analysis.

    View details for DOI 10.1136/thorax-2023-220130

    View details for Web of Science ID 001079410300001

    View details for PubMedID 37813544

    View details for PubMedCentralID PMC10850835

  • Elevated Plasma Interleukin-18 Identifies High-Risk Acute Respiratory Distress Syndrome Patients not Distinguished by Prior Latent Class Analyses Using Traditional Inflammatory Cytokines: A Retrospective Analysis of Two Randomized Clinical Trials. Critical care medicine Moore, A. R., Pienkos, S. M., Sinha, P., Guan, J., O'Kane, C. M., Levitt, J. E., Wilson, J. G., Shankar-Hari, M., Matthay, M. A., Calfee, C. S., Baron, R. M., McAuley, D. F., Rogers, A. J. 2023

    Abstract

    Interleukin-18 (IL-18) plasma level and latent class analysis (LCA) have separately been shown to predict prognosis and treatment response in acute respiratory distress syndrome (ARDS). IL-18 is a measure of inflammasome activation, a pathway potentially distinct from inflammation captured by biomarkers defining previously published LCA classes. We hypothesized that elevated IL-18 would identify distinct "high-risk" patients not captured by prior LCA classifications.Statins for acutely injured lungs from sepsis (SAILS) and hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in acute lung injury to reduce pulmonary dysfunction trial (HARP-2) are two large randomized, controlled trials in ARDS in which both LCA assignments and IL-18 levels were shown to predict mortality. We first evaluated the overlap between high IL-18 levels (≥ 800 pg/mL) with prior LCA class assignments using McNemar's test and then tested the correlation between IL-18 and LCA biomarkers using Pearson's exact test on log-2 transformed values. Our primary analysis was the association of IL-18 level with 60-day mortality in the hypoinflammatory LCA class, which was assessed using the Fisher exact test and Cox proportional hazards modeling adjusting for age, Acute Physiology and Chronic Health Evaluation score, and gender. Secondary analyses included the association of IL-18 and LCA with mortality within each IL-18/LCA subgroup.Secondary analysis of two multicenter, randomized controlled clinical trials of ARDS patients.Six hundred eighty-three patients in SAILS and 511 patients in HARP-2.None.We found that 33% of patients in SAILS and HARP-2 were discordant by IL-18 level and LCA class. We further found that IL-18 level was only modestly correlated (0.17-0.47) with cytokines used in the LCA assignment. A substantial subset of individuals classified as hypoinflammatory by LCA (14% of SAILS and 43% of HARP-2) were classified as high risk by elevated IL-18. These individuals were at high risk for mortality in both SAILS (42% 60-d mortality, odds ratio [OR] 3.3; 95% CI, 1.8-6.1; p < 0.001) and HARP-2 (27% 60-d mortality, OR 2.1; 95% CI, 1.2-3.8; p = 0.009).Plasma IL-18 level provides important additional prognostic information to LCA subphenotypes defined largely by traditional inflammatory biomarkers in two large ARDS cohorts.

    View details for DOI 10.1097/CCM.0000000000006028

    View details for PubMedID 37695136

  • Leveraging Data Science and Novel Technologies to Develop and Implement Precision Medicine Strategies in Critical Care CRITICAL CARE CLINICS Sanchez-Pinto, L. N., V. Bhavani, S., Atreya, M. R., Sinha, P. 2023; 39 (4): 627-646

    Abstract

    Precision medicine aims to identify treatments that are most likely to result in favorable outcomes for subgroups of patients with similar clinical and biological characteristics. The gaps for the development and implementation of precision medicine strategies in the critical care setting are many, but the advent of data science and multi-omics approaches, combined with the rich data ecosystem in the intensive care unit, offer unprecedented opportunities to realize the promise of precision critical care. In this article, the authors review the data-driven and technology-based approaches being leveraged to discover and implement precision medicine strategies in the critical care setting.

    View details for DOI 10.1016/j.ccc.2023.03.002

    View details for Web of Science ID 001075246300001

    View details for PubMedID 37704331

  • Subphenotypes Assigned to Pediatric Acute Respiratory Failure Patients Show Differing Outcomes AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE Flori, H. R., Zhang, M., Xie, J., Yang, G., Sapru, A., Calfee, C. S., Delucchi, K. L., Sinha, P., Curley, M. A. Q., Dahmer, M. K., RESTORE Bali Study Investigators, Pediat Acute Lung Injury Sepsis I 2023; 208 (3): 331-333

    View details for DOI 10.1164/rccm.202301-0070LE

    View details for Web of Science ID 001045323700023

    View details for PubMedID 37311208

    View details for PubMedCentralID PMC10395717

  • Advancing specificity in delirium: The delirium subtyping initiative ALZHEIMERS & DEMENTIA Bowman, E. M. L., Brummel, N. E. E., Caplan, G. A. A., Cunningham, C., Evered, L. A. A., Fiest, K. M. M., Girard, T. D. D., Jackson, T. A. A., LaHue, S. C. C., Lindroth, H. L. L., Maclullich, A. M. J., McAuley, D. F. F., Oh, E. S. S., Oldham, M. A. A., Page, V. J. J., Pandharipande, P. P. P., Potter, K. M. M., Sinha, P., Slooter, A. J. C., Sweeney, A. M. M., Tieges, Z., Van Dellen, E., Wilcox, M., Zetterberg, H., Cunningham, E. L. L. 2024; 20 (1): 183-194

    Abstract

    Delirium, a common syndrome with heterogeneous etiologies and clinical presentations, is associated with poor long-term outcomes. Recording and analyzing all delirium equally could be hindering the field's understanding of pathophysiology and identification of targeted treatments. Current delirium subtyping methods reflect clinically evident features but likely do not account for underlying biology.The Delirium Subtyping Initiative (DSI) held three sessions with an international panel of 25 experts.Meeting participants suggest further characterization of delirium features to complement the existing Diagnostic and Statistical Manual of Mental Disorders Fifth Edition Text Revision diagnostic criteria. These should span the range of delirium-spectrum syndromes and be measured consistently across studies. Clinical features should be recorded in conjunction with biospecimen collection, where feasible, in a standardized way, to determine temporal associations of biology coincident with clinical fluctuations.The DSI made recommendations spanning the breadth of delirium research including clinical features, study planning, data collection, and data analysis for characterization of candidate delirium subtypes.Delirium features must be clearly defined, standardized, and operationalized. Large datasets incorporating both clinical and biomarker variables should be analyzed together. Delirium screening should incorporate communication and reasoning.

    View details for DOI 10.1002/alz.13419

    View details for Web of Science ID 001041694200001

    View details for PubMedID 37522255

    View details for PubMedCentralID PMC10917010

  • Estimating the attributable fraction of mortality from acute respiratory distress syndrome to inform enrichment in future randomised clinical trials. Thorax Saha, R., Pham, T., Sinha, P., Maddali, M. V., Bellani, G., Fan, E., Summers, C., Douiri, A., Rubenfeld, G. D., Calfee, C. S., Laffey, J. G., McAuley, D. F., Shankar-Hari, M., LUNG-SAFE investigators, Pesenti, A., Laffey, J. G., Brochard, L., Esteban, A., Gattinoni, L., Haren, F. v., Larsson, A., McAuley, D. F., Ranieri, M., Rubenfeld, G., Taylor Thompson, B., Wrigge, H., Slutsky, A. S., Laffey, J. G., Giacomo, B., Pham, T., Fan, E., Rios, F., Sottiaux, T., Depuydt, P., Lora, F. S., Azevedo, L. C., Fan, E., Bugedo, G., Qiu, H., Gonzalez, M., Silesky, J., Cerny, V., Nielsen, J., Jibaja, M., Pham, T., Wrigge, H., Matamis, D., Ranero, J. L., Amin, P., Hashemian, S. M., Clarkson, K., Bellani, G., Kurahashi, K., Villagomez, A., Zeggwagh, A. A., Heunks, L. M., Laake, J. H., Palo, J. E., Fernandes, A. d., Sandesc, D., Arabi, Y., Bumbasierevic, V., Nin, N., Lorente, J. A., Larsson, A., Piquilloud, L., Abroug, F., McAuley, D. F., McNamee, L., Hurtado, J., Bajwa, E., Dempaire, G. 2023

    Abstract

    BACKGROUND: Efficiency of randomised clinical trials of acute respiratory distress syndrome (ARDS) depends on the fraction of deaths attributable to ARDS (AFARDS) to which interventions are targeted. Estimates of AFARDS in subpopulations of ARDS could improve design of ARDS trials.METHODS: We performed a matched case-control study using the Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE cohort. Primary outcome was intensive care unit mortality. We used nearest neighbour propensity score matching without replacement to match ARDS to non-ARDS populations. We derived two separate AFARDS estimates by matching patients with ARDS to patients with non-acute hypoxaemic respiratory failure (non-AHRF) and to patients with AHRF with unilateral infiltrates only (AHRF-UL). We also estimated AFARDS in subgroups based on severity of hypoxaemia, number of lung quadrants involved and hyperinflammatory versus hypoinflammatory phenotypes. Additionally, we derived AFAHRF estimates by matching patients with AHRF to non-AHRF controls, and AFAHRF-UL estimates by matching patients with AHRF-UL to non-AHRF controls.RESULTS: Estimated AFARDS was 20.9% (95% CI 10.5% to 31.4%) when compared with AHRF-UL controls and 38.0% (95% CI 34.4% to 41.6%) compared with non-AHRF controls. Within subgroups, estimates for AFARDS compared with AHRF-UL controls were highest in patients with severe hypoxaemia (41.1% (95% CI 25.2% to 57.1%)), in those with four quadrant involvement on chest radiography (28.9% (95% CI 13.4% to 44.3%)) and in the hyperinflammatory subphenotype (26.8% (95% CI 6.9% to 46.7%)). Estimated AFAHRF was 33.8% (95% CI 30.5% to 37.1%) compared with non-AHRF controls. Estimated AFAHRF-UL was 21.3% (95% CI 312.8% to 29.7%) compared with non-AHRF controls.CONCLUSIONS: Overall AFARDS mean values were between 20.9% and 38.0%, with higher AFARDS seen with severe hypoxaemia, four quadrant involvement on chest radiography and hyperinflammatory ARDS.

    View details for DOI 10.1136/thorax-2023-220262

    View details for PubMedID 37495364

  • Individualized Treatment Effects of Bougie versus Stylet for Tracheal Intubation in Critical Illness AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE Seitz, K. P., Spicer, A. B., Casey, J. D., Buell, K. G., Qian, E. T., Linck, E., Driver, B. E., Self, W. H., Ginde, A. A., Trent, S. A., Gandotra, S., Smith, L. M., Page, D. B., Vonderhaar, D. J., West, J. R., Joffe, A. M., Doerschug, K. C., Hughes, C. G., Whitson, M. R., Prekker, M. E., Rice, T. W., Sinha, P., Semler, M. W., Churpek, M. M. 2023; 207 (12): 1602-1611

    Abstract

    Rationale: A recent randomized trial found that using a bougie did not increase the incidence of successful intubation on first attempt in critically ill adults. The average effect of treatment in a trial population, however, may differ from effects for individuals. Objective: We hypothesized that application of a machine learning model to data from a clinical trial could estimate the effect of treatment (bougie vs. stylet) for individual patients based on their baseline characteristics ("individualized treatment effects"). Methods: This was a secondary analysis of the BOUGIE (Bougie or Stylet in Patients Undergoing Intubation Emergently) trial. A causal forest algorithm was used to model differences in outcome probabilities by randomized group assignment (bougie vs. stylet) for each patient in the first half of the trial (training cohort). This model was used to predict individualized treatment effects for each patient in the second half (validation cohort). Measurements and Main Results: Of 1,102 patients in the BOUGIE trial, 558 (50.6%) were the training cohort, and 544 (49.4%) were the validation cohort. In the validation cohort, individualized treatment effects predicted by the model significantly modified the effect of trial group assignment on the primary outcome (P value for interaction = 0.02; adjusted qini coefficient, 2.46). The most important model variables were difficult airway characteristics, body mass index, and Acute Physiology and Chronic Health Evaluation II score. Conclusions: In this hypothesis-generating secondary analysis of a randomized trial with no average treatment effect and no treatment effect in any prespecified subgroups, a causal forest machine learning algorithm identified patients who appeared to benefit from the use of a bougie over a stylet and from the use of a stylet over a bougie using complex interactions between baseline patient and operator characteristics.

    View details for DOI 10.1164/rccm.202209-1799OC

    View details for Web of Science ID 001006213300013

    View details for PubMedID 36877594

    View details for PubMedCentralID PMC10273111

  • Tight Glycemic Control, Inflammation, and the ICU: Evidence for Heterogeneous Treatment Effects in Two Randomized Controlled Trials AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE Zinter, M. S., Markovic, D., Asaro, L. A., Nadkarni, V. M., McQuillen, P. S., Sinha, P., Matthay, M. A., Jeschke, M. G., Agus, M. S. D., Sapru, A., PALISI Network 2023; 207 (7): 945-949

    View details for DOI 10.1164/rccm.202210-1988LE

    View details for Web of Science ID 000964287500026

    View details for PubMedID 36656551

    View details for PubMedCentralID PMC10111993

  • Are There Distinct Cardiovascular Subclasses in Acute Respiratory Distress Syndrome? Maybe CRITICAL CARE MEDICINE Sinha, P., Lawler, P. R. 2023; 51 (4): 546-549

    View details for DOI 10.1097/CCM.0000000000005816

    View details for Web of Science ID 000952806700016

    View details for PubMedID 36928014

  • Ultrasensitive lateral-flow assays via plasmonically active antibody-conjugated fluorescent nanoparticles NATURE BIOMEDICAL ENGINEERING Gupta, R., Gupta, P., Wang, S., Melnykov, A., Jiang, Q., Seth, A., Wang, Z., Morrissey, J. J., George, I., Gandra, S., Sinha, P., Storch, G. A., Parikh, B. A., Genin, G. M., Singamaneni, S. 2023; 7 (12): 1556-+

    Abstract

    Lateral-flow assays (LFAs) are rapid and inexpensive, yet they are nearly 1,000-fold less sensitive than laboratory-based tests. Here we show that plasmonically active antibody-conjugated fluorescent gold nanorods can make conventional LFAs ultrasensitive. With sample-to-answer times within 20 min, plasmonically enhanced LFAs read out via a standard benchtop fluorescence scanner attained about 30-fold improvements in dynamic range and in detection limits over 4-h-long gold-standard enzyme-linked immunosorbent assays, and achieved 95% clinical sensitivity and 100% specificity for antibodies in plasma and for antigens in nasopharyngeal swabs from individuals with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Comparable improvements in the assay's performance can also be achieved via an inexpensive portable scanner, as we show for the detection of interleukin-6 in human serum samples and of the nucleocapsid protein of SARS-CoV-2 in nasopharyngeal samples. Plasmonically enhanced LFAs outperform standard laboratory tests in sensitivity, speed, dynamic range, ease of use and cost, and may provide advantages in point-of-care diagnostics.

    View details for DOI 10.1038/s41551-022-01001-1

    View details for Web of Science ID 000941080900001

    View details for PubMedID 36732621

    View details for PubMedCentralID PMC12723709

  • Plasma metabolic profiling implicates dysregulated lipid metabolism and glycolytic shift in hyperinflammatory ARDS. American journal of physiology. Lung cellular and molecular physiology Alipanah-Lechner, N., Neyton, L., Mick, E., Willmore, A., Leligdowicz, A., Contrepois, K., Jauregui, A., Zhuo, H., Hendrickson, C., Gomez, A., Sinha, P., Kangelaris, K. N., Liu, K. D., Matthay, M. A., Rogers, A. J., Calfee, C. S. 2023

    Abstract

    Using latent class analysis (LCA) of clinical and protein biomarkers, researchers have identified two phenotypes of the acute respiratory distress syndrome (ARDS) with divergent clinical trajectories and treatment responses. We investigated whether plasma metabolites differed amongst patients with LCA-derived hyperinflammatory and hypoinflammatory ARDS, and tested the prognostic utility of adding metabolic clusters to LCA phenotypes. We analyzed data from 93 ARDS patients with sepsis enrolled in a multi-center prospective cohort of critically ill patients, comparing 970 metabolites between the two LCA-derived phenotypes. 188 metabolites were differentially abundant between the two LCA-derived phenotypes. After adjusting for age, sex, confounding medications, and comorbid liver and kidney disease, 82 metabolites remained significantly different. Hyperinflammatory ARDS patients had reduced circulating lipids but high levels of pyruvate, lactate, and malate. Metabolic cluster and LCA-derived phenotypes were each significantly and independently associated with survival. Hyperinflammatory ARDS patients may be experiencing a glycolytic shift leading to dysregulated lipid metabolism. Metabolic profiling offers prognostic information beyond what is captured by LCA phenotypes alone. Deeper biologic profiling may identify key differences in pathogenesis among patients with ARDS and lead to novel targeted therapies.

    View details for DOI 10.1152/ajplung.00278.2022

    View details for PubMedID 36648136

  • Biological Phenotyping in Sepsis and Acute Respiratory Distress Syndrome ANNUAL REVIEW OF MEDICINE Sinha, P., Meyer, N. J., Calfee, C. S. 2023; 74: 457-471

    Abstract

    Heterogeneity in sepsis and acute respiratory distress syndrome (ARDS) is increasingly being recognized as one of the principal barriers to finding efficacious targeted therapies. The advent of multiple high-throughput biological data ("omics"), coupled with the widespread access to increased computational power, has led to the emergence of phenotyping in critical care. Phenotyping aims to use a multitude of data to identify homogenous subgroups within an otherwise heterogenous population. Increasingly, phenotyping schemas are being applied to sepsis and ARDS to increase understanding of these clinical conditions and identify potential therapies. Here we present a selective review of the biological phenotyping schemas applied to sepsis and ARDS. Further, we outline some of the challenges involved in translating these conceptual findings to bedside clinical decision-making tools.

    View details for DOI 10.1146/annurev-med-043021-014005

    View details for Web of Science ID 000920258800032

    View details for PubMedID 36469902

    View details for PubMedCentralID PMC10617629

  • IDENTIFICATION OF MOLECULAR ENDOTYPES IN TWO COHORTS OF PEDIATRIC ARDS Yehya, N., Zinter, M., Thompson, J., Lim, M., Hanudel, M., Alkhouli, M., Alder, M., McKeone, D., Halstead, E., Sinha, P., Sapru, A. LIPPINCOTT WILLIAMS & WILKINS. 2023: 12
  • Multistate Modeling of Clinical Trajectories and Outcomes in the ICU: A Proof-of- Concept Evaluation of Acute Kidney Injury Among Critically Ill Patients With COVID-19 CRITICAL CARE EXPLORATIONS Lyons, P. G., Mody, A., Bewley, A. F., Schoer, M., Raju, B., Geng, E., Payne, P. R. O., Sinha, P., Vijayan, A. 2022; 4 (12)
  • Multistate Modeling of Clinical Trajectories and Outcomes in the ICU: A Proof-of-Concept Evaluation of Acute Kidney Injury Among Critically Ill Patients With COVID-19. Critical care explorations Lyons, P. G., Mody, A., Bewley, A. F., Schoer, M., Neelam Raju, B., Geng, E., Payne, P. R., Sinha, P., Vijayan, A. 2022; 4 (12): e0784

    Abstract

    Multistate models yield high-fidelity analyses of the dynamic state transition and temporal dimensions of a clinical condition's natural history, offering superiority over aggregate modeling techniques for addressing these types of problems.To demonstrate the utility of these models in critical care, we examined acute kidney injury (AKI) development, progression, and outcomes in COVID-19 critical illness through multistate analyses.Retrospective cohort study at an urban tertiary-care academic hospital in the United States. All patients greater than or equal to 18 years in an ICU with COVID-19 in 2020, excluding patients with preexisting end-stage renal disease.Using electronic health record data, we determined AKI presence/stage in discrete 12-hour time windows and fit multistate models to determine longitudinal transitions and outcomes.Of 367 encounters, 241 (66%) experienced AKI (maximal stages: 88 stage-1, 49 stage-2, 104 stage-3 AKI [51 received renal replacement therapy (RRT), 53 did not]). Patients receiving RRT overwhelmingly received invasive mechanical ventilation (IMV) (n = 60, 95%) compared with the AKI-without-RRT (n = 98, 53%) and no-AKI groups (n = 39, 32%; p < 0.001), with similar mortality patterns (RRT: n = 36, 57%; AKI: n = 74, 40%; non-AKI: n = 23, 19%; p < 0.001). After 24 hours in the ICU, almost half the cohort had AKI (44.9%; 95% CI, 41.6-48.2%). At 7 days after stage-1 AKI, 74.0% (63.6-84.4) were AKI-free or discharged. By contrast, fewer patients experiencing stage-3 AKI were recovered (30.0% [24.1-35.8%]) or discharged (7.9% [5.2-10.7%]) after 7 days. Early AKI occurred with similar frequency in patients receiving and not receiving IMV: after 24 hours in the ICU, 20.9% of patients (18.3-23.6%) had AKI and IMV, while 23.4% (20.6-26.2%) had AKI without IMV.In a multistate analysis of critically ill patients with COVID-19, AKI occurred early and heterogeneously in the course of critical illness. Multistate methods are useful and underused in ICU care delivery science as tools for understanding trajectories, prognoses, and resource needs.

    View details for DOI 10.1097/CCE.0000000000000784

    View details for PubMedID 36479445

    View details for PubMedCentralID PMC9722556

  • Integrated host-microbe plasma metagenomics for sepsis diagnosis in a prospective cohort of critically ill adults NATURE MICROBIOLOGY Kalantar, K. L., Neyton, L., Abdelghany, M., Mick, E., Jauregui, A., Caldera, S., Serpa, P., Ghale, R., Albright, J., Sarma, A., Tsitsiklis, A., Leligdowicz, A., Christenson, S. A., Liu, K., Kangelaris, K. N., Hendrickson, C., Sinha, P., Gomez, A., Neff, N., Pisco, A., Doernberg, S. B., Derisi, J. L., Matthay, M. A., Calfee, C. S., Langelier, C. R. 2022; 7 (11): 1805-+

    Abstract

    We carried out integrated host and pathogen metagenomic RNA and DNA next generation sequencing (mNGS) of whole blood (n = 221) and plasma (n = 138) from critically ill patients following hospital admission. We assigned patients into sepsis groups on the basis of clinical and microbiological criteria. From whole-blood gene expression data, we distinguished patients with sepsis from patients with non-infectious systemic inflammatory conditions using a trained bagged support vector machine (bSVM) classifier (area under the receiver operating characteristic curve (AUC) = 0.81 in the training set; AUC = 0.82 in a held-out validation set). Plasma RNA also yielded a transcriptional signature of sepsis with several genes previously reported as sepsis biomarkers, and a bSVM sepsis diagnostic classifier (AUC = 0.97 training set; AUC = 0.77 validation set). Pathogen detection performance of plasma mNGS varied on the basis of pathogen and site of infection. To improve detection of virus, we developed a secondary transcriptomic classifier (AUC = 0.94 training set; AUC = 0.96 validation set). We combined host and microbial features to develop an integrated sepsis diagnostic model that identified 99% of microbiologically confirmed sepsis cases, and predicted sepsis in 74% of suspected and 89% of indeterminate sepsis cases. In summary, we suggest that integrating host transcriptional profiling and broad-range metagenomic pathogen detection from nucleic acid is a promising tool for sepsis diagnosis.

    View details for DOI 10.1038/s41564-022-01237-2

    View details for Web of Science ID 000870624300005

    View details for PubMedID 36266337

    View details for PubMedCentralID PMC9613463

  • Hospital trajectories and early predictors of clinical outcomes differ between SARS-CoV-2 and influenza pneumonia EBIOMEDICINE Lyons, P. G., V. Bhavani, S., Mody, A., Bewley, A., Dittman, K., Doyle, A., Windham, S. L., Patel, T. M., Raju, B., Keller, M., Churpek, M. M., Calfee, C. S., Michelson, A. P., Kannampallil, T., Geng, E. H., Sinha, P. 2022; 85: 104295

    Abstract

    A comparison of pneumonias due to SARS-CoV-2 and influenza, in terms of clinical course and predictors of outcomes, might inform prognosis and resource management. We aimed to compare clinical course and outcome predictors in SARS-CoV-2 and influenza pneumonia using multi-state modelling and supervised machine learning on clinical data among hospitalised patients.This multicenter retrospective cohort study of patients hospitalised with SARS-CoV-2 (March-December 2020) or influenza (Jan 2015-March 2020) pneumonia had the composite of hospital mortality and hospice discharge as the primary outcome. Multi-state models compared differences in oxygenation/ventilatory utilisation between pneumonias longitudinally throughout hospitalisation. Differences in predictors of outcome were modelled using supervised machine learning classifiers.Among 2,529 hospitalisations with SARS-CoV-2 and 2,256 with influenza pneumonia, the primary outcome occurred in 21% and 9%, respectively. Multi-state models differentiated oxygen requirement progression between viruses, with SARS-CoV-2 manifesting rapidly-escalating early hypoxemia. Highly contributory classifier variables for the primary outcome differed substantially between viruses.SARS-CoV-2 and influenza pneumonia differ in presentation, hospital course, and outcome predictors. These pathogen-specific differential responses in viral pneumonias suggest distinct management approaches should be investigated.This project was supported by NIH/NCATS UL1 TR002345, NIH/NCATS KL2 TR002346 (PGL), the Doris Duke Charitable Foundation grant 2015215 (PGL), NIH/NHLBI R35 HL140026 (CSC), and a Big Ideas Award from the BJC HealthCare and Washington University School of Medicine Healthcare Innovation Lab and NIH/NIGMS R35 GM142992 (PS).

    View details for DOI 10.1016/j.ebiom.2022.104295

    View details for Web of Science ID 000884781500012

    View details for PubMedID 36202054

    View details for PubMedCentralID PMC9527494

  • The prognostic value of early measures of the ventilatory ratio in the ARDS ROSE trial CRITICAL CARE Monteiro, A., Vangala, S., Wick, K. D., Delucchi, K. L., Siegel, E. R., Thompson, B., Liu, K. D., Sapru, A., Sinha, P., Matthay, M. A., NHLBI PETAL Network 2022; 26 (1): 297

    Abstract

    The ventilatory ratio (VR, [minute ventilation × PaCO2]/[predicted body weight × 100 × 37.5]) is associated with mortality in ARDS. The aims of this study were to test whether baseline disease severity or neuromuscular blockade (NMB) modified the relationship between VR and mortality.This was a post hoc analysis of the PETAL-ROSE trial, which randomized moderate-to-severe ARDS patients to NMB or control. Survival among patients with different VR trajectories or VR cutoff above and below the median was assessed by Kaplan-Meier analysis. The relationships between single-day or 48-h VR trajectories with 28- or 90-day mortality were tested by logistic regression. Randomization allocation to NMB and markers of disease severity were tested as confounders by multivariable regression and interaction term analyses.Patients with worsening VR trajectories had significantly lower survival compared to those with improving VR (n = 602, p < 0.05). Patients with VR > 2 (median) at day 1 had a significantly lower 90-day survival compared to patients with VR ≤ 2 (HR 1.36, 95% CI 1.10-1.69). VR at day 1 was significantly associated with 28-day mortality (OR = 1.40, 95% CI 1.15-1.72). There was no interaction between NMB and VR for 28-day mortality. APACHE-III had a significant interaction with VR at baseline for the outcome of 28-day mortality, such that the relationship between VR and mortality was stronger among patients with lower APACHE-III. There was a significant association between rising VR trajectory and mortality that was independent of NMB, baseline PaO2/FiO2 ratio and generalized markers of disease severity (Adjusted OR 1.81, 95% CI 1.28-2.84 for 28-day and OR 2.07 95% CI 1.41-3.10 for 90-day mortality). APACHE-III and NMB were not effect modifiers in the relationship between VR trajectory and mortality.Elevated baseline and day 1 VR were associated with higher 28-day mortality. The relationship between baseline VR and mortality was stronger among patients with lower APACHE-III. APACHE-III was not an effect modifier for the relationship between VR trajectory and mortality, so that the VR trajectory may be optimally suited for prognostication and predictive enrichment. VR was not different between patients randomized to NMB or control, indicating that VR can be utilized without correcting for NMB.

    View details for DOI 10.1186/s13054-022-04179-7

    View details for Web of Science ID 000861876500001

    View details for PubMedID 36175982

    View details for PubMedCentralID PMC9521854

  • Plasma SARS-CoV-2 nucleocapsid antigen levels are associated with progression to severe disease in hospitalized COVID-19 CRITICAL CARE Wick, K. D., Leligdowicz, A., Willmore, A., Carrillo, S. A., Ghale, R., Jauregui, A., Chak, S. S., Viet Nguyen, Lee, D., Jones, C., Dewar, R., Lane, H., Kangelaris, K. N., Hendrickson, C. M., Liu, K. D., Sinha, P., Erle, D. J., Langelier, C. R., Krummell, M. F., Woodruff, P. G., Calfee, C. S., Matthay, M. A., COMET Consortium 2022; 26 (1): 278

    Abstract

    Studies quantifying SARS-CoV-2 have focused on upper respiratory tract or plasma viral RNA with inconsistent association with clinical outcomes. The association between plasma viral antigen levels and clinical outcomes has not been previously studied. Our aim was to investigate the relationship between plasma SARS-CoV-2 nucleocapsid antigen (N-antigen) concentration and both markers of host response and clinical outcomes.SARS-CoV-2 N-antigen concentrations were measured in the first study plasma sample (D0), collected within 72 h of hospital admission, from 256 subjects admitted between March 2020 and August 2021 in a prospective observational cohort of hospitalized patients with COVID-19. The rank correlations between plasma N-antigen and plasma biomarkers of tissue damage, coagulation, and inflammation were assessed. Multiple ordinal regression was used to test the association between enrollment N-antigen plasma concentration and the primary outcome of clinical deterioration at one week as measured by a modified World Health Organization (WHO) ordinal scale. Multiple logistic regression was used to test the association between enrollment plasma N-antigen concentration and the secondary outcomes of ICU admission, mechanical ventilation at 28 days, and death at 28 days. The prognostic discrimination of an externally derived "high antigen" cutoff of N-antigen ≥ 1000 pg/mL was also tested.N-antigen on D0 was detectable in 84% of study participants. Plasma N-antigen levels significantly correlated with RAGE (r = 0.61), IL-10 (r = 0.59), and IP-10 (r = 0.59, adjusted p = 0.01 for all correlations). For the primary outcome of clinical status at one week, each 500 pg/mL increase in plasma N-antigen level was associated with an adjusted OR of 1.05 (95% CI 1.03-1.08) for worse WHO ordinal status. D0 plasma N-antigen ≥ 1000 pg/mL was 77% sensitive and 59% specific (AUROC 0.68) with a positive predictive value of 23% and a negative predictive value of 93% for a worse WHO ordinal scale at day 7 compared to baseline. D0 N-antigen concentration was independently associated with ICU admission and 28-day mechanical ventilation, but not with death at 28 days.Plasma N-antigen levels are readily measured and provide important insight into the pathogenesis and prognosis of COVID-19. The measurement of N-antigen levels early in-hospital course may improve risk stratification, especially for identifying patients who are unlikely to progress to severe disease.

    View details for DOI 10.1186/s13054-022-04153-3

    View details for Web of Science ID 000853905900001

    View details for PubMedID 36104754

    View details for PubMedCentralID PMC9472195

  • Ventilatory Ratio Is a Valuable Prognostic Indicator in an Observational Cohort of Patients With ARDS RESPIRATORY CARE Siegel, E. R., Zhuo, H., Sinha, P., Papolos, A., Ni, S. A., Vessel, K., Belzer, A., Minus, E. B., Calfee, C. S., Matthay, M. A., Wick, K. D. 2022; 67 (9): 1075-1081

    Abstract

    How indices specific to respiratory compromise contribute to prognostication in patients with ARDS is not well characterized in general clinical populations. The primary objective of this study was to identify variables specific to respiratory failure that might add prognostic value to indicators of systemic illness severity in an observational cohort of subjects with ARDS.Fifty subjects with ARDS were enrolled in a single-center, prospective, observational cohort. We tested the contribution of respiratory variables (oxygenation index, ventilatory ratio [VR], and the radiographic assessment of lung edema score) to logistic regression models of 28-d mortality adjusted for indicators of systemic illness severity (the Acute Physiology and Chronic Health Evaluation [APACHE] III score or severity of shock as measured by the number of vasopressors required at baseline) using likelihood ratio testing. We also compared a model utilizing APACHE III with one including baseline number of vasopressors by comparing the area under the receiver operating curve (AUROC).VR significantly improved model performance by likelihood ratio testing when added to APACHE III (P = .036) or the number of vasopressors at baseline (P = .01). Number of vasopressors required at baseline had similar prognostic discrimination to the APACHE III. A model including the number of vasopressors and VR (AUROC 0.77 [95% CI 0.64-0.90]) was comparable to a model including APACHE III and VR (AUROC 0.81 [95% CI 0.68-0.93]; P for comparison = .58.).In this observational cohort of subjects with ARDS, the VR significantly improved discrimination for mortality when combined with indicators of severe systemic illness. The number of vasopressors required at baseline and APACHE III had similar discrimination for mortality when combined with VR. VR is easily obtained at the bedside and offers promise for clinical prognostication.

    View details for DOI 10.4187/respcare.09854

    View details for Web of Science ID 000848665300002

    View details for PubMedID 35641002

    View details for PubMedCentralID PMC9994339

  • Opportunities for improved clinical trial designs in acute respiratory distress syndrome. The Lancet. Respiratory medicine Wick, K. D., Aggarwal, N. R., Curley, M. A., Fowler, A. A., Jaber, S., Kostrubiec, M., Lassau, N., Laterre, P. F., Lebreton, G., Levitt, J. E., Mebazaa, A., Rubin, E., Sinha, P., Ware, L. B., Matthay, M. A. 2022; 10 (9): 916-924

    Abstract

    The acute respiratory distress syndrome (ARDS) is a common critical illness syndrome with high morbidity and mortality. There are no proven pharmacological therapies for ARDS. The current definition of ARDS is based on shared clinical characteristics but does not capture the heterogeneity in clinical risk factors, imaging characteristics, physiology, timing of onset and trajectory, and biology of the syndrome. There is increasing interest within the ARDS clinical trialist community to design clinical trials that reduce heterogeneity in the trial population. This effort must be balanced with ongoing work to craft an inclusive, global definition of ARDS, with important implications for trial design. Ultimately, the two aims-to design trials that are applicable to the diverse global ARDS population while also advancing opportunities to identify targetable traits-should coexist. In this Personal View, we recommend two primary strategies to improve future ARDS trials: the development of new methods to target treatable traits in clinical trial populations, and improvements in the representativeness of ARDS trials, with the inclusion of global populations. We emphasise that these two strategies are complementary. We also discuss how a proposed expansion of the definition of ARDS could affect the future of clinical trials.

    View details for DOI 10.1016/S2213-2600(22)00294-6

    View details for PubMedID 36057279

  • Opportunities for improved clinical trial designs in acute respiratory distress syndrome LANCET RESPIRATORY MEDICINE Wick, K. D., Aggarwal, N. R., Curley, M. A. Q., Fowler, A. A., Jaber, S., Kostrubiec, M., Lassau, N., Laterre, P., Lebreton, G., Levitt, J. E., Mebazaa, A., Rubin, E., Sinha, P., Ware, L. B., Matthay, M. A. 2022; 10 (9): 916-924
  • Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: Results from the IMPACC study. EBioMedicine Ozonoff, A., Schaenman, J., Jayavelu, N. D., Milliren, C. E., Calfee, C. S., Cairns, C. B., Kraft, M., Baden, L. R., Shaw, A. C., Krammer, F., van Bakel, H., Esserman, D. A., Liu, S., Sesma, A. F., Simon, V., Hafler, D. A., Montgomery, R. R., Kleinstein, S. H., Levy, O., Bime, C., Haddad, E. K., Erle, D. J., Pulendran, B., Nadeau, K. C., Davis, M. M., Hough, C. L., Messer, W. B., Higuita, N. I., Metcalf, J. P., Atkinson, M. A., Brakenridge, S. C., Corry, D., Kheradmand, F., Ehrlich, L. I., Melamed, E., McComsey, G. A., Sekaly, R., Diray-Arce, J., Peters, B., Augustine, A. D., Reed, E. F., Altman, M. C., Becker, P. M., Rouphael, N. 2022; 83: 104208

    Abstract

    Better understanding of the association between characteristics of patients hospitalized with coronavirus disease 2019 (COVID-19) and outcome is needed to further improve upon patient management.Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) is a prospective, observational study of 1164 patients from 20 hospitals across the United States. Disease severity was assessed using a 7-point ordinal scale based on degree of respiratory illness. Patients were prospectively surveyed for 1 year after discharge for post-acute sequalae of COVID-19 (PASC) through quarterly surveys. Demographics, comorbidities, radiographic findings, clinical laboratory values, SARS-CoV-2 PCR and serology were captured over a 28-day period. Multivariable logistic regression was performed.The median age was 59 years (interquartile range [IQR] 20); 711 (61%) were men; overall mortality was 14%, and 228 (20%) required invasive mechanical ventilation. Unsupervised clustering of ordinal score over time revealed distinct disease course trajectories. Risk factors associated with prolonged hospitalization or death by day 28 included age ≥ 65 years (odds ratio [OR], 2.01; 95% CI 1.28-3.17), Hispanic ethnicity (OR, 1.71; 95% CI 1.13-2.57), elevated baseline creatinine (OR 2.80; 95% CI 1.63- 4.80) or troponin (OR 1.89; 95% 1.03-3.47), baseline lymphopenia (OR 2.19; 95% CI 1.61-2.97), presence of infiltrate by chest imaging (OR 3.16; 95% CI 1.96-5.10), and high SARS-CoV2 viral load (OR 1.53; 95% CI 1.17-2.00). Fatal cases had the lowest ratio of SARS-CoV-2 antibody to viral load levels compared to other trajectories over time (p=0.001). 589 survivors (51%) completed at least one survey at follow-up with 305 (52%) having at least one symptom consistent with PASC, most commonly dyspnea (56% among symptomatic patients). Female sex was the only associated risk factor for PASC.Integration of PCR cycle threshold, and antibody values with demographics, comorbidities, and laboratory/radiographic findings identified risk factors for 28-day outcome severity, though only female sex was associated with PASC. Longitudinal clinical phenotyping offers important insights, and provides a framework for immunophenotyping for acute and long COVID-19.NIH.

    View details for DOI 10.1016/j.ebiom.2022.104208

    View details for PubMedID 35952496

  • Towards a biological definition of ARDS: are treatable traits the solution? INTENSIVE CARE MEDICINE EXPERIMENTAL Bos, L. D. J., Laffey, J. G., Ware, L. B., Heijnen, N. F. L., Sinha, P., Patel, B., Jabaudon, M., Bastarache, J. A., McAuley, D. F., Summers, C., Calfee, C. S., Shankar-Hari, M. 2022; 10 (1)
  • Towards a biological definition of ARDS: are treatable traits the solution? Intensive care medicine experimental Bos, L. D., Laffey, J. G., Ware, L. B., Heijnen, N. F., Sinha, P., Patel, B., Jabaudon, M., Bastarache, J. A., McAuley, D. F., Summers, C., Calfee, C. S., Shankar-Hari, M. 2022; 10 (1): 8

    Abstract

    The pathophysiology of acute respiratory distress syndrome (ARDS) includes the accumulation of protein-rich pulmonary edema in the air spaces and interstitial areas of the lung, variable degrees of epithelial injury, variable degrees of endothelial barrier disruption, transmigration of leukocytes, alongside impaired fluid and ion clearance. These pathophysiological features are different between patients contributing to substantial biological heterogeneity. In this context, it is perhaps unsurprising that a wide range of pharmacological interventions targeting these pathophysiological processes have failed to improve patient outcomes. In this manuscript, our goal is to provide a narrative summary of the potential methods to capture the underlying biological heterogeneity of ARDS and discuss how this information could inform future ARDS redefinitions. We discuss what biological tests are available to identify patients with any of the following predominant biological patterns: (1) epithelial and/or endothelial injury, (2) protein rich pulmonary edema and (3) systemic or within lung inflammatory responses.

    View details for DOI 10.1186/s40635-022-00435-w

    View details for PubMedID 35274164

    View details for PubMedCentralID PMC8913033

  • Identification of phenotypes in paediatric patients with acute respiratory distress syndrome: a latent class analysis LANCET RESPIRATORY MEDICINE Dahmer, M. K., Yang, G., Zhang, M., Quasney, M. W., Sapru, A., Weeks, H. M., Sinha, P., Curley, M. A. Q., Delucchi, K. L., Calfee, C. S., Flori, H., RESTORE BALI Study Investigators P 2022; 10 (3): 289-297

    Abstract

    Previous latent class analysis of adults with acute respiratory distress syndrome (ARDS) identified two phenotypes, distinguished by the degree of inflammation. We aimed to identify phenotypes in children with ARDS in whom developmental differences might be important, using a latent class analysis approach similar to that used in adults.This study was a secondary analysis of data aggregated from the Randomized Evaluation of Sedation Titration for Respiratory Failure (RESTORE) clinical trial and the Genetic Variation and Biomarkers in Children with Acute Lung Injury (BALI) ancillary study. We used latent class analysis, which included demographic, clinical, and plasma biomarker variables, to identify paediatric ARDS (PARDS) phenotypes within a cohort of children included in the RESTORE and BALI studies. The association of phenotypes with clinically relevant outcomes and the performance of paediatric data in adult ARDS classification algorithms were also assessed.304 children with PARDS were included in this secondary analysis. Using latent class analysis, a two-class model was a better fit for the cohort than a one-class model (p<0·001). Latent class analysis identified two classes: class 1 (181 [60%] of 304 patients with PARDS) and class 2 (123 [40%] of 304 patients with PARDS), referred to as phenotype 1 and 2 hereafter. Phenotype 2 was characterised by higher concentrations of inflammatory biomarkers, a higher incidence of vasopressor use, and more frequent diagnosis of sepsis, consistent with the adult hyperinflammatory phenotype. All levels of severity of PARDS were observed across both phenotypes. Children with the hyperinflammatory phenotype (phenotype 2) had worse clinical outcomes than those with the hypoinflammatory phenotype (phenotype 1), with a longer duration of mechanical ventilation (median 10·0 days [IQR 6·3-21·0] for phenotype 2 vs 6·6 days [4·1-10·8] for phenotype 1, p<0·0001), and higher incidence of mortality (17 [13·8%] of 123 patients vs four [2·2%] of 181 patients, p=0·0001). When using adult phenotype classification algorithms in children, the soluble tumour necrosis factor receptor-1 (sTNFr1), vasopressor use, and interleukin (IL)-6 variables gave an area under the curve (AUC) of 0·956, and the sTNFr1, vasopressor use, and IL-8 variables gave an AUC of 0·954, compared with the gold standard of latent class analysis.Latent class analysis identified two phenotypes in children with ARDS with characteristics similar to those in adults, including worse outcomes among patients with the hyperinflammatory phenotype. PARDS phenotypes should be considered in design and analysis of future clinical trials in children.US National Institutes of Health.

    View details for DOI 10.1016/S2213-2600(21)00382

    View details for Web of Science ID 000764892500019

    View details for PubMedID 34883088

    View details for PubMedCentralID PMC8897230

  • Time to Tailor the One-Size-Fits-All Approach? Reply AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE Furfaro, D. M., Sinha, P., Calfee, C. S., Brodie, D., O'Donnell, M. R. 2022; 205 (4): 480-+
  • Reply to Kuindersma and Spronk: Time to Tailor the One-Size-Fits-All Approach? American journal of respiratory and critical care medicine Furfaro, D. M., Sinha, P., Calfee, C. S., Brodie, D., O'Donnell, M. R. 2022; 205 (4): 480-481

    View details for DOI 10.1164/rccm.202111-2488LE

    View details for PubMedID 34818142

    View details for PubMedCentralID PMC8886940

  • Cutting the Gordian knot of heterogeneity: Can integrated systems biology modelling rescue critical care syndromes? EBioMedicine Maddali, M. V., Sinha, P. 2022; 77: 103884

    View details for DOI 10.1016/j.ebiom.2022.103884

    View details for PubMedID 35176550

  • Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis. The Lancet. Respiratory medicine Maddali, M. V., Churpek, M., Pham, T., Rezoagli, E., Zhuo, H., Zhao, W., He, J., Delucchi, K. L., Wang, C., Wickersham, N., McNeil, J. B., Jauregui, A., Ke, S., Vessel, K., Gomez, A., Hendrickson, C. M., Kangelaris, K. N., Sarma, A., Leligdowicz, A., Liu, K. D., Matthay, M. A., Ware, L. B., Laffey, J. G., Bellani, G., Calfee, C. S., Sinha, P., LUNG SAFE Investigators and the ESICM Trials Group, Rios, F., Van Haren, F., Sottiaux, T., Lora, F. S., Azevedo, L. C., Depuydt, P., Fan, E., Bugedo, G., Qiu, H., Gonzalez, M., Silesky, J., Cerny, V., Nielsen, J., Jibaja, M., Pham, T., Wrigge, H., Matamis, D., Ranero, J. L., Hashemian, S. M., Amin, P., Clarkson, K., Bellani, G., Kurahashi, K., Villagomez, A., Zeggwagh, A. A., Heunks, L. M., Laake, J. H., Palo, J. E., do Vale Fernandes, A., Sandesc, D., Arabi, Y., Bumbasierevic, V., Nin, N., Lorente, J. A., Larsson, A., Piquilloud, L., Abroug, F., McAuley, D. F., McNamee, L., Hurtado, J., Bajwa, E., Dempaire, G., Francois, G. M., Sula, H., Nunci, L., Cani, A., Zazu, A., Dellera, C., Insaurralde, C. S., Alejandro, R. V., Daldin, J., Vinzio, M., Fernandez, R. O., Cardonnet, L. P., Bettini, L. R., Bisso, M. C., Osman, E. M., Setten, M. G., Lovazzano, P., Alvarez, J., Villar, V., Milstein, C., Pozo, N. C., Grubissich, N., Plotnikow, G. A., Vasquez, D. N., Ilutovich, S., Tiribelli, N., Chena, A., Pellegrini, C. A., Saenz, M. G., Estenssoro, E., Brizuela, M., Gianinetto, H., Gomez, P. E., Cerrato, V. I., Bezzi, M. G., Borello, S. A., Loiacono, F. A., Fernandez, A. M., Knowles, S., Reynolds, C., Inskip, D. M., Miller, J. J., Kong, J., Whitehead, C., Bihari, S., Seven, A., Krstevski, A., Rodgers, H. J., Millar, R. T., Mckenna, T. E., Bailey, I. M., Hanlon, G. C., Aneman, A., Lynch, J. M., Azad, R., Neal, J., Woods, P. W., Roberts, B. L., Kol, M. R., Wong, H. S., Riss, K. C., Staudinger, T., Wittebole, X., Berghe, C., Bulpa, P. A., Dive, A. M., Verstraete, R., Lebbinck, H., Depuydt, P., Vermassen, J., Meersseman, P., Ceunen, H., Rosa, J. I., Beraldo, D. O., Piras, C., Ampinelli, A. M., Nassar, A. P., Mataloun, S., Moock, M., Thompson, M. M., Goncalves, C. H., Antonio, A. C., Ascoli, A., Biondi, R. S., Fontenele, D. C., Nobrega, D., Sales, V. M., Shindhe, S., Ismail, D. M., Laffey, J., Beloncle, F., Davies, K. G., Cirone, R., Manoharan, V., Ismail, M., Goligher, E. C., Jassal, M., Nishikawa, E., Javeed, A., Curley, G., Rittayamai, N., Parotto, M., Ferguson, N. D., Mehta, S., Knoll, J., Pronovost, A., Canestrini, S., Bruhn, A. R., Garcia, P. H., Aliaga, F. A., Farias, P. A., Yumha, J. S., Ortiz, C. A., Salas, J. E., Saez, A. A., Vega, L. D., Labarca, E. F., Martinez, F. T., Carreno, N. G., Lora, P., Liu, H., Qiu, H., Liu, L., Tang, R., Luo, X., An, Y., Zhao, H., Gao, Y., Zhai, Z., Ye, Z. L., Wang, W., Li, W., Li, Q., Zheng, R., Yu, W., Shen, J., Li, X., Yu, T., Lu, W., Wu, Y. Q., Huang, X. B., He, Z., Lu, Y., Han, H., Zhang, F., Sun, R., Wang, H. X., Qin, S. H., Zhu, B. H., Zhao, J., Liu, J., Li, B., Liu, J. L., Zhou, F. C., Li, Q. J., Zhang, X. Y., Li-Xin, Z., Xin-Hua, Q., Jiang, L., Gao, Y. N., Zhao, X. Y., Li, Y. Y., Li, X. L., Wang, C., Yao, Q., Yu, R., Chen, K., Shao, H., Qin, B., Huang, Q. Q., Zhu, W. H., Hang, A. Y., Hua, M. X., Li, Y., Xu, Y., Di, Y. D., Ling, L. L., Qin, T. H., Wang, S. H., Qin, J., Han, Y., Zhou, S., Vargas, M. P., Silesky Jimenez, J. I., Gonzalez Rojas, M. A., Solis-Quesada, J. E., Ramirez-Alfaro, C. M., Maca, J., Sklienka, P., Gjedsted, J., Christiansen, A., Nielsen, J., Villamagua, B. G., Llano, M., Burtin, P., Buzancais, G., Beuret, P., Pelletier, N., Mortaza, S., Mercat, A., Chelly, J., Jochmans, S., Terzi, N., Daubin, C., Carteaux, G., de Prost, N., Chiche, J., Daviaud, F., Pham, T., Fartoukh, M., Barberet, G., Biehler, J., Dellamonica, J., Doyen, D., Arnal, J., Briquet, A., Hraiech, S., Papazian, L., Follin, A., Roux, D., Messika, J., Kalaitzis, E., Dangers, L., Combes, A., Au, S., Beduneau, G., Carpentier, D., Zogheib, E. H., Dupont, H., Ricome, S., Santoli, F. L., Besset, S. L., Michel, P., Gelee, B., Danin, P., Goubaux, B., Crova, P. J., Phan, N. T., Berkelmans, F., Badie, J. C., Tapponnier, R., Gally, J., Khebbeb, S., Herbrecht, J., Schneider, F., Declercq, P. M., Rigaud, J., Duranteau, J., Harrois, A., Chabanne, R., Marin, J., Bigot, C., Thibault, S., Ghazi, M., Boukhazna, M., Ould Zein, S., Richecoeur, J. R., Combaux, D. M., Grelon, F., Le Moal, C., Sauvadet, E. P., Robine, A., Lemiale, V., Reuter, D., Dres, M., Demoule, A., Goldgran-Toledano, D., Baboi, L., Guerin, C., Lohner, R., KraSSler, J., Schafer, S., Zacharowski, K. D., Meybohm, P., Reske, A. W., Simon, P., Hopf, H. F., Schuetz, M., Baltus, T., Papanikolaou, M. N., Papavasilopoulou, T. G., Zacharas, G. A., Ourailogloy, V., Mouloudi, E. K., Massa, E. V., Nagy, E. O., Stamou, E. E., Kiourtzieva, E. V., Oikonomou, M. A., Avila, L. E., Cortez, C. A., Citalan, J. E., Jog, S. A., Sable, S. D., Shah, B., Gurjar, M., Baronia, A. K., Memon, M., Muthuchellappan, R., Ramesh, V. J., Shenoy, A., Unnikrishnan, R., Dixit, S. B., Rhayakar, R. V., Ramakrishnan, N., Bhardwaj, V. K., Mahto, H. L., Sagar, S. V., Palaniswamy, V., Ganesan, D., Mohammadreza Hashemian, S., Jamaati, H., Heidari, F., Meaney, E. A., Nichol, A., Knapman, K. M., O'Croinin, D., Dunne, E. S., Breen, D. M., Clarkson, K. P., Jaafar, R. F., Dwyer, R., Amir, F., Ajetunmobi, O. O., O'Muircheartaigh, A. C., Black, C. S., Treanor, N., Collins, D. V., Altaf, W., Zani, G., Fusari, M., Spadaro, S., Volta, C. A., Graziani, R., Brunettini, B., Palmese, S., Formenti, P., Umbrello, M., Lombardo, A., Pecci, E., Botteri, M., Savioli, M., Protti, A., Mattei, A., Schiavoni, L., Tinnirello, A., Todeschini, M., Giarratano, A., Cortegiani, A., Sher, S., Rossi, A., Antonelli, M. M., Montini, L. M., Casalena, P., Scafetti, S., Panarello, G., Occhipinti, G., Patroniti, N., Pozzi, M., Biscione, R. R., Poli, M. M., Raimondi, F., Albiero, D., Crapelli, G., Beck, E., Pota, V., Schiavone, V., Molin, A., Tarantino, F., Monti, G., Frati, E., Mirabella, L., Cinnella, G., Fossali, T., Colombo, R., Terragni, P., Pattarino, I., Mojoli, F., Braschi, A., Borotto, E. E., Cracchiolo, A. N., Palma, D. M., Raponi, F., Foti, G., Vascotto, E. R., Coppadoro, A., Brazzi, L., Floris, L., Iotti, G. A., Venti, A., Yamaguchi, O., Takagi, S., Maeyama, H. N., Watanabe, E., Yamaji, Y., Shimizu, K., Shiozaki, K., Futami, S., Ryosuke, S., Saito, K., Kameyama, Y., Ueno, K., Izawa, M., Okuda, N., Suzuki, H., Harasawa, T., Nasu, M., Takada, T., Ito, F., Nunomiya, S., Koyama, K., Abe, T., Andoh, K., Kusumoto, K., Hirata, A., Takaba, A., Kimura, H., Matsumoto, S., Higashijima, U., Honda, H., Aoki, N., Imai, H., Ogino, Y., Mizuguchi, I., Ichikado, K., Nitta, K., Mochizuki, K., Hashida, T., Tanaka, H., Nakamura, T., Niimi, D., Ueda, T., Kashiwa, Y., Uchiyama, A., Sabelnikovs, O., Oss, P., Haddad, Y., Liew, K. Y., Namendys-Silva, S. A., Jarquin-Badiola, Y. D., Sanchez-Hurtado, L. A., Gomez-Flores, S. S., Marin, M. C., Villagomez, A. J., Lemus, J. S., Fierro, J. M., Cervantes, M. R., Mejia, F. J., Gonzalez, D. R., Dector, D. M., Estrella, C. R., Sanchez-Medina, J. R., Ramirez-Gutierrez, A., George, F. G., Aguirre, J. S., Buensuseso, J. A., Poblano, M., Dendane, T., Zeggwagh, A. A., Balkhi, H., Elkhayari, M., Samkaoui, N., Ezzouine, H., Benslama, A., Amor, M., Maazouzi, W., Cimic, N., Beck, O., Bruns, M. M., Schouten, J. A., Rinia, M., Raaijmakers, M., Heunks, L. M., Van Wezel, H. M., Heines, S. J., Buise, M. P., Simonis, F. D., Schultz, M. J., Goodson, J. C., Rowne, T. S., Navarra, L., Hunt, A., Hutchison, R. A., Bailey, M. B., Newby, L., Mcarthur, C., Kalkoff, M., Mcleod, A., Casement, J., Hacking, D. J., Andersen, F. H., Dolva, M. S., Laake, J. H., Barratt-Due, A., Noremark, K. A., Soreide, E., Sjobo, B. A., Guttormsen, A. B., Yoshido, H. H., Aguilar, R. Z., Oscanoa, F. A., Alisasis, A. U., Robles, J. B., Pasanting-Lim, R. A., Tan, B. C., Andruszkiewicz, P., Jakubowska, K., Cox, C. M., Alvarez, A. M., Oliveira, B. S., Montanha, G. M., Barros, N. C., Pereira, C. S., Messias, A. M., Monteiro, J. M., Araujo, A. M., Catorze, N. T., Marum, S. M., Bouw, M. J., Gomes, R. M., Brito, V. A., Castro, S., Estilita, J. M., Barros, F. M., Serra, I. M., Martinho, A. M., Tomescu, D. R., Marcu, A., Bedreag, O. H., Papurica, M., Corneci, D. E., Negoita, S. I., Grigoriev, E., Gritsan, A. I., Gazenkampf, A. A., Almekhlafi, G., Albarrak, M. M., Mustafa, G. M., Maghrabi, K. A., Salahuddin, N., Aisa, T. M., Al Jabbary, A. S., Tabhan, E., Arabi, Y. M., Trinidad, O. A., Al Dorzi, H. M., Tabhan, E. E., Bolon, S., Smith, O., Mancebo, J., Aguirre-Bermeo, H., Lopez-Delgado, J. C., Esteve, F., Rialp, G., Forteza, C., De Haro, C., Artigas, A., Albaiceta, G. M., De Cima-Iglesias, S., Seoane-Quiroga, L., Ceniceros-Barros, A., Ruiz-Aguilar, A. L., Claraco-Vega, L. M., Soler, J. A., Lorente, M. D., Hermosa, C., Gordo, F., Prieto-Gonzalez, M., Lopez-Messa, J. B., Perez, M. P., Pere, C. P., Allue, R. M., Roche-Campo, F., Ibanez-Santacruz, M., Temprano, S., Pintado, M. C., De Pablo, R., Gomez, P. R., Ruiz, S. R., Moles, S. I., Jurado, M. T., Arizmendi, A., Piacentini, E. A., Franco, N., Honrubia, T., Perez Cheng, M., Perez Losada, E., Blanco, J., Yuste, L. J., Carbayo-Gorriz, C., Cazorla-Barranquero, F. G., Alonso, J. G., Alda, R. S., Algaba, A., Navarro, G., Cereijo, E., Diaz-Rodriguez, E., Marcos, D. P., Montero, L. A., Para, L. H., Sanchez, R. J., Blasco Navalpotro, M. A., Abad, R. D., Montiel Gonzalez, R., Toribio, D. P., Castro, A. G., Artiga, M. J., Penuelas, O., Roser, T. P., Olga, M. F., Curto, E. G., Sanchez, R. M., Imma, V. P., Elisabet, G. M., Claverias, L., Magret, M., Pellicer, A. M., Rodriguez, L. L., Sanchez-Ballesteros, J., Gonzalez-Salamanca, A., Jimenez, A. G., Huerta, F. P., Diaz, J. C., Lopez, E. B., Moya, D. D., Alfonso, A. A., Eugenio Luis, P. S., Cesar, P. S., Rafael, S. I., Virgilio, C. G., Recio, N. N., Adamsson, R. O., Rylander, C. C., Holzgraefe, B., Broman, L. M., Wessbergh, J., Persson, L., Schioler, F., Kedelv, H., Tibblin, A. O., Appelberg, H., Hedlund, L., Helleberg, J., Eriksson, K. E., Glietsch, R., Larsson, N., Nygren, I., Nunes, S. L., Morin, A., Kander, T., Adolfsson, A., Piquilloud, L., Zender, H. O., Leemann-Refondini, C., Elatrous, S., Bouchoucha, S., Chouchene, I., Ouanes, I., Ben Souissi, A., Kamoun, S., Demirkiran, O., Aker, M., Erbabacan, E., Ceylan, I., Girgin, N. K., Ozcelik, M., Unal, N., Meco, B. C., Akyol, O. O., Derman, S. S., Kennedy, B., Parhar, K., Srinivasa, L., McNamee, L., McAuley, D., Steinberg, J., Hopkins, P., Mellis, C., Stansil, F., Kakar, V., Hadfield, D., Brown, C., Vercueil, A., Bhowmick, K., Humphreys, S. K., Ferguson, A., Mckee, R., Raj, A. S., Fawkes, D. A., Watt, P., Twohey, L., Thomas, R. R., Morton, A., Kadaba, V., Smith, M. J., Hormis, A. P., Kannan, S. G., Namih, M., Reschreiter, H., Camsooksai, J., Kumar, A., Rugonfalvi, S., Nutt, C., Oneill, O., Seasman, C., Dempsey, G., Scott, C. J., Ellis, H. E., Mckechnie, S., Hutton, P. J., Di Tomasso, N. N., Vitale, M. N., Griffin, R. O., Dean, M. N., Cranshaw, J. H., Willett, E. L., Ioannou, N., Gillis, S., Csabi, P., Macfadyen, R., Dawson, H., Preez, P. D., Williams, A. J., Boyd, O., De Gordoa, L. O., Bramall, J., Symmonds, S., Chau, S. K., Wenham, T., Szakmany, T., Toth-Tarsoly, P., Mccalman, K. H., Alexander, P., Stephenson, L., Collyer, T., Chapman, R., Cooper, R., Allan, R. M., Sim, M., Wrathall, D. W., Irvine, D. A., Zantua, K. S., Adams, J. C., Burtenshaw, A. J., Sellors, G. P., Welters, I. D., Williams, K. E., Hessell, R. J., Oldroyd, M. G., Battle, C. E., Pillai, S., Kajtor, I., Sivashanmugave, M., Okane, S. C., Donnelly, A., Frigyik, A. D., Careless, J. P., May, M. M., Stewart, R., Trinder, T. J., Hagan, S. J., Wise, M. P., Cole, J. M., MacFie, C. C., Dowling, A. T., Hurtado, J., Hurtado, J., Nunez, E., Pittini, G., Rodriguez, R., Imperio, M. C., Santos, C., Franca, A. G., Ebeid, A., Deicas, A., Serra, C., Uppalapati, A., Kamel, G., Banner-Goodspeed, V. M., Beitler, J. R., Mukkera, S. R., Kulkarni, S., Lee, J., Mesar, T., Shinn Iii, J. O., Gomaa, D., Tainter, C., Mesar, T., Cowley, R. A., Yeatts, D. J., Warren, J., Lanspa, M. J., Miller, R. R., Grissom, C. K., Brown, S. M., Bauer, P. R., Gosselin, R. J., Kitch, B. T., Cohen, J. E., Beegle, S. H., Gueret, R. M., Tulaimat, A., Choudry, S., Stigler, W., Batra, H., Huff, N. G., Lamb, K. D., Oetting, T. W., Mohr, N. M., Judy, C., Saito, S., Kheir, F. M., Schlichting, A. B., Delsing, A., Elmasri, M., Crouch, D. R., Ismail, D., Blakeman, T. C., Dreyer, K. R., Gomaa, D., Baron, R. M., Grijalba, C. Q., Hou, P. C., Seethala, R., Aisiku, I., Henderson, G., Frendl, G., Hou, S., Owens, R. L., Schomer, A., Bumbasirevic, V., Jovanovic, B., Surbatovic, M., Veljovic, M. 1800

    Abstract

    BACKGROUND: Two acute respiratory distress syndrome (ARDS) subphenotypes (hyperinflammatory and hypoinflammatory) with distinct clinical and biological features and differential treatment responses have been identified using latent class analysis (LCA) in seven individual cohorts. To facilitate bedside identification of subphenotypes, clinical classifier models using readily available clinical variables have been described in four randomised controlled trials. We aimed to assess the performance of these models in observational cohorts of ARDS.METHODS: In this observational, multicohort, retrospective study, we validated two machine-learning clinical classifier models for assigning ARDS subphenotypes in two observational cohorts of patients with ARDS: Early Assessment of Renal and Lung Injury (EARLI; n=335) and Validating Acute Lung Injury Markers for Diagnosis (VALID; n=452), with LCA-derived subphenotypes as the gold standard. The primary model comprised only vital signs and laboratory variables, and the secondary model comprised all predictors in the primary model, with the addition of ventilatory variables and demographics. Model performance was assessed by calculating the area under the receiver operating characteristic curve (AUC) and calibration plots, and assigning subphenotypes using a probability cutoff value of 0·5 to determine sensitivity, specificity, and accuracy of the assignments. We also assessed the performance of the primary model in EARLI using data automatically extracted from an electronic health record (EHR; EHR-derived EARLI cohort). In Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure (LUNG SAFE; n=2813), a multinational, observational ARDS cohort, we applied a custom classifier model (with fewer variables than the primary model) to determine the prognostic value of the subphenotypes and tested their interaction with the positive end-expiratory pressure (PEEP) strategy, with 90-day mortality as the dependent variable.FINDINGS: The primary clinical classifier model had an area under receiver operating characteristic curve (AUC) of 0·92 (95% CI 0·90-0·95) in EARLI and 0·88 (0·84-0·91) in VALID. Performance of the primary model was similar when using exclusively EHR-derived predictors compared with manually curated predictors (AUC=0·88 [95% CI 0·81-0·94] vs 0·92 [0·88-0·97]). In LUNG SAFE, 90-day mortality was higher in patients assigned the hyperinflammatory subphenotype than in those with the hypoinflammatory phenotype (414 [57%] of 725 vs 694 [33%] of 2088; p<0·0001). There was a significant treatment interaction with PEEP strategy and ARDS subphenotype (p=0·041), with lower 90-day mortality in the high PEEP group of patients with the hyperinflammatory subphenotype (hyperinflammatory subphenotype: 169 [54%] of 313 patients in the high PEEP group vs 127 [62%] of 205 patients in the low PEEP group; hypoinflammatory subphenotype: 231 [34%] of 675 patients in the high PEEP group vs 233 [32%] of 734 patients in the low PEEP group).INTERPRETATION: Classifier models using clinical variables alone can accurately assign ARDS subphenotypes in observational cohorts. Application of these models can provide valuable prognostic information and could inform management strategies for personalised treatment, including application of PEEP, once prospectively validated.FUNDING: US National Institutes of Health and European Society of Intensive Care Medicine.

    View details for DOI 10.1016/S2213-2600(21)00461-6

    View details for PubMedID 35026177

  • Latent Class Analysis Reveals COVID-19-related Acute Respiratory Distress Syndrome Subgroups with Differential Responses to Corticosteroids AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE Sinha, P., Furfaro, D., Cummings, M. J., Abrams, D., Delucchi, K., Maddali, M., He, J., Thompson, A., Murn, M., Fountain, J., Rosen, A., Robbins-Juarez, S. Y., Adan, M. A., Satish, T., Madhavan, M., Gupta, A., Lyashchenko, A. K., Agerstrand, C., Yip, N. H., Burkart, K. M., Beitler, J. R., Baldwin, M. R., Calfee, C. S., Brodie, D., O'Donnell, M. R. 2021; 204 (11): 1274-1285

    Abstract

    Rationale: Two distinct subphenotypes have been identified in acute respiratory distress syndrome (ARDS), but the presence of subgroups in ARDS associated with coronavirus disease (COVID-19) is unknown. Objectives: To identify clinically relevant, novel subgroups in COVID-19-related ARDS and compare them with previously described ARDS subphenotypes. Methods: Eligible participants were adults with COVID-19 and ARDS at Columbia University Irving Medical Center. Latent class analysis was used to identify subgroups with baseline clinical, respiratory, and laboratory data serving as partitioning variables. A previously developed machine learning model was used to classify patients as the hypoinflammatory and hyperinflammatory subphenotypes. Baseline characteristics and clinical outcomes were compared between subgroups. Heterogeneity of treatment effect for corticosteroid use in subgroups was tested. Measurements and Main Results: From March 2, 2020, to April 30, 2020, 483 patients with COVID-19-related ARDS met study criteria. A two-class latent class analysis model best fit the population (P = 0.0075). Class 2 (23%) had higher proinflammatory markers, troponin, creatinine, and lactate, lower bicarbonate, and lower blood pressure than class 1 (77%). Ninety-day mortality was higher in class 2 versus class 1 (75% vs. 48%; P < 0.0001). Considerable overlap was observed between these subgroups and ARDS subphenotypes. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RT-PCR cycle threshold was associated with mortality in the hypoinflammatory but not the hyperinflammatory phenotype. Heterogeneity of treatment effect to corticosteroids was observed (P = 0.0295), with improved mortality in the hyperinflammatory phenotype and worse mortality in the hypoinflammatory phenotype, with the caveat that corticosteroid treatment was not randomized. Conclusions: We identified two COVID-19-related ARDS subgroups with differential outcomes, similar to previously described ARDS subphenotypes. SARS-CoV-2 PCR cycle threshold had differential value for predicting mortality in the subphenotypes. The subphenotypes had differential treatment responses to corticosteroids.

    View details for DOI 10.1164/rccm.202105-1302OC

    View details for Web of Science ID 000726576300011

    View details for PubMedID 34543591

    View details for PubMedCentralID PMC8786071

  • Comparison of machine learning clustering algorithms for detecting heterogeneity of treatment effect in acute respiratory distress syndrome: A secondary analysis of three randomised controlled trials EBIOMEDICINE Sinha, P., Spicer, A., Delucchi, K. L., McAuley, D. F., Calfee, C. S., Churpek, M. M. 2021; 74: 103697

    Abstract

    Heterogeneity in Acute Respiratory Distress Syndrome (ARDS), as a consequence of its non-specific definition, has led to a multitude of negative randomised controlled trials (RCTs). Investigators have sought to identify heterogeneity of treatment effect (HTE) in RCTs using clustering algorithms. We evaluated the proficiency of several commonly-used machine-learning algorithms to identify clusters where HTE may be detected.Five unsupervised: Latent class analysis (LCA), K-means, partition around medoids, hierarchical, and spectral clustering; and four supervised algorithms: model-based recursive partitioning, Causal Forest (CF), and X-learner with Random Forest (XL-RF) and Bayesian Additive Regression Trees were individually applied to three prior ARDS RCTs. Clinical data and research protein biomarkers were used as partitioning variables, with the latter excluded for secondary analyses. For a clustering schema, HTE was evaluated based on the interaction term of treatment group and cluster with day-90 mortality as the dependent variable.No single algorithm identified clusters with significant HTE in all three trials. LCA, XL-RF, and CF identified HTE most frequently (2/3 RCTs). Important partitioning variables in the unsupervised approaches were consistent across algorithms and RCTs. In supervised models, important partitioning variables varied between algorithms and across RCTs. In algorithms where clusters demonstrated HTE in the same trial, patients frequently interchanged clusters from treatment-benefit to treatment-harm clusters across algorithms. LCA aside, results from all other algorithms were subject to significant alteration in cluster composition and HTE with random seed change. Removing research biomarkers as partitioning variables greatly reduced the chances of detecting HTE across all algorithms.Machine-learning algorithms were inconsistent in their abilities to identify clusters with significant HTE. Protein biomarkers were essential in identifying clusters with HTE. Investigations using machine-learning approaches to identify clusters to seek HTE require cautious interpretation.NIGMS R35 GM142992 (PS), NHLBI R35 HL140026 (CSC); NIGMS R01 GM123193, Department of Defense W81XWH-21-1-0009, NIA R21 AG068720, NIDA R01 DA051464 (MMC).

    View details for DOI 10.1016/j.ebiom.2021.103697

    View details for Web of Science ID 000730209800010

    View details for PubMedID 34861492

    View details for PubMedCentralID PMC8645454

  • Longitudinal respiratory subphenotypes in patients with COVID-19-related acute respiratory distress syndrome: results from three observational cohorts LANCET RESPIRATORY MEDICINE Bos, L. D. J., Sjoding, M., Sinha, P., Bhavani, S., Lyons, P. G., Bewley, A. F., Botta, M., Tsonas, A. M., Neto, A., Schultz, M. J., Dickson, R. P., Paulus, F. 2021; 9 (12): 1377-1386

    Abstract

    Patients with COVID-19-related acute respiratory distress syndrome (ARDS) have been postulated to present with distinct respiratory subphenotypes. However, most phenotyping schema have been limited by sample size, disregard for temporal dynamics, and insufficient validation. We aimed to identify respiratory subphenotypes of COVID-19-related ARDS using unbiased data-driven approaches.PRoVENT-COVID was an investigator-initiated, national, multicentre, prospective, observational cohort study at 22 intensive care units (ICUs) in the Netherlands. Consecutive patients who had received invasive mechanical ventilation for COVID-19 (aged 18 years or older) served as the derivation cohort, and similar patients from two ICUs in the USA served as the replication cohorts. COVID-19 was confirmed by positive RT-PCR. We used latent class analysis to identify subphenotypes using clinically available respiratory data cross-sectionally at baseline, and longitudinally using 8-hourly data from the first 4 days of invasive ventilation. We used group-based trajectory modelling to evaluate trajectories of individual variables and to facilitate potential clinical translation. The PRoVENT-COVID study is registered with ClinicalTrials.gov, NCT04346342.Between March 1, 2020, and May 15, 2020, 1007 patients were admitted to participating ICUs in the Netherlands, and included in the derivation cohort. Data for 288 patients were included in replication cohort 1 and 326 in replication cohort 2. Cross-sectional latent class analysis did not identify any underlying subphenotypes. Longitudinal latent class analysis identified two distinct subphenotypes. Subphenotype 2 was characterised by higher mechanical power, minute ventilation, and ventilatory ratio over the first 4 days of invasive mechanical ventilation than subphenotype 1, but PaO2/FiO2, pH, and compliance of the respiratory system did not differ between the two subphenotypes. 185 (28%) of 671 patients with subphenotype 1 and 109 (32%) of 336 patients with subphenotype 2 had died at day 28 (p=0·10). However, patients with subphenotype 2 had fewer ventilator-free days at day 28 (median 0, IQR 0-15 vs 5, 0-17; p=0·016) and more frequent venous thrombotic events (109 [32%] of 336 patients vs 176 [26%] of 671 patients; p=0·048) compared with subphenotype 1. Group-based trajectory modelling revealed trajectories of ventilatory ratio and mechanical power with similar dynamics to those observed in latent class analysis-derived trajectory subphenotypes. The two trajectories were: a stable value for ventilatory ratio or mechanical power over the first 4 days of invasive mechanical ventilation (trajectory A) or an upward trajectory (trajectory B). However, upward trajectories were better independent prognosticators for 28-day mortality (OR 1·64, 95% CI 1·17-2·29 for ventilatory ratio; 1·82, 1·24-2·66 for mechanical power). The association between upward ventilatory ratio trajectories (trajectory B) and 28-day mortality was confirmed in the replication cohorts (OR 4·65, 95% CI 1·87-11·6 for ventilatory ratio in replication cohort 1; 1·89, 1·05-3·37 for ventilatory ratio in replication cohort 2).At baseline, COVID-19-related ARDS has no consistent respiratory subphenotype. Patients diverged from a fairly homogenous to a more heterogeneous population, with trajectories of ventilatory ratio and mechanical power being the most discriminatory. Modelling these parameters alone provided prognostic value for duration of mechanical ventilation and mortality.Amsterdam UMC.

    View details for DOI 10.1016/S2213-2600(21)00365-9

    View details for Web of Science ID 000729806800023

    View details for PubMedID 34653374

    View details for PubMedCentralID PMC8510633

  • A Research Agenda for Precision Medicine in Sepsis and Acute Respiratory Distress Syndrome An Official American Thoracic Society Research Statement AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE Shah, F., Meyer, N. J., Angus, D. C., Awdish, R., Azoulay, E., Calfee, C. S., Clermont, G., Gordon, A. C., Kwizera, A., Leligdowicz, A., Marshall, J. C., Mikacenic, C., Sinha, P., Venkatesh, B., Wong, H. R., Zampieri, F. G., Yende, S., Amer Thoracic Soc Assembly Critica 2021; 204 (8): 891-901

    Abstract

    Background: Precision medicine focuses on the identification of therapeutic strategies that are effective for a group of patients based on similar unifying characteristics. The recent success of precision medicine in non-critical care settings has resulted from the confluence of large clinical and biospecimen repositories, innovative bioinformatics, and novel trial designs. Similar advances for precision medicine in sepsis and in the acute respiratory distress syndrome (ARDS) are possible but will require further investigation and significant investment in infrastructure. Methods: This project was funded by the American Thoracic Society Board of Directors. A multidisciplinary and diverse working group reviewed the available literature, established a conceptual framework, and iteratively developed recommendations for the Precision Medicine Research Agenda for Sepsis and ARDS. Results: The following six priority recommendations were developed by the working group: 1) the creation of large richly phenotyped and harmonized knowledge networks of clinical, imaging, and multianalyte molecular data for sepsis and ARDS; 2) the implementation of novel trial designs, including adaptive designs, and embedding trial procedures in the electronic health record; 3) continued innovation in the data science and engineering methods required to identify heterogeneity of treatment effect; 4) further development of the tools necessary for the real-time application of precision medicine approaches; 5) work to ensure that precision medicine strategies are applicable and available to a broad range of patients varying across differing racial, ethnic, socioeconomic, and demographic groups; and 6) the securement and maintenance of adequate and sustainable funding for precision medicine efforts. Conclusions: Precision medicine approaches that incorporate variability in genomic, biologic, and environmental factors may provide a path forward for better individualizing the delivery of therapies and improving care for patients with sepsis and ARDS.

    View details for DOI 10.1164/rccm.202108-1908ST

    View details for Web of Science ID 000709615500010

    View details for PubMedID 34652268

    View details for PubMedCentralID PMC8534611

  • Pathophysiology of the Acute Respiratory Distress Syndrome: Insights from Clinical Studies CRITICAL CARE CLINICS Sinha, P., Bos, L. D. 2021; 37 (4): 795-815

    Abstract

    Acute respiratory distress syndrome (ARDS) is a heterogeneous clinical syndrome that manifests secondary to numerous etiologic insults, and consequently it is associated with a multitude of pathophysiological abnormalities. Despite more than 50 years of experimental studies, translation of these benchside discoveries into effective biological therapies has been elusive. In this review, some of the key advances made in our knowledge of the pathophysiology of ARDS, based on histopathology, imaging, protein, and transcriptomic biomarkers, are presented. Finally, the role of such human studies in understanding the pathophysiology of coronavirus disease 2019-related ARDS is reviewed.

    View details for DOI 10.1016/j.ccc.2021.05.005

    View details for Web of Science ID 000709166800007

    View details for PubMedID 34548134

    View details for PubMedCentralID PMC8149201

  • Tracheal aspirate RNA sequencing identifies distinct immunological features of COVID-19 ARDS. Nature communications Sarma, A., Christenson, S. A., Byrne, A., Mick, E., Pisco, A. O., DeVoe, C., Deiss, T., Ghale, R., Zha, B. S., Tsitsiklis, A., Jauregui, A., Moazed, F., Detweiler, A. M., Spottiswoode, N., Sinha, P., Neff, N., Tan, M., Serpa, P. H., Willmore, A., Ansel, K. M., Wilson, J. G., Leligdowicz, A., Siegel, E. R., Sirota, M., DeRisi, J. L., Matthay, M. A., COMET Consortium, Hendrickson, C. M., Kangelaris, K. N., Krummel, M. F., Woodruff, P. G., Erle, D. J., Calfee, C. S., Langelier, C. R., Abe-Jones, Y., Asthana, S., Beagle, A., Bhakta, T., Bhide, S., Cai, C., Caldera, S., Calfee, C., Calvo, M., Carrillo, S., Cattamanchi, A., Chak, S., Chan, V., Chew, N., Christenson, S., Collins, Z., Combes, A., Courau, T., Darmanis, S., Erle, D., Esmaili, A., Fragiadakis, G. K., Ghale, R., Giberson, J., Gonzalez, A., Serpa, P. H., Hendrickson, C., Hiam, K., Hu, K., Huang, B., Jauregui, A., Jones, C., Jones, N., Kangelaris, K., Krummel, M., Kumar, N., Kushnoor, D., Lea, T., Lee, D., Lee, D., Liu, K. D., Liu, Y., Mahboob, S., Matthay, M., Milush, J., Munoz-Sandoval, P., Nguyen, V., Ortiz, G., Parada, R., Phelps, M., Pierce, L., Prasad, P., Rao, A., Rashid, S., Reeder, G., Rodriguez, N., Samad, B., Scarlet, D., Shaw, C., Shen, A., Sigman, A., Spitzer, M., Sun, Y., Sunshine, S., Tang, K., Altamirano, L. T., Tsui, J., Tumurbaatar, E., Turner, K., Ward, A., Willmore, A., Wilson, M., Winkler, J., Withers, R., Wong, K., Woodruff, P., Ye, J., Yee, K., Yu, M., Zha, S., Zhan, J., Zhou, M., Zhu, W. S. 2021; 12 (1): 5152

    Abstract

    The immunological features that distinguish COVID-19-associated acute respiratory distress syndrome (ARDS) from other causes of ARDS are incompletely understood. Here, we report the results of comparative lower respiratory tract transcriptional profiling of tracheal aspirate from 52 critically ill patients with ARDS from COVID-19 or from other etiologies, as well as controls without ARDS. In contrast to a "cytokine storm," we observe reduced proinflammatory gene expression in COVID-19 ARDS when compared to ARDS due to other causes. COVID-19 ARDS is characterized by a dysregulated host response with increased PTEN signaling and elevated expression of genes with non-canonical roles in inflammation and immunity. In silico analysis of gene expression identifies several candidate drugs that may modulate gene expression in COVID-19 ARDS, including dexamethasone and granulocyte colony stimulating factor. Compared to ARDS due to other types of viral pneumonia, COVID-19 is characterized by impaired interferon-stimulated gene (ISG) expression. The relationship between SARS-CoV-2 viral load and expression of ISGs is decoupled in patients with COVID-19 ARDS when compared to patients with mild COVID-19. In summary, assessment of host gene expression in the lower airways of patients reveals distinct immunological features of COVID-19 ARDS.

    View details for DOI 10.1038/s41467-021-25040-5

    View details for PubMedID 34446707

  • Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. The New England journal of medicine REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators, Goligher, E. C., Bradbury, C. A., McVerry, B. J., Lawler, P. R., Berger, J. S., Gong, M. N., Carrier, M., Reynolds, H. R., Kumar, A., Turgeon, A. F., Kornblith, L. Z., Kahn, S. R., Marshall, J. C., Kim, K. S., Houston, B. L., Derde, L. P., Cushman, M., Tritschler, T., Angus, D. C., Godoy, L. C., McQuilten, Z., Kirwan, B., Farkouh, M. E., Brooks, M. M., Lewis, R. J., Berry, L. R., Lorenzi, E., Gordon, A. C., Berry, S. M., McArthur, C. J., Neal, M. D., Hochman, J. S., Webb, S. A., Zarychanski, R., Ahuja, T., Al-Beidh, F., Annane, D., Arabi, Y. M., Aryal, D., Baumann Kreuziger, L., Beane, A., Bhimani, Z., Bihari, S., Billett, H. H., Bond, L., Bonten, M., Brunkhorst, F., Buxton, M., Buzgau, A., Castellucci, L. A., Chekuri, S., Chen, J., Cheng, A. C., Chkhikvadze, T., Coiffard, B., Contreras, A., Costantini, T. W., de Brouwer, S., Detry, M. A., Duggal, A., Dzavik, V., Effron, M. B., Eng, H. F., Escobedo, J., Estcourt, L. J., Everett, B. M., Fergusson, D. A., Fitzgerald, M., Fowler, R. A., Froess, J. D., Fu, Z., Galanaud, J. P., Galen, B. T., Gandotra, S., Girard, T. D., Goodman, A. L., Goossens, H., Green, C., Greenstein, Y. Y., Gross, P. L., Haniffa, R., Hegde, S. M., Hendrickson, C. M., Higgins, A. M., Hindenburg, A. A., Hope, A. A., Horowitz, J. M., Horvat, C. M., Huang, D. T., Hudock, K., Hunt, B. J., Husain, M., Hyzy, R. C., Jacobson, J. R., Jayakumar, D., Keller, N. M., Khan, A., Kim, Y., Kindzelski, A., King, A. J., Knudson, M. M., Kornblith, A. E., Kutcher, M. E., Laffan, M. A., Lamontagne, F., Le Gal, G., Leeper, C. M., Leifer, E. S., Lim, G., Gallego Lima, F., Linstrum, K., Litton, E., Lopez-Sendon, J., Lother, S. A., Marten, N., Saud Marinez, A., Martinez, M., Mateos Garcia, E., Mavromichalis, S., McAuley, D. F., McDonald, E. G., McGlothlin, A., McGuinness, S. P., Middeldorp, S., Montgomery, S. K., Mouncey, P. R., Murthy, S., Nair, G. B., Nair, R., Nichol, A. D., Nicolau, J. C., Nunez-Garcia, B., Park, J. J., Park, P. K., Parke, R. L., Parker, J. C., Parnia, S., Paul, J. D., Pompilio, M., Quigley, J. G., Rosenson, R. S., Rost, N. S., Rowan, K., Santos, F. O., Santos, M., Santos, M. O., Satterwhite, L., Saunders, C. T., Schreiber, J., Schutgens, R. E., Seymour, C. W., Siegal, D. M., Silva, D. G., Singhal, A. B., Slutsky, A. S., Solvason, D., Stanworth, S. J., Turner, A. M., van Bentum-Puijk, W., van de Veerdonk, F. L., van Diepen, S., Vazquez-Grande, G., Wahid, L., Wareham, V., Widmer, R. J., Wilson, J. G., Yuriditsky, E., Zhong, Y., Manax, V., Connor, J., Bion, J., Gates, S., Reynolds, J., van der Poll, T., Al-Beidh, F., Angus, D., Annane, D., Arabi, Y., Beane, A., van Bentum-Pujik, W., Berry, S., Bhimani, Z., Bonten, M., Bradbury, C., Brunkhorst, F., Buxton, M., Cheng, A., Derde, L., Estcourt, L., Goossens, H., Gordon, A., Green, C., Haniffa, R., Lamontagne, F., Lawler, P., Linstrum, K., Litton, E., Marshall, J., McArthur, C., McAuley, D., McGuinness, S., McVerry, B., Montgomery, S., Mouncey, P., Murthy, S., Nichol, A., Parke, R., Parker, J., Rowan, K., Santos, M., Seymour, C., Turgeon, A., Turner, A., van de Veerdonk, F., Webb, S., Zarychanski, R., Campbell, L., Forbes, A., Gattas, D., Heritier, S., Kruger, P., Peake, S., Presneill, J., Seppelt, I., Trapani, T., Young, P., Cuthbertson, B., Fowler, R., Manoharan, V., Aryal, D., Dondrop, A. M., Hashmi, M., Jayakumar, D., Tolppa, T., Singh, V., Brillinger, N., Cecconi, M., Ermann, S., Francois, B., Hullegie, S., Markgraff, R., Pletz, M., Povoa, P., Rohde, G., Parker, L., Scheepstra-Beukers, I., Alexander, B., Basile, K., Girard, T., Horvat, C., Huang, D., Mayr, F., Beasley, R., Daneman, N., Fowler, R., McGloughlin, S., Morpeth, S., Paterson, D., Venkatesh, A. N., de Jong, M., Uyeki, T., Baillie, K., Duffy, E., Hills, T., Orr, K., Patanwala, A., Tong, S., Cooper, N., Cremer, O., Galea, J., King, A., Leavis, H., Netea, M., Ogungbenro, K., Patawala, A., Pettila, V., Rademaker, E., Saxena, M., Sligl, W., Tong, S., Youngstein, T., Seymour, C. W., Aryal, D. A., Bihari, S., Carrier, M., Fergusson, D., Goligher, E., Hunt, B., Jayakumar, D., Kumar, A., Laffan, M., Lother, S., Middeldorp, S., McQuilten, Z., Neal, M., Schutgens, R., Stanworth, S., Adhikari, N., Anstey, M., Brant, E., de Man, A., Lamonagne, F., Masse, M., Udy, A., Arnold, D., Begin, P., Charlewood, R., Chasse, M., Coyne, M., Cooper, J., Daly, J., Gosbell, I., Harvala-Simmonds, H., Hills, T., MacLennan, S., Menon, D., McDyer, J., Pridee, N., Roberts, D., Shankar-Hari, M., Thomas, H., Tinmouth, A., Triulzi, D., Walsh, T., Wood, E., Calfee, C., O'Kane, C., Shyamsundar, M., Sinha, P., Thompson, T., Young, I., Haidar, G., Lawless, P., Weissman, A., Ferguson, N., Hodgson, C., Laffey, J., Orford, N., Neto, A., Baron, R., Epelman, S., Frankfurter, C., Gommans, F., Kim, E., Leaf, D., Vaduganathan, M., van Kimmenade, R., Detry, M., Fitzgerald, M., Lewis, R., McGlothlin, A., Sanil, A., Saunders, C., Berry, L., Lorenzi, E., Buzgau, A., Higgins, A., Parker, P., Zammit, C., Groeneveld, E., Peters, S., Okundaye, C., van Hout, D., Smit, A., Rikkert, L., Bari, S., Raymakers, K., Kwakkenbos-Craanen, M., Post, S., Schreuder, G., Markgraf, R., Ainscough, K., Brickell, K., Doran, P., Anjum, A., Lane, J., Fagbodun, E., Miller, L., Parry-Billings, K., Peters, S., Richards-Belle, A., Saull, M., Sprinckmoller, S., Wiley, D., Wunderley, R., van Beurden, M., Effelaar, E., Schotsman, J., Boyd, C., Harland, C., Shearer, A., Wren, J., Clermont, G., Garrard, W., Kalchthaler, K., Ricketts, D., Malakoutis, S., Marroquin, O., Music, E., Quinn, K., Attanayaka, U., Darshana, S., Ishani, P., Jawad, I., Pabasara, U., Udayanga, I., Gilmour, K., Pearson, K., Siewerski, C., Hurford, S., Marsh, E., Campbell, D., Williams, P., Shirley, K., Logan, M., Hanson, J., Dilley, B., Phillips, L., Oliver, A., Sutu, M., Murphy, S., Aravindan, L., Collins, J., Monaghan, H., Unsworth, A., Beddows, S., Dawson, L. A., Dyas, S., Asghar, A., Donaldson, K., Skinner, T., Mguni, N., Muzengi, N., Luo, J., O'Reilly, J., Levett, C., Potter, A., Porter, D., Lockett, T., Bartholomew, J., Rook, C., McKay, R., Williams, H., Hall, A., Campbell, H., Speight, H., Halden, S., Harrison, S., Naz, M., Lomme, K., Sharratt, P., Sheffield, J., Van't Hoff, W., Williamson, J. D., Barnard, A., Birch, C., Brend, M., Chambers, E., Crawshaw, S., Drake, C., Duckles-Leech, H., Graham, J., Harper, H., Lock, S., McMillan, N., O'Flaherty, C., OKell, E., Hayes, A., Sam, S., Slade, H., Walker, S., Wilding, K., Goodwin, J., Hodgson, H., Ellis, Y., Williamson, D., Bayne, M., Jackson, S., Byrne, R., McKenna, S., Clinton, A., McCracken, P., Young, M., Board, J., Martin, E., El-Khawas, K., Richardson, A., Hill, D., Commons, R. J., Abdelkharim, H., Knott, C., Smith, J., Boschert, C., Affleck, J., Apte, Y., Subbanna, U., Bartholdy, R., Frakking, T., Keat, K., Bhonagiri, D., Sanghavi, R., Nema, J., Ford, M., Parikh, H. G., Avard, B., Nourse, M., Cheung, W., Kol, M., Wong, H., Shah, A., Wagh, A., Simpson, J., Duke, G., Chan, P., Carter, B., Hunter, S., Laver, R. D., Shrestha, T., Jin, X., Regli, A., Pellicano, S., Palermo, A., Eroglu, E., French, C., Bates, S., Towns, M., Yang, Y., McGain, F., McCullough, J., Tallott, M., Kumar, N., Panwar, R., Brinkerhoff, G., Koppen, C., Cazzola, F., Brain, M., Mineall, S., Fischer, R., Biradar, V., Soar, N., White, H., Estensen, K., Morrison, L., Sutton, J., Cooper, M., Shehabi, Y., Al-Bassam, W., Hulley, A., Kadam, U., Sathianathan, K., Whitehead, C., Lowrey, J., Gresham, R., Masters, K., Walsham, J., Meyer, M. J., Harward, M., Venz, E., Brady, K., Vale, C., Shekar, K., Lavana, J., Parmar, D., Williams, P., Kurenda, C., Miles, H., Attokaran, A., Gluck, S., O'Connor, S., Chapman, M., Glasby, K., Smyth, K., Phillips, M., Barge, D., Byrne, K., Driscoll, A., Fortune, L., Janin, P., Yarad, E., Bass, F., Hammond, N., O'Connor, A., Waterson, S., McNamara, R., Buhr, H., Coles, J., Schweikert, S., Wibrow, B., Rauniyar, R., Deshpande, K., Konecny, P., Miller, J., Kintono, A., Tung, R., Fysh, E., Dawda, A., Mevavala, B., De Keulenaer, A. R., Litton, E., Ferrier, J., Nair, P., Buscher, H., Reynolds, C., Newman, S., Santamaria, J., Barbazza, L., Homes, J., Smith, R., Garrett, P., Murray, L., Brailsford, J., Forbes, L., Maguire, T., Fennessy, G., Mulder, J., Morgan, R., McEldrew, R., Naeem, A., Fagan, L., Ryan, E., Mariappa, V., Smith, J., Simpson, S., Maiden, M., Bone, A., Horton, M., Salerno, T., Sterba, M., Geng, W., Depuydt, P., De Waele, J., De Bus, L., Fierens, J., Bracke, S., Vermassen, J., Vermeiren, D., Reeve, B., Dechert, W., Lellouche, F., Lizotte, P., Chasse, M., Carrier, F. M., Boumahni, D., Benettaib, F., Ghamraoui, A., Bellemare, D., Cloutier, E., Daher, R., Costerousse, O., Boulanger, M., Couillard-Chenard, E., Lauzier, F., Francoeur, C., Lamontagne, F., D'Aragon, F., Carbonneau, E., Leblond, J., Vazquez-Grande, G., Marten, N., Liu, T., Siddiqui, A., Wilson, M., Albert, M., Serri, K., Cavayas, A., Duplaix, M., Williams, V., Rochwerg, B., Karachi, T., Oczkowski, S., Centofanti, J., Millen, T., Khwaja, K., Campisi, J., Duan, E., Tsang, J., Patterson, L., Sy, E., Gupta, C., Kassir, S. S., Kutsogiannis, D., Thompson, P., Kamra, M., Marinoff, N., Cook, D., Clarke, F., Kruisselbrink, R., Brochard, L., Burns, K., Sandhu, G., Khalid, I., English, S., Watpool, I., Porteous, R., Miezitis, S., McIntyre, L., Wilcox, E., Del Sorbo, L., Abdelhady, H., Romagnuolo, T., Baig, N., Rewa, O., Bagshaw, S., Binnie, A., Powell, E., McMillan, A., Luk, T., Aref, N., Pratheema, R., Babu, S., Vignesh, C., Kumar, B., Ramakrishnan, N., James, A., Elvira, E., Ebenezer, R., Krishnaoorthy, S., Ranganathan, L., Shree, M. M., Mani, A. K., Mathew, M., Revathi, R., Khanal, S., Amatya, S., Paneru, H. R., Koirala, S., Paudel, P., Koirala, K., Rai, N., Luitel, S., Bhattarai, B., Panjwani, A., Umrani, Z. A., Siddiq, S., Shaikh, M., Salahuddin, N., Masood, S., Andric, Z., Cviljevic, S., Dimoti, R., Zapalac, M., Gordan, G., Barsic, B., Kutlesa, M., Kotarski, V., Vujaklija Brajkovic, A., Babel, J., Sever, H., Dragija, L., Kusan, I., Vaara, S., Pettila, L., Heinonen, J., Kuitunen, A., Karlsson, S., Vahtera, A., Kiiski, H., Ristimaki, S., Azaiz, A., Charron, C., Godement, M., Geri, G., Vieillard-Baron, A., Pourcine, F., Monchi, M., Luis, D., Mercier, R., Sagnier, A., Verrier, N., Caplin, C., Richecoeu, J., Combaux, D., Siami, S., Aparicio, C., Vautier, S., Jeblaoui, A., Lemaire-Brunel, D., Fartoukh, M., Courtin, L., Labbe, V., Voiriot, G., Nesrine Salhi, S., Plantefeve, G., Leparco, C., Contou, D., Muller, G., Nay, M., Kamel, T., Benzekri, D., Jacquier, S., Runge, I., Mathonnet, A., Barbier, F., Bretagnol, A., Mercier, E., Chartier, D., Salmon, C., Dequin, P., Garot, D., Schneider, F., Castelain, V., Morel, G., L'Hotellier, S., Badie, J., Berdaguer, F. D., Malfroy, S., Mezher, C., Bourgoin, C., Moneger, G., Bouvier, E., Megarbane, B., Voicu, S., Deye, N., Malissin, I., Sutterlin, L., Mrad, A., Pepin Lehalleur, A., Naim, G., Nguyen, P., Ekherian, J., Boue, Y., Sideris, G., Vodovar, D., Guerin, E., Grant, C., Guitton, C., Darreau, C., Landais, M., Chudeau, N., Robert, A., Tirot, P., Callahan, J. C., Saint Martin, M., Le Moal, C., Marnai, R., Leroyer, M. H., Moine, P., Heming, N., Maxime, V., Bossard, I., Nicholier, T. B., Clair, B., Orlikowski, D., Bounab, R., Abdeladim, L., Colin, G., Zinzoni, V., Maquigneau, N., Henri-Lagarrigue, M., Pouplet, C., Soukup, J., Wetzold, R., Lobel, M., Ing, D., Starke, L., Grimm, P., Finn, A., KreSS, G., Hoff, U., Hinrichs, C. F., Nee, J., Pletz, M. W., Hagel, S., Ankert, J., Kolanos, S., Bloos, F., Nickoleit-Bitzenberger, D., Schaaf, B., Meermeier, W., Prebeg, K., Azzaui, H. S., Hower, M., Brieger, K., Elender, C., Sabelhaus, T., Riepe, A., Akamp, C., Kremling, J., Klein, D., Landsiedel-Mechenbier, E., Petros, S., Kunz, K., Schutze, B., Kluge, S., Nierhaus, A., Jarczak, D., Roedl, K., Gerhard, G., Rohde, U., Grunewaldt, A., Bojunga, J., Weismann, D., Frey, A., Drayss, M., Goebeler, M. E., Flor, T., Fragner, G., Wahl, N., Totzke, J., Sayehli, C., Reill, L., Distler, M., Maselli, A., Belteczki, J., Magyar, I., Fazekas, A., Kovacs, S., Szoke, V., Szigligeti, G., Leszkoven, J., Collins, D., Reid, L., Smyth, M., Breen, P., Spain, S., Curley, G., McEvoy, N., Geoghegan, P., Clarke, J., Laffeyirbre McNicholas, J., Scully, M., Casey, S., Kernan, M., Brennan, A., Rangan, R., Tully, R., Corbett, S., McCarthy, A., Duffy, O., Burke, D., Hayes, L., Murphy, L., Neill, A., Reidy, B., O'Dwyer, M., Ryan, D., Hoiting, O., Peters, M., Rengers, E., Evers, M., Prinssen, A., van den Oever, H. L., Kruisdijk-Gerritsen, A., Simons, K., van Zuylen, T., Bouman, A., van Gulik, L., Schouten, J., Pickkers, P., Roovers, N., Klop-Riehl, M., van der Eng, H., de Jonge, E., Wigbers, J., Del Prado, M., Mulier, J. H., Peters, A. L., Romberg, B., van Bree, S., Bouw-Ruiterrbara Festen, M., van Gelder, F., van Iperen, M., Osinga, M., Schellaars, R., Tjan, D., van der Wekken, R., Melchers, M., van Zanten, A., van Nieuwkoop, K., Ottens, T., Visser, Y., Juffermans, N., Koopmans, M., Guilder, E., Butler, M., Cowdrey, K., Woollett, M., Newby, L., Chen, Y., Simmonds, C., McConnochie, R., O'Connor, C., Ritzema Carter, J., Henderson, S., Van Der Heyden, K., Mehrtens, J., Morris, A., Morgan, S., Williams, T., Kazemi, A., Song, R., Lai, V., Girijadevi, D., Everitt, R., Russell, R., Hackin, D., Buehner, U., Williams, E., Browne, T., Grimwade, K., Goodson, J., Keet, O., Callender, O., Martynoga, R., Trask, K., Butler, A., Young, C., Lesona, E., Olatunji, S., MClinIm, M., Navarra, L., Sol Cruz, R., Perry, K., Fuchs, R., Lambert, B., Albrett, J., Jackson, C., Kirkham, S., Amaro Dos Santos Catorze, N. J., Lima Pereira, T. N., Castro Ferreira, R. M., Pereira Sousa Bastos, J. M., Oliveira Batista, T. M., Florescu, S. A., Stanciu, D., Zaharia, M. F., Kosa, A. G., Codreanu, D., Arabi, Y. M., Qasim, E. A., Tlayjeh, H., Alswaidan, L., Naidu, B., Munoz-Bermudez, R., Marin-Corral, J., Salazar Degracia, A., Parrilla Gomez, F., Mateo Lopez, M. I., Lopez, R. L., Rodriguez, J., Carcel, S., Carmona, R., de la Fuente, C., Rodriguez, M., Kaye, C., Allan, A., Summers, C., Polgarova, P., McWilliam, S. J., Hawcutt, D. B., Rad, L., O'Malley, L., Whitbread, J., Kelsall, O., Cowley, N., Wild, L., Thrush, J., Wood, H., Austin, K., Donnelly, A., Kelly, M., Smyth, N., O'Kane, S., McClintock, D., Warnock, M., Campbell, R., McCallion, E., Johnson, P., McKenna, S., Hanley, J., Currierbara Allen, A., McGoldrick, C., McMaster, M., Jha, R., Kalogirou, M., Ellis, C., Krishnamurthy, V., Deelchand, V., O'Connor, A., Silversides, J., McGuigan, P., Ward, K., O'Neill, A., Finn, S., Phillips, B., Ortiz-Ruiz de Gordoa, L., Bewley, J., Thomas, M., Sweet, K., Grimmer, L., Johnson, R., Pinnell, J., Robinson, M., Gledhill, L., Wood, T., Morgan, M., Cole, J., Hill, H., Davies, M., Angharad, A., Williams, W., Thomas, E., Davies, R., Wise, M., Antcliffe, D., Templeton, M., Rojo, R., Coghlan, P., Smee, J., Mackay, E., Cort, J., Whileman, A., Spencer, T., Spittle, N., Beavis, S., Padmakumar, A., Dale, K., Hawes, J., Moakes, E., Gascoyne, R., Pritchard, K., Stevenson, L., Cooke, J., Nemeth-Roszpopa, K., Kasipandian, V., Patel, A., Allibone, S., Mary-Genetu, R., Ramali, M., Ghosh, A., Osagie, R., Jayasinghe Arachchige, M., Hartley, M., Bamford, P., London, E., Cawley, K., Faulkner, M., Jeffrey, H., Sundar Raj, A., Tsinaslanidis, G., Nair Khade, R., Nwajei Agha, G., Nalumansi Sekiwala, R., Smith, T., Brewer, C., Gregory, J., Limb, J., Cowton, A., O'Brien, J., Postlethwaite, K., Nikitas, N., Wells, C., Lankester, L., McMillan, H., Pulletz, M., Birch, J., Wiseman, S., Horton, S., Alegria, A., Turki, S., Elsefi, T., Crisp, N., Allen, L., Smith, M., Chukkambotla, S., Goddard, W., Duberley, S., McCullagh, I. J., Robinson, P., Patel, B., Kelly, S., Touma, O., Holland, S., Hodge, C., Taylor, H., Alderman, M., Barnes, N., Da Rocha, J., Smith, C., Brooks, N., Weerasinghe, T., Sinclair, J., Abusamra, Y., Doherty, R., Cudlipp, J., Singh, R., Yu, H., Daebis, A., Ng, C., Kendrick, S., Saran, A., Makky, A., Greener, D., Rowe-Leete, L., Edwards, A., Bland, Y., Dolman, R., Foster, T., Linnett, V., Sanderson, A., Ritzema, J., Wild, H., Khare, D., Pinder, M., Selvamoni, S., Gopinath, A., Pugh, R., Menzies, D., Lean, R., Qiu, X., Scanlon, J. J., Puxty, K., Cathcart, S., Govern, C. M., Carmichael, S., Rimmer, D., Yusuff, H., Isgro, G., Brightling, C., Bourne, M., Craner, M., Boyles, R., Szakmany, T., Cherian, S., Williams, G., James, C., Waters, A., Watters, M., Prout, R., Davies, L., Pegler, S., Kyeremeh, L., Mian, A., Ostermann, M., Marotti, M., Novellas, N. G., Bociek, A., Brett, S., Sousa Arias, S., Hall, R. E., Jain, S., Gupta, A., Holbrook, C., Henning, J., Bonner, S., Hugill, K., Cirstea, E., Wilkinson, D., Jones, J., Karlikowski, M., Sutherland, H., Wilhelmsen, E., Woods, J., North, J., Sundaran, D., Hollos, L., Coburn, S., Williams, A., Saunders, S., Hopkins, P., Smith, J., Noble, H., Depante, M. T., Clarey, E., Laha, S., Verlander, M., Williams, A., Paramasivam, E., Wilby, E., Ogg, B., Howcroft, C., Aspinwall, A., Charlton, S., Gould, R., Mistry, D., Awan, S., Bedford, C., Hall, A., Cooke, J., Gardiner-Hill, C., Maloney, C., Brunskill, N., QureshiI, H. R., Flint, N., Nicholson, S., Southin, S., Nicholson, A., Ghattaoraya, A., Harding, D., O'Halloran, S., Collins, A., Smith, E., Trues, E., Borgatta, B., Turner-Bone, I., Reddy, A., Wilding, L., Wilson, C., Surti, Z., Chamara Warnapura, L., Agno, R., Sathianathan, P., Shaw, D., Ijaz, N., Burns, D., Nisar, M., Quick, V., Alexander, C., Patel, S., Hussain, N., Croucher, Y., Langnu Rudran, E., Gilani, S., Wieder, T., Tate, M. L., Golden, D., Davey, M., Seaman, R., Felton, T., Bannard-Smith, J., Henry, J., Clark, R., Birchall, K., Pomeroy, F., Quayle, R., Wylie, K., Sukuraman, A., McNamarra, J., Makowski, A., Misztal, B., Ahmed, I., Neicker, K., Millington, S., Squires, R., Phulpoto, M., Stewart, R., Mwaura, E., Mew, L. E., Wren, L., Willams, F., Oborska, A., Maeda, R., Kalchko-Veyssal, S., Prabakaran, R. O., Hadebe, B., Makmur, E., Nicholls, G., Innes, R., Doble, P., Graham, L., Shovelton, C., Hamlyn, V., Hawkins, N., Roynon-Reed, A., Cutler, S., Lewis, S., Lazaro, J. M., Newman, T., Austin, P., Chapman, S., Cabrelli, L., Fletcher, S., Nortje, J., Fottrell-Gould, D., Randell, G., Stammers, K., Zaman, M., Elmahi, E., Jones, A., Hall, K., Mills, G. H., Ryalls, K., Harrington, K., Bowler, H., Sall, J., Bourne, R., Borrill, Z., Duncan, T., Lamb, T., Shaw, J., Fox, C., Smith, K., Holland, S., Blackledge, B., McMorrow, L., Durrans, L., Harris, J., Moreno Cuesta, J., Xavier, K., Purohit, D., Elhassan, M., Haldeos, A., Vincent, R., Abdelrazik, M., Jenkins, S., Ganesan, A., Kumar, R., Carter, D., Bakthavatsalam, D., Rowland, M., Hutton, P., Bashyal, A., Davidson, N., Hird, C., Beer, S., Chhablani, M., Phalod, G., Kirkby, A., Archer, S., Netherton, K., Philips, B., Mullan, D., Skinner, D., Gaylard, J., Newman, J., Arun Sathe, S., Roche, L., Davies, E., Turner, K., Reschreiter, H., Camsooksai, J., Patch, S., Jenkins, S., Humphrey, C., Pogson, D., Rose, S., Daly, Z., Brimfield, L., Nown, A., Parekh, D., Bergin, C., Bates, M., McGhee, C., Lynch, D., Bhandal, K., Tsakiridou, K., Bamford, A., Cooper, L., Whitehouse, T., Veenith, T., Sim, M. A., Kennedy Hay, S., Henderson, S., Nygren, M., Valentine, E., Katary, A., Bell, G., Wilcox, L., English, K., Adams, A., Phull, M., Zaidi, A., Pogreban, T., Rosaroso, L. P., Harvey, D., Lowe, B., Meredith, M., Ryan, L., Hormis, A., Walker, R., Collier, D., Kimpton, S., Oakley, S., Rooney, K., Rodden, N., Hughes, E., Thomson, N., McGlynn, D., Clark, C., Clark, P., Walden, A., Keating, L., Frise, M., Okeke, T., Jacques, N., Coles, H., Tilney, E., Vowell, E., Schuster-Bruce, M., Pitts, S., Miln, R., Purandare, L., Vamplew, L., Patel, B., Dempster, D., Gummadi, M., Dormand, N., Wang, S. F., Spivey, M., Bean, S., Burt, K., Moore, L., Day, C., Gibson, C., Gordon, E., Zitter, L., Keenan, S., Singh, J., Lynch, C., Mikusek, J., Deacon, B., Baker, E., Hickey, J., Champanerkar, S., Aitken, L., Lewis Prosser, L., Raithatha, A., Bauchmuller, K., Ahmad, N., Wiles, M., Willson, J., Grecu, I., Martin, J., Wrey Brown, C., Arias, A., Bevan, E., Craven, T. H., Hope, D., Singleton, J., Clark, S., McCulloch, C., Welters, I. D., Hamilton, D. O., Williams, K., Waugh, V., Shaw, D., Mulla, S., Waite, A., Fernandez Roman, J., Lopez Martinez, M., Puthucheary, Z., Martin, T., Santos, F., Uddin, R., Fernandez, M., Seidu, F., Somerville, A., Pakats, M. L., Dias, P., Begum, S., Shahid, T., Bhagani, S., De Neef, M., Filipe, H., Mingos, S., Maharajh, A., Pakou, G., Nandani, A., Tatham, K. C., Jhanji, S., Blackurs, E., Dela Rosaurs, A., Howle, R., Baikady, R. R., Tully, R. P., Drummond, A., Dearden, J., Philbin, J. E., Munt, S., Gopal, S., Pooni, J., Ganguly, S., Smallwood, A., Metherell, S., Vuylsteke, A., Chan, C., Victor, S., Hospital, P., Matsa, R., Gellamucho, M., Creagh-Brown, B., Tooley, J., Montague, L., De Beaux, F., Bullman, L., Kerslake, I., Demetriou, C., Mitchard, S., Ramos, L., White, K., Reay, M., Jenkins, S., Tuckwell, C., Watts, A., Traverse, E., Jennings, S., Donnison, P., Johns, M., Casey, R., Mattocks, L., Salisbury, S., Dark, P., Harvey, A., Reece, R., Doonan, D., Knowles, K., Hulme, J., Kannan, S., Joseph, S., Kinney, F., Senya, H. J., Ratnam, V., Gill, M., Kirk, J., Shelton, S., Frey, C., Scano, R., McKee, M., Murphy, P., Thomas, M., Worner, R., Faulkner, B., Gendall, E., Hayes, K., Blakemore, H., Borislavova, B., Hamilton-Davies, C., Chan, C., Mfuko, C., Abbass, H., Mandadapu, V., Leaver, S., Patel, K., Farnell-Ward, S., Pepermans Saluzzio, R., Rawlins, J., Banach, D., Fernandez de Pinedo Artaraz, Z., Cabreros, L., White, I., Croft, M., Holland, N., Pereira, R., Zaki, A., Johnson, D., Jackson, M., Garrard, H., Juhaz, V., Brown, L., Roy, A., Rostron, A., Woods, L., Cornell, S., Pillai, S., Harford, R., Ivatt, H., Evans, D., Richards, S., Roberts, E., Bowen, J., Ainsworth, J., Clark, T., Foulds, A., Atkins, S., Lee, K., Barber, R., Hilldrith, A., Hewitt, C., Bremmer, P., Ward, G., Bassford, C., Brohi, F., Jagannath, V., Clark, M., Purvis, S., Wetherill, B., Dushianthan, A., Cusack, R., de Courcy-Golder, K., Salmon, K., Burnish, R., Smith, S., Jackson, S., Ruiz, W., Duke, Z., Johns, M., Male, M., Gladas, K., Virdee, S., Swabe, J., Tomlinson, H., Attwood, B., Parsons, P., Campbell, B., Smith, A., Page, V. J., Zhao, X. B., Oza, D., Abrahamson, G., Sheath, B., Ellis, C., Rhodes, J., Anderson, T., Morris, S., Xia Le Tai, C., Thomas, A., Keen, A., Tridente, A., Shuker, K., Anders, J., Greer, S., Scott, P., Millington, A., Buchanan, P., Kirk, J., Denmade, C., Sadera, G., Jacob, R., Jones, C., Hughes, D., Digby, S., Southern, D., Reddy, H., Hulse, S., Campbell, A., Garton, M., Watkins, C., Smuts, S., Quinn, A., Simpson, B., McMillan, C., Finch, C., Hill, C., Cooper, J., Budd, J., Small, C., O'Leary, R., Birch, J., Collins, E., Alexander, P. D., Ferguson, S., Sellers, K., Bradley-Potts, J., Yates, D., Birkinshaw, I., Kell, K., Scott, Z., Pearson, H., Stavor, D., Burbee, D., McNamara, A., Bensen, N., Richardson, A., Adams, P., Vita, T., Buhay, M., Scholl, D., Gilliam, M., Winters, J., Doherty, K., Berryman, E., Ghaffari, M., Fitzpatrick, M., Bagavathy, K., Drapola, D., Hussain, M., Donadee, C., Bryan-Morris, K., Arnold, J., Reynolds, B., Beard, G., McAdams, D., Walker, G., Dunsavage, J., Saiyed, S., Hernandez, E., Goldman, J., Brown, C., Comp, S., Raczek, J., Morris, J. L., Vargas, J. J., Weiss, D., Hensley, J. W., Kochert, E., Wnuk, C., Nemeth, C., Mowery, B., Hutchinson, C., Winters, L., McCreary, E., Martin, E., Bariola, R., Viehman, A., Daley, J., Lopus, A., Schmidhofer, M., Sackrowitz, R., Skrtich, A., Minnier, T., Wisniewski, M. K., Mayak, K., Ambrosino, R., Keen, S., Della Toffalo, S., Stambaugh, M., Trimmer, K., Perri, R., Casali, S., Medva, R., Massar, B., Beyerl, A., Burkey, J., Keeler, S., Lowery, M., Oncea, L., Daugherty, J., Sevilla, C., Woelke, A., Dice, J., Weber, L., Roth, J., Ferringer, C., Beer, D., Fesz, J., Carpio, L., Malakouti, S., Clermont, G., Bart, R., Yealy, D., Barton, D., Talia, N., Schoenling, A., Andreae, M., Shetty, V., Malley, B., Bain, W., Barbash, I., Franz, C., Kitsios, G., Moghbeli, K., Rosborough, B., Shah, F., Suber, T., Roberts, T., Becker, R. C., Del Zoppo, G., Henke, P., Holubkov, R., Kerr, K., Lee, A., Lurie, F., Vesely, S. K., Hochman, J. S., Neal, M. D., Berger, J. S., Cushman, M., Baumann Kreuziger, L., Farkouh, M., Gong, M. N., Hudock, K., Mstr, M., Kim, K. S., Kornblith, L. Z., Lawler, P. R., Leifer, E., McVerry, B. J., Reynolds, H. R., Wilson, J. G., Hochman, J., Berger, J., Reynolds, H., Contreras, A., Mavromichalis, S., Gilsenan, M., Naumova, A., Roberts, A., Wisniewski, S., Leeper, C., Eng, H., Brooks, M., Martinez, M., Schreiber, J., Froess, J., Fu, Z., Zhong, Y., Vadlamudi, A., Sciurba, F., Morris, A., Kirwan, B., de Brouwer, S., Perrin, E., Gombault, C., Bula, S., Nelson, M., Daelemans, C., Wegmuller, R., La Framboise, D., Hoots, W. K., Kindzelski, A., Mondoro, T., Punturieri, A., Weinmann, G., Troendle, J. F., Kendrick, A. S., Nolen, T. L., Thomas, S., Sin, D., Diene, E., Gwiszcz, E., Hogan, I., Holden, A., Gong, M., Ringwood, N., Fitzgerald, L., Sharer, J., Ceusters, D., Hintlian, C., Kornblith, L., Nunez-Garcia, B., Uribe, V., Hendrickson, C., Barua, C., Knudson, M. M., Park, J., Gonzalez, A., Lopez-Sendon, J., Moraga Alapont, P., Prieto, P., Hernandez, V., Broaddrick, S., Kim, K., Quigley, S., Kamel, H., Khatri, P., Frasure, J., Silken, A., Lopez-Sendon Moreno, J. L., Morillo Guerrero, R., Garcia Madrona, S., Molinera, A., Navarro Carrion, O., Besse Diaz, R., Diz Farina, S., Hidalgo Salinas, F., Gonzalez Ferrandiz, P., Zhilina, S., Alpanes Buesa, M., Gonzalez Garcia, A., Marcos Martin, M., Sanchez, M., Hernandez, J., Alvarez Navid, F., Garcia, M. B., Carbonell Munoz, C., Hernandez Perez, G., Lopez Bernus, A., Oterino, J. A., Keller, N., Yuriditsky, E., Ahuja, T., Horowitz, J., Hindenburg, A., Chkhikvadze, T., Parnia, S., Moran, Z., Fadzan, M., Levine, J., Cobos, S., Roberts, A., Mamistvalova, L., Garabedian, M., Ahmed, F., Zapata, G., Robinson, M., Quigley, J., Jacobson, J., Atal, N., Amosu, O., Tzehaie, H., Nair, R., Lopez, B., Hache Marliere, M., Fein, D., Offor, O., Kiyatkin, M., Chekuri, S., Galen, B., Hambardzumyan, A., Desai, A., Akhter, M., Aleem, H., Virdi, S., Shah, R., Hope, A., Chen, J., Mohamed, A., Kornblith, A., Shelley, I., Ambachew, B., Abaye, M., Yang, A., Amin, S. S., King, A. J., Franz, C. A., Kitsios, G. D., Mayr, F. B., Shah, F. A., Shetty, V. U., Schaefer, C., Muir, M., Urbanek, K. L., Greenstein, Y., Teeter, R., Plump, M., Kovalenko, O., Obando, E., Taveras, Y., Fanka, B., Suri, N., Patel, S., Kaur, M., Hite, R., Roads, T., Gebremedhen, A., Kiran, S., More, H., Costantini, T., Curry, T., Trinidad, E., Tyler, M., Berndtson, A., Allison, M., Bhatia, H., Denenberg, J., Marsh-Armstrong, B., Verzhbinsky, I., Morris, T., Fernandes, T., Elliott, A., Eastman, A., Lim, G., Hendey, G., Chang, S., Qadir, N., Beutler, R., Agarwal, T., Vargas, J., Singer, J., Haase, D., Murphy, J., Brzezinski, A., Yap, A., Yao, D. H., Bolduc, C., Antonuk, C., Spungen, H., Vuong, A., Wilson, J., Rogers, A., Levitt, J., Vojnik, R., Roque, J., Perez, C., Khan, A., Krol, O., Mistry, K., Nguyen, K., Lu, Z., Jouzestani, M. K., Singh, A., Mcdougal, M., Salar, A., Florea, S., Adi, R., Anadkat, C., Mills, E., Zouyed, Z., Deshmukh, R., Hough, C., Widmer, R., Fikes, W., Kiesle, E., Hyzy, R., Park, P., Jia, S., McSparron, J., Wang, B., Hanna, S., McDonough, K., Melvin, A., Nelson, K., Olbrich, N., Goodman, A., Hank, H. E., Quillen, D., Shamsuddin, A., Michl, L., Harper, M., Phipps, M., Braker, C., Wahid, L., Mohammed, O., Gazda, S., Craven, J., Jackson, R., Abuchowski, K., Dolor, R., Ortel, T., Manson, M., Vergara, L., Pinero, G., Freel, S., Krishnan, V., Newman, C., Leo, P., Greenwood, C., Wright, A., Warren, E. L., Thornton, J. D., Frolkis, C., Matthay, M., Kangelaris, K., Liu, K., Zhuo, H., Daniel, B., Yee, K., Jauregui, A., Ghale, R., Chak, S., Wick, K., Siegel, E., Jones, C., Ashktorab, K., Satterwhite, L., Harris, P., Lovell, K., Mourad, M., Bengtson, C., Atieh, T., Brownback, K., Aguiar, C., White, M., Deculus, K., Scott, L., English, L., Greer, S., Murry, S., Woodring, L., Nazir, U., Truong, A., Mallett, N., Williams, S., Hellwig, H., Burton, M., Pandey, A., Bates, C., Lewis, B., Tarbutton, J., Kondamudi, N., Huet, R. G., Xu, X., Berger-Nagele, M., Molina, E., Duggal, A., Mucha, S., Mehkri, O., King, A., Poynter, B., Ashok, K., Thiruchelvam, N., Sahoo, D., Goyanes, A., Siuba, M., Sunderkrishnan, R., Minear, S., Hernandez-Montfort, J., Mehta, J., McWilliams, C., Anekwe, C., Van, A., Calderon, A., Arazo, L., Sohaib Nasim, S., De Carvalho Teixeira, C., Zelaya, D., Malhotra, S., Nedeltcheva, A., Rezai, K., Hoffman, M., Hernandez Acosta, R., Sarmiento, J., Uday, S., Hanna, N., Malik, A., Merritt, S., Davenport, J., Mears, K., Bryce, J., Arnold, M., Norwood, J., Urias, C., Kutcher, M., Galbraith, J., Jones, A., Nandi, U., Garla, V., Peacock, R., Davis, J., Grenn, E., Shaw, T., Moore, M., Prekker, M., Puskarich, M., Driver, B., Baker, J., Frosch, A., Kolb, A., Hubbard, L., Dunn, A., Hendrickson, A., Maruggi, E., Andersen, T., Miller, W., Raiter, A., Edpuganti, R., Ehlen, Q., Leland, G., Roth, M., Scharber, T., Tordsen, W., Reing, M., Isaksen, A., Erickson, H., Sheehan, J., Stewart, S., Kumfer, K., Veintimilla, R., Roginski, C., Bonk, N., Ensminger, S., Shahzeb Munir, M., Octain, J., Sheehy, A., Waters, A., Wilson, S., Hamburg, N., Minetti, E. T., Damus, K., Eberhardt, R., Klings, E., Zheng, R., Behrooz, L., Gao, A., Cohen, M., Robinson, C., Byars, A., Fitzpatrik-Wilson, M., Ling, K., Bendelow, T., Wallace, J., Douglas, I., Gandotra, S., Dransfield, M., Westfall, E., Whitson, M., Harris, D., Russell, D., Patel, S., Shah, B., Maranan, L., Choy-Shan, A., Smilowitz, N., Donnino, R., Lorin, J., Keary, M., Moore, S., Karamchandani, K., Go, P., Bonavia, A., Fender, L., Campbell, N., Howrylak, J., Gardner, K., Fox, L., Trump, P., Loffredo, K., Snyder, M., O Brien, S., Schultz, L., Kinard, S., Bochicchio, G., Bochicchio, K., Reese, S., Fonseca, R., Sato, B., Ferguson, K., Machica, C., McCarthy, J., Aldana, J., Rasane, R., Canas, M., Afzal, H., Osborn, T., Hoofnagle, M., Leonard, J., Snyder, J., Schuerer, D., Stewart, M., Kopar, P., Vallar, K., Kramer, J., Turnbull, I., Douketis, J., Scales, D., Nickerson, P., Rosenson, R., Nicolau, J., Escobedo, J., Turgeon, A. F., Dzavik, V., Gibson McDonald, E., Gross, P., Houston, B., Hussain, M., Kahn, S., Slutsky, A., Tritschler, T., Ostrowski, M., Dubois, S., Bond, L., Amaral, J., Wareham, V., Trafford, K., Khanna, M., Solvason, D., Hayes, K., Hiebert, L., Musto, H., Kannu, M., Martinez, A., Ohara, P., Bacca, J., de Jesus, N., Zier, S., Assis, D., Huemer, N., Martins, N., Nakajima, F., Everett, B., van Diepen, S., Le Gal, G., Siegal, D., Galanaud, J., Hegde, S., Kim, Y., Rost, N., Singhal, A., Selby, R., Alias, S., Silva, R., Dao, V., Hutmacher, M., Rigaux, L., Tays, Q., Kashani, H., Drobot, G., Choi, N., Dunbar-Yaffe, R., Shafiee, M., Wong, J., Zondag, M., Castellucci, L., Philips, P., Meteb, M., Couillard-Chenrd, E., Duceppe, E., Carling, R., Durand, M., Tagalakis, V., Shulikovsky, E., Florencio, S., McDonald, E., Elsayed, S., Moran, K., Lavoie, A., Townsend, K., Ovakim, D., Parfett, D., Gross, F. A., Michele, M., Carrier, Z. M., Carrier, M., Paul, J., Arevalo, C., Molignoni, K., Effron, M. B., Cohen, S., McDaniel, H., Nair, G. B., Osentoski, T., Schoen, M., Courtright, K., Reno, K., Meyer, D., Gerry, T., Aday, A., Shardelow, E., Burton, M., Kaatz, S., Ellsworth, S., Wells, B., Merlin, C., Fieback, A., Iyer, V., Johnson, M., Mistry, N., Turner, A., Puri, N., Schorr, C., Go, R., Canino, P., Billett, H., Mazniku, E., Gallego Lima, F., Vieira, A., Maia, R., Mostachio, A., Braga, W., Lima, S., Santos, F., Siciliano, R., Furtado, R., Ferraz Assir, F., Moraes, B., Santos, M., Barros, L., Herdy, A., Pereira, V., Hernandes, M., Amorim, R., Bandeira, M., Kormann, A., Spricigo, J., Zimmerman, S., Tumelero, R., Giordani, A., Ghizzoni, F., Manenti, E., Ruschel, K., Borba, A., Saraiva, J., Vicente, C., Silva Joao Moraes, M. J., Ribeiro, S., Barros Delcio Silva, T. J., Serafin, P., Dutra, J. X., Brum, A., Procopio, A., Alves, M., Grumach, A., Bertolini, L., Porto, C., Oliveira, S., Burihan, M., Santos Delcio Silva, M. J., Nery, E., Saporito, W., Pereira, T., Mancini, B., Kowalski Neto, E., Andrade, B., Santos, J., Pompilio, M., Pompilio, R., Grava, S., Koga, K., Silva, M., Lemos, D., Villegas, B., Garcia, E. M., Cortes Vazquez, M. A., Perez Gonzalez, Y. S., Carreno Perez, P., Valenzuela, J., Santillan, J. A. 2021

    Abstract

    BACKGROUND: Thrombosis and inflammation may contribute to morbidity and mortality among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation would improve outcomes in critically ill patients with Covid-19.METHODS: In an open-label, adaptive, multiplatform, randomized clinical trial, critically ill patients with severe Covid-19 were randomly assigned to a pragmatically defined regimen of either therapeutic-dose anticoagulation with heparin or pharmacologic thromboprophylaxis in accordance with local usual care. The primary outcome was organ support-free days, evaluated on an ordinal scale that combined in-hospital death (assigned a value of -1) and the number of days free of cardiovascular or respiratory organ support up to day 21 among patients who survived to hospital discharge.RESULTS: The trial was stopped when the prespecified criterion for futility was met for therapeutic-dose anticoagulation. Data on the primary outcome were available for 1098 patients (534 assigned to therapeutic-dose anticoagulation and 564 assigned to usual-care thromboprophylaxis). The median value for organ support-free days was 1 (interquartile range, -1 to 16) among the patients assigned to therapeutic-dose anticoagulation and was 4 (interquartile range, -1 to 16) among the patients assigned to usual-care thromboprophylaxis (adjusted proportional odds ratio, 0.83; 95% credible interval, 0.67 to 1.03; posterior probability of futility [defined as an odds ratio <1.2], 99.9%). The percentage of patients who survived to hospital discharge was similar in the two groups (62.7% and 64.5%, respectively; adjusted odds ratio, 0.84; 95% credible interval, 0.64 to 1.11). Major bleeding occurred in 3.8% of the patients assigned to therapeutic-dose anticoagulation and in 2.3% of those assigned to usual-care pharmacologic thromboprophylaxis.CONCLUSIONS: In critically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulation with heparin did not result in a greater probability of survival to hospital discharge or a greater number of days free of cardiovascular or respiratory organ support than did usual-care pharmacologic thromboprophylaxis. (REMAP-CAP, ACTIV-4a, and ATTACC ClinicalTrials.gov numbers, NCT02735707, NCT04505774, NCT04359277, and NCT04372589.).

    View details for DOI 10.1056/NEJMoa2103417

    View details for PubMedID 34351722

  • Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. The New England journal of medicine ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, Lawler, P. R., Goligher, E. C., Berger, J. S., Neal, M. D., McVerry, B. J., Nicolau, J. C., Gong, M. N., Carrier, M., Rosenson, R. S., Reynolds, H. R., Turgeon, A. F., Escobedo, J., Huang, D. T., Bradbury, C. A., Houston, B. L., Kornblith, L. Z., Kumar, A., Kahn, S. R., Cushman, M., McQuilten, Z., Slutsky, A. S., Kim, K. S., Gordon, A. C., Kirwan, B., Brooks, M. M., Higgins, A. M., Lewis, R. J., Lorenzi, E., Berry, S. M., Berry, L. R., Angus, D. C., McArthur, C. J., Webb, S. A., Farkouh, M. E., Hochman, J. S., Zarychanski, R., Aday, A. W., Al-Beidh, F., Annane, D., Arabi, Y. M., Aryal, D., Baumann Kreuziger, L., Beane, A., Bhimani, Z., Bihari, S., Billett, H. H., Bond, L., Bonten, M., Brunkhorst, F., Buxton, M., Buzgau, A., Castellucci, L. A., Chekuri, S., Chen, J., Cheng, A. C., Chkhikvadze, T., Coiffard, B., Costantini, T. W., de Brouwer, S., Derde, L. P., Detry, M. A., Duggal, A., Dzavik, V., Effron, M. B., Estcourt, L. J., Everett, B. M., Fergusson, D. A., Fitzgerald, M., Fowler, R. A., Galanaud, J. P., Galen, B. T., Gandotra, S., Garcia-Madrona, S., Girard, T. D., Godoy, L. C., Goodman, A. L., Goossens, H., Green, C., Greenstein, Y. Y., Gross, P. L., Hamburg, N. M., Haniffa, R., Hanna, G., Hanna, N., Hegde, S. M., Hendrickson, C. M., Hite, R. D., Hindenburg, A. A., Hope, A. A., Horowitz, J. M., Horvat, C. M., Hudock, K., Hunt, B. J., Husain, M., Hyzy, R. C., Iyer, V. N., Jacobson, J. R., Jayakumar, D., Keller, N. M., Khan, A., Kim, Y., Kindzelski, A. L., King, A. J., Knudson, M. M., Kornblith, A. E., Krishnan, V., Kutcher, M. E., Laffan, M. A., Lamontagne, F., Le Gal, G., Leeper, C. M., Leifer, E. S., Lim, G., Lima, F. G., Linstrum, K., Litton, E., Lopez-Sendon, J., Lopez-Sendon Moreno, J. L., Lother, S. A., Malhotra, S., Marcos, M., Saud Marinez, A., Marshall, J. C., Marten, N., Matthay, M. A., McAuley, D. F., McDonald, E. G., McGlothlin, A., McGuinness, S. P., Middeldorp, S., Montgomery, S. K., Moore, S. C., Morillo Guerrero, R., Mouncey, P. R., Murthy, S., Nair, G. B., Nair, R., Nichol, A. D., Nunez-Garcia, B., Pandey, A., Park, P. K., Parke, R. L., Parker, J. C., Parnia, S., Paul, J. D., Perez Gonzalez, Y. S., Pompilio, M., Prekker, M. E., Quigley, J. G., Rost, N. S., Rowan, K., Santos, F. O., Santos, M., Olombrada Santos, M., Satterwhite, L., Saunders, C. T., Schutgens, R. E., Seymour, C. W., Siegal, D. M., Silva, D. G., Shankar-Hari, M., Sheehan, J. P., Singhal, A. B., Solvason, D., Stanworth, S. J., Tritschler, T., Turner, A. M., van Bentum-Puijk, W., van de Veerdonk, F. L., van Diepen, S., Vazquez-Grande, G., Wahid, L., Wareham, V., Wells, B. J., Widmer, R. J., Wilson, J. G., Yuriditsky, E., Zampieri, F. G., Connor, J., Manax, V., Bion, J., Gates, S., Reynolds, J., Douketis, J., Scales, D., Zarychanski, R., Lawler, P., Goligher, E., Rosenson, R., Nicolau, J., Escobedo, J., Farkouh, M., Fergusson, D., Kumar, A., Marten, N., Marshall, J., Turgeon, A. F., Bradbury, C., Carrier, M., Dzavik, V., Fowler, R., Gibson McDonals, E., Gross, P., Houston, B., Hussain, M., Kahn, S., Murthy, S., Slutsky, A., Tritschler, T., Ostrowski, M., Dubois, S., Bond, L., Amaral, J., Wareham, V., Trafford, K., Khanna, M., Solvason, D., Hayes, K., Hiebert, L., Musto, H., Kannu, M., Kirwan, B., de Brouwer, S., Perrin, E., Martinez, A., Ohara, P., Bacca, J., de Jesus, N., Zier, S., Assis, D., Huemer, N., Martins, N., Nakajima, F., Everett, B., Diepen, S. v., Le Gal, G., Siegal, D., Galanaud, J., Hegde, S., Kim, Y., Rost, N., Singhal, A., Lewis, R., Detry, M., McGlothlin, A., Fitzgerald, M., Saunders, C., Brooks, M., Selby, R., Alias, S., Silva, R., Dao, V., Hutmacher, M., Rigaux, L., Tays, Q., Kashani, H., Drobot, G., Marten, N., Hutmacher, M., Choi, N., Dunbar-Yaffe, R., Shafiee, M., Wong, J., Zondag, M., Castellucci, L., Philips, P., Meteb, M., Watpool, I., Porteous, R., Bellemare, D., Costerousse, O., Cloutier, E., Daher, R., Boulanger, M., Couillard-Chenrd, E., Lauzier, F., Francoeur, C., Duceppe, E., Carling, R., Durand, M., Tagalakis, V., Shulikovsky, E., Florencio, S., McDonald, E., Elsayed, S., Moran, K., Lellouche, F., Lizotte, P., Lavoie, A., Townsend, K., Ovakim, D., Parfett, D., Auld, F., Michele, M., Carrier, Z. M., Potvin, M., Lamontagne, F., Carbonneau, E., Bouchard, M., Paul, J., Arevalo, C., Molignoni, K., Effron, M. B., Cohen, S., McDaniel, H., Nair, G. B., Osentoski, T., Schoen, M., Courtright, K., Reno, K., Meyer, D., Gerry, T., Levesque, A., Aday, A., Shardelow, E., Burton, M., Kaatz, S., Ellsworth, S., Wells, B., Merlin, C., Fieback, A., Iyer, V., Johnson, M., Mistry, N., Turner, A., Puri, N., Schorr, C., Go, R., Canino, P., Billett, H., Mazniku, E., Lima, F. G., Vieira, A., Maia, R., Mostachio, A., Braga, W., Lima, S., Santos, F., Siciliano, R., Furtado, R., Ferraz Assir, F., Moraes, B., Santos, M., Barros, L., Herdy, A., Pereira, V., Hernandes, M., Amorim, R., Bandeira, M., Kormann, A., Spricigo, J., Zimmerman, S., Tumelero, R., Giordani, A., Ghizzoni, F., Manenti, E., Ruschel, K., Borba, A., Saraiva, J., Vicente, C., Silva Joao Moraes, M. J., Ribeiro, S., Barros Delcio Silva, T. J., Serafin, P., Dutra, J. X., Brum, A., Procopio, A., Alves, M., Grumach, A., Bertolini, L., Porto, C., Oliveira, S., Burihan, M., Santos Delcio Silva, M. J., Nery, E., Saporito, W., Pereira, T., Mancini, B., Kowalski Neto, E., Andrade, B., Santos, J., Pompilio, M., Pompilio, R., Agostinho, T., Grava, S., Koga, K., Silva, M., Lemos, D., Villegas, B., Medina, O., Gudino, H., Borja, P., Mateos Garcia, E., Cortes Vazquez, M. A., Perez Gonzalez, Y. S., Carreno Perez, P., Santillan, J. A., Becker, R. C., Del Zoppo, G., Henke, P., Holubkov, R., Kerr, K., Lee, A., Lurie, F., Vesely, S. K., Hochman, J. S., Neal, M. D., Berger, J. S., Cushman, M., Baumann Kreuziger, L., Berry, S., Gong, M. N., Hudock, K., Kim, K. S., Kornblith, L. Z., Lawler, P. R., Leifer, E., McVerry, B. J., Reynolds, H. R., Wilson, J. G., Hochman, J., Berger, J., Reynolds, H., Bragat, A., Goldfeld, K., Hade, E., Contreras, A., Mavromichalis, S., Iturrate, E., Gilsenan, M., Naumova, A., Roberts, A., Neal, M., Wisniewski, S., Leeper, C., Angus, D., Eng, H., Linstrum, K., Seymour, C., Girard, T., Montgomery, S., Martinez, M., Schreiber, J., Froess, J., Fu, Z., Zhong, Y., Vadlamudi, A., Sciurba, F., Morris, A., Gombault, C., Bula, S., Nelson, M., Daelemans, C., Wegmuller, R., La Framboise, D., Hoots, W. K., Kindzelski, A., Mondoro, T., Punturieri, A., Weinmann, G., Troendle, J. F., Kendrick, A. S., Nolen, T. L., Thomas, S., Sin, D., Diene, E., Gwiszcz, E., Hogan, I., Holden, A., Gong, M., Ringwood, N., Fitzgerald, L., Sharer, J., Ceusters, D., Hintlian, C., Kornblith, L., Nunez-Garcia, B., Uribe, V., Hendrickson, C., Barua, C., Knudson, M. M., Park, J., Gonzalez, A., Lopez-Sendon, J., Moraga Alapont, P., Prieto, P., Hernandez, V., Broaddrick, S., Kim, K., Quigley, S., McVerry, B., Huang, D., Buxton, M., Roberts, T., Kamel, H., Khatri, P., Frasure, J., Silken, A., Lopez-Sendon Moreno, J. L., Morillo Guerrero, R., Garcia Madrona, S., Molinera, A., Navarro Carrion, O., Besse Diaz, R., Diz Farina, S., Hidalgo Salinas, F., Gonzalez Ferrandiz, P., Zhilina, S., Alpanes Buesa, M., Gonzalez Garcia, A., Marcos Martin, M., Sanchez, M., Hernandez, J., Alvarez Navid, F., Belhassen Garcia, M., Carbonell Munoz, C., Hernandez Perez, G., Lopez Bernus, A., Martin Oterino, J. A., Sanchez Fernandez, P. L., de Tapia Majado, B., Gonzalez Juanatey, J. R., Seijas, J., Dominguez Santallas, M. J., Pose Reino, A., Valdes Cuadrado, L., Rodriguez Nunez, N., Keller, N., Yuriditsky, E., Ahuja, T., Horowitz, J., Hindenburg, A., Chkhikvadze, T., Parnia, S., Moran, Z., Fadzan, M., Levine, J., Cobos, S., Roberts, A., Mamistvalova, L., Garabedian, M., Ahmed, F., Zapata, G., Robinson, M., Quigley, J., Jacobson, J., Atal, N., Amosu, O., Tzehaie, H., Nair, R., Lopez, B., Hache Marliere, M., Fein, D., Offor, O., Kiyatkin, M., Chekuri, S., Galen, B., Hambardzumyan, A., Desai, A., Akhter, M., Aleem, H., Virdi, S., Shah, R., Hope, A., Chen, J., Mohamed, A., Kornblith, A., Shelley, I., Ambachew, B., Bensen, N., Burbee, D., Richardson, A., McNamara, A., Stavor, D., Abaye, M., Scholl, D., Wunderley, R., Yang, A., Amin, S. S., Berryman, E., Gilliam, M., Basile, K., Clermont, G., Garrard, W., Horvat, C., Kalchthaler, K., King, A. J., Ricketts, D., Malakouti, S., Marroquin, O., Music, E., Quinn, K., Andreae, M., Bain, W., Barbash, I., Brant, E., Barton, D., Fitzpatrick, M., Franz, C. A., Haidar, G., Hussain, M., Kitsios, G. D., Mayr, F. B., Malley, B., McCreary, E., Moghbeli, K., Rosborough, B., Schoenling, A., Shah, F. A., Shetty, V. U., Suber, T., Talia, N., Weissman, A., Schaefer, C., Muir, M., Urbanek, K. L., Greenstein, Y., Teeter, R., Plump, M., Kovalenko, O., Obando, E., Taveras, Y., Fanka, B., Suri, N., Patel, S., Kaur, M., Hite, R., Roads, T., Gebremedhen, A., Kiran, S., More, H., Costantini, T., Curry, T., Trinidad, E., Tyler, M., Berndtson, A., Allison, M., Bhatia, H., Denenberg, J., Marsh-Armstrong, B., Verzhbinsky, I., Morris, T., Fernandes, T., Elliott, A., Eastman, A., Lim, G., Hendey, G., Chang, S., Qadir, N., Beutler, R., Agarwal, T., Vargas, J., Singer, J., Haase, D., Murphy, J., Brzezinski, A., Yap, A., Yao, D. H., Bolduc, C., Antonuk, C., Spungen, H., Vuong, A., Wilson, J., Rogers, A., Levitt, J., Vojnik, R., Roque, J., Perez, C., Khan, A., Krol, O., Mistry, K., Nguyen, K., Lu, Z., Jouzestani, M. K., Singh, A., Mcdougal, M., Salar, A., Florea, S., Adi, R., Anadkat, C., Mills, E., Zouyed, Z., Deshmukh, R., Hough, C., Widmer, R., Fikes, W., Kiesle, E., Hyzy, R., Park, P., Jia, S., McSparron, J., Wang, B., Hanna, S., McDonough, K., Melvin, A., Nelson, K., Olbrich, N., Goodman, A., Hank, H. E., Quillen, D., Shamsuddin, A., Michl, L., Harper, M., Phipps, M., Braker, C., Wahid, L., Mohammed, O., Gazda, S., Craven, J., Jackson, R., Abuchowski, K., Dolor, R., Ortel, T., Manson, M., Vergara, L., Pinero, G., Freel, S., Krishnan, V., Newman, C., Leo, P., Greenwood, C., Wright, A., Warren, E. L., Thornton, J. D., Frolkis, C., Matthay, M., Kirsten, K., Kangelaris, K., Liu, K., Calfee, C., Zhuo, H., Daniel, B., Yee, K., Jauregui, A., Ghale, R., Chak, S., Wick, K., Siegel, E., Jones, C., Ashktorab, K., Satterwhite, L., Harris, P., Lovell, K., Mourad, M., Bengtson, C., Atieh, T., Brownback, K., Aguiar, C., White, M., Deculus, K., Scott, L., English, L., Greer, S., Murry, S., Woodring, L., Nazir, U., Truong, A., Mallett, N., Williams, S., Hellwig, H., Burton, M., Pandey, A., Bates, C., Lewis, B., Tarbutton, J., Kondamudi, N., Huet, R. G., Xu, X., Berger-Nagele, M., Molina, E., Duggal, A., Mucha, S., Mehkri, O., King, A., Poynter, B., Ashok, K., Thiruchelvam, N., Sahoo, D., Goyanes, A., Siuba, M., Sunderkrishnan, R., Minear, S., Hernandez-Montfort, J., Mehta, J., McWilliams, C., Anekwe, C., Van, A., Calderon, A., Arazo, L., Nasim, S. S., De Carvalho Teixeira, C., Zelaya, D., Malhotra, S., Nedeltcheva, A., Rezai, K., Hoffman, M., Hernandez Acosta, R., Sarmiento, J., Uday, S., Hanna, N., Malik, A., Merritt, S., Davenport, J., Mears, K., Bryce, J., Arnold, M., Norwood, J., Urias, C., Kutcher, M., Galbraith, J., Jones, A., Nandi, U., Garla, V., Peacock, R., Davis, J., Grenn, E., Shaw, T., Moore, M., Prekker, M., Puskarich, M., Driver, B., Baker, J., Frosch, A., Kolb, A., Hubbard, L., Dunn, A., Hendrickson, A., Maruggi, E., Andersen, T., Miller, W., Raiter, A., Edpuganti, R., Ehlen, Q., Leland, G., Roth, M., Scharber, T., Tordsen, W., Reing, M., Isaksen, A., Erickson, H., Sheehan, J., Stewart, S., Kumfer, K., Veintimilla, R., Roginski, C., Bonk, N., Ensminger, S., Munir, M. S., Octain, J., Sheehy, A., Waters, A., Wilson, S., Hamburg, N., Minetti, E. T., Damus, K., Eberhardt, R., Klings, E., Zheng, R., Behrooz, L., Gao, A., Cohen, M., Robinson, C., Byars, A., Fitzpatrik-Wilson, M., Ling, K., Bendelow, T., Wallace, J., Douglas, I., Gandotra, S., Dransfield, M., Westfall, E., Whitson, M., Harris, D., Russell, D., Patel, S., Shah, B., Maranan, L., Choy-Shan, A., Smilowitz, N., Donnino, R., Lorin, J., Keary, M., Moore, S., Karamchandani, K., Go, P., Bonavia, A., Fender, L., Campbell, N., Howrylak, J., Gardner, K., Fox, L., Trump, P., Loffredo, K., Snyder, M., O Brien, S., Schultz, L., Kinard, S., Bochicchio, G., Bochicchio, K., Reese, S., Fonseca, R., Sato, B., Ferguson, K., Machica, C., McCarthy, J., Aldana, J., Rasane, R., Canas, M., Afzal, H., Osborn, T., Hoofnagle, M., Leonard, J., Snyder, J., Schuerer, D., Stewart, M., Kopar, P., Vallar, K., Kramer, J., Turnbull, I., van der Poll, T., Al-Beidh, F., Annane, D., Arabi, Y., Beane, A., van Bentum-Puijk, W., Bhimani, Z., Bonten, M., Brunkhorst, F., Cheng, A., Derde, L., Estcourt, L., Goossens, H., Gordon, A., Green, C., Haniffa, R., Litton, E., McArthur, C., McAuley, D., McGuinness, S., Mouncey, P., Nichol, A., Parke, R., Parker, J., Rowan, K., Santos, M., Shankar-Hari, M., Turgeon, A., Turner, A., van de Veerdonk, F., Webb, S., Campbell, L., Forbes, A., Gattas, D., Heritier, S., Kruger, P., Peake, S., Presneill, J., Seppelt, I., Trapani, T., Young, P., Cuthbertson, B., Manoharan, V., Aryal, D., Beane, A., Dondrop, A. M., Hashmi, M., Jayakumar, D., Tolppa, T., Singh, V., Brillinger, N., Cecconi, M., Ermann, S., Francois, B., Hullegie, S., Markgraff, R., Pletz, M., Povoa, P., Rohde, G., Parker, L., Scheepstra-Beukers, I., Alexander, B., Mayr, F., Beasley, R., Daneman, N., Fowler, R., McGloughlin, S., Morpeth, S., Paterson, D., Venkatesh, B., de Jong, M., Uyeki, T., Baillie, K., Duffy, E., Hills, T., Orr, K., Patanwala, A., Tong, S., Cooper, N., Cremer, O., Galea, J., King, A., Leavis, H., Netea, M., Ogungbenro, K., Patawala, A., Pettila, V., Rademaker, E., Saxena, M., Sligl, W., Tong, S., Youngstein, T., Seymour, C. W., Bihari, S., Hunt, B., Jayakumar, D., Laffan, M., Lother, S., Middeldorp, S., McQuilten, Z., Schutgens, R., Stanworth, S., Adhikari, N., Anstey, M., de Man, A., Lamonagne, F., Masse, M., Udy, A., Arnold, D., Begin, P., Charlewood, R., Chasse, M., Coyne, M., Cooper, J., Daly, J., Gosbell, I., Harvala-Simmonds, H., Hills, T., MacLennan, S., Menon, D., McDyer, J., Pridee, N., Roberts, D., Thomas, H., Tinmouth, A., Triulzi, D., Walsh, T., Wood, E., O'Kane, C., Shyamsundar, M., Sinha, P., Thompson, T., Young, I., Lawless, P., Ferguson, N., Hodgson, C., Laffey, J., Orford, N., Neto, A., Baron, R., Epelman, S., Frankfurter, C., Gommans, F., Kim, E., Leaf, D., Vaduganathan, M., van Kimmenade, R., Sanil, A., Berry, L., Lorenzi, E., Buzgau, A., Higgins, A., Zammit, C., Groeneveld, E., Peters, S., Okundaye, C., van Hout, D., Smit, A., Rikkert, L., Bari, S., Raymakers, K., Kwakkenbos-Craanen, M., Post, S., Schreuder, G., Markgraf, R., Ainscough, K., Brickell, K., Doran, P., Anjum, A., Lane, J., Fagbodun, E., Miller, L., Parry-Billings, K., Peters, S., Richards-Belle, A., Saull, M., Sprinckmoller, S., Wiley, D., van Beurden, M., Effelaar, E., Schotsman, J., Boyd, C., Harland, C., Shearer, A., Wren, J., Quinn, K., Attanayaka, U., Darshana, S., Ishani, P., Jawad, I., Pabasara, U., Udayanga, I., Gilmour, K., Pearson, K., Siewerski, C., Hurford, S., Marsh, E., Campbell, D., Williams, P., Shirley, K., Logan, M., Hanson, J., Dilley, B., Phillips, L., Oliver, A., Sutu, M., Murphy, S., Aravindan, L., Collins, J., Monaghan, H., Unsworth, A., Beddows, S., Dawson, L. A., Dyas, S., Asghar, A., Donaldson, K., Skinner, T., Mguni, N., Muzengi, N., Luo, J., O'Reilly, J., Levett, C., Potter, A., Porter, D., Lockett, T., Bartholomew, J., Rook, C., McKay, R., Williams, H., Hall, A., Campbell, H., Speight, H., Halden, S., Harrison, S., Naz, M., Lomme, K., Sharratt, P., Sheffield, J., Van't Hoff, W., Williamson, J. D., Barnard, A., Birch, C., Brend, M., Chambers, E., Crawshaw, S., Drake, C., Duckles-Leech, H., Graham, J., Harper, H., Lock, S., McMillan, N., O'Flaherty, C., OKell, E., Hayes, A., Sam, S., Slade, H., Walker, S., Wilding, K., Goodwin, J., Hodgson, H., Ellis, Y., Williamson, D., Bayne, M., Jackson, S., Byrne, R., McKenna, S., Clinton, A., Debigare, S., Devine, D. V., Germain, M., Arnold, D. M., Begin, P., Callum, J. L., Chasse, M., Cook, D. J., English, S. W., Fergusson, D. A., Fowler, R. A., Goligher, E. C., Houston, B. L., Lawler, P. R., Marshall, J. C., Moore, L., Paunovic, B., Robitaille, N., Tinmouth, A. T., McCracken, P., Young, M., Board, J., Martin, E., El-Khawas, K., Richardson, A., Hill, D., Commons, R. J., Abdelkharim, H., Knott, C., Smith, J., Boschert, C., Affleck, J., Apte, Y., Subbanna, U., Bartholdy, R., Frakking, T., Keat, K., Bhonagiri, D., Sanghavi, R., Nema, J., Ford, M., Parikh, H. G., Avard, B., Nourse, M., Cheung, W., Kol, M., Wong, H., Shah, A., Wagh, A., Simpson, J., Duke, G., Chan, P., Carter, B., Hunter, S., Laver, R. D., Shrestha, T., Jin, X., Regli, A., Pellicano, S., Palermo, A., Eroglu, E., French, C., Bates, S., Towns, M., Yang, Y., McGain, F., McCullough, J., Tallott, M., Kumar, N., Panwar, R., Brinkerhoff, G., Koppen, C., Cazzola, F., Brain, M., Mineall, S., Fischer, R., Biradar, V., Soar, N., White, H., Estensen, K., Morrison, L., Sutton, J., Cooper, M., Shehabi, Y., Al-Bassam, W., Hulley, A., Kadam, U., Sathianathan, K., Whitehead, C., Lowrey, J., Gresham, R., Masters, K., Walsham, J., Meyer, J., Harward, M., Venz, E., Brady, K., Vale, C., Shekar, K., Lavana, J., Parmar, D., Williams, P., Kurenda, C., Miles, H., Attokaran, A., Gluck, S., O'Connor, S., Chapman, M., Glasby, K., Smyth, K., Phillips, M., Barge, D., Byrne, K., Driscoll, A., Fortune, L., Janin, P., Yarad, E., Bass, F., Hammond, N., O'Connor, A., Waterson, S., McNamara, R., Buhr, H., Coles, J., Schweikert, S., Wibrow, B., Rauniyar, R., Deshpande, K., Konecny, P., Miller, J., Kintono, A., Tung, R., Fysh, E., Dawda, A., Mevavala, B., De Keulenaer, A. R., Litton, E., Ferrier, J., Nair, P., Buscher, H., Reynolds, C., Newman, S., Santamaria, J., Barbazza, L., Homes, J., Smith, R., Garrett, P., Murray, L., Brailsford, J., Forbes, L., Maguire, T., Fennessy, G., Mulder, J., Morgan, R., McEldrew, R., Naeem M, A., Fagan, L., Ryan, E., Mariappa, V., Smith, J., Simpson, S., Maiden, M., Bone, A., Horton, M., Salerno, T., Sterba, M., Geng, W., Depuydt, P., Waele, J. D., De Bus, L., Fierens, J., Bracke, S., Vermassen, J., Vermeiren, D., Reeve, B., Dechert, W., Chasse, M., Carrier, F. M., Boumahni, D., Benettaib, F., Ghamraoui, A., Couillard-Chenard, E., Lauzier, F., Francoeur, C., Lamontagne, F., D'Aragon, F., Carbonneau, E., Leblond, J., Vazquez-Grande, G., Liu, T., Siddiqui, A., Wilson, M., Albert, M., Serri, K., Cavayas, A., Duplaix, M., Williams, V., Rochwerg, B., Karachi, T., Oczkowski, S., Centofanti, J., Millen, T., Khwaja, K., Campisi, J., Duan, E., Tsang, J., Patterson, L., Sy, E., Gupta, C., Kassir, S. S., Kutsogiannis, D., Thompson, P., Kamra, M., Marinoff, N., Cook, D., Clarke, F., Kruisselbrink, R., Brochard, L., Burns, K., Sandhu, G., Khalid, I., English, S., Miezitis, S., McIntyre, L., Wilcox, E., Del Sorbo, L., Abdelhady, H., Romagnuolo, T., Baig, N., Rewa, O., Bagshaw, S., Binnie, A., Powell, E., McMillan, A., Luk, T., Aref, N., Pratheema, R., Babu, S., Vignesh, C., Kumar, B., Ramakrishnan, N., James, A., Elvira, E., Ebenezer, R., Krishnaoorthy, S., Ranganathan, L., Shree, M. M., Mani, A. K., Mathew, M., Khanal, R. S., Amatya, S., Paneru, H. R., Koirala, S., Paudel, P., Koirala, K., Rai, N., Luitel, S., Bhattarai, B., Hashmi, M., Panjwani, A., Umrani, Z. A., Siddiq, S., Shaikh, M., Salahuddin, N., Masood, S., Andric, Z., Cviljevic, S., Dimoti, R., Zapalac, M., Mirkovic, G., Barsic, B., Kutlesa, M., Kotarski, V., Vujaklija Brajkovic, A., Babel, J., Sever, H., Dragija, L., Kusan, I., Vaara, S., Pettila, L., Heinonen, J., Kuitunen, A., Karlsson, S., Vahtera, A., Kiiski, H., Ristimaki, S., Azaiz, A., Charron, C., Godement, M., Geri, G., Vieillard-Baron, A., Pourcine, F., Monchi, M., Luis, D., Mercier, R., Sagnier, A., Verrier, N., Caplin, C., Richecoeu, J., Combaux, D., Siami, S., Aparicio, C., Vautier, S., Jeblaoui, A., Lemaire-Brunel, D., Fartoukh, M., Courtin, L., Labbe, V., Voiriot, G., Salhi, S. N., Plantefeve, G., Leparco, C., Contou, D., Muller, G., Nay, M., Kamel, T., Benzekri, D., Jacquier, S., Runge, I., Mathonnet, A., Barbier, F., Bretagnol, A., Mercier, E., Chartier, D., Salmon, C., Dequin, P. F., Garot, D., Schneider, F., Castelain, V., Morel, G., L'Hotellier, S., Badie, J., Berdaguer, F. D., Malfroy, S., Mezher, C., Bourgoin, C., Moneger, G., Bouvier, E., Megarbane, B., Voicu, S., Deye, N., Malissin, I., Sutterlin, L., Mrad, A., Pepin Lehalleur, A., Naim, G., Nguyen, P., Ekherian, J., Boue, Y., Sideris, G., Vodovar, D., Guerin, E., Grant, C., Guitton, C., Darreau, C., Landais, M., Chudeau, N., Robert, A., Tirot, P., Callahan, J. C., Saint Martin, M., Le Moal, C., Marnai, R., Leroyer, M. H., Moine, P., Heming, N., Maxime, V., Bossard, I., Nicholier, T. B., Clair, B., Orlikowski, D., Bounab, R., Abdeladim, L., Colin, G., Zinzoni, V., Maquigneau, N., Henri-Lagarrigue, M., Pouplet, C., Soukup, J., Wetzold, R., Lobel, M., Ing, D., Starke, L., Grimm, P., Finn, A., KreSS, G., Hoff, U., Hinrichs, C. F., Nee, J., Pletz, M. W., Hagel, S., Ankert, J., Kolanos, S., Bloos, F., Nickoleit-Bitzenberger, D., Schaaf, B., Meermeier, W., Prebeg, K., Azzaui, H. S., Hower, M., Brieger, K., Elender, C., Sabelhaus, T., Riepe, A., Akamp, C., Kremling, J., Klein, D., Landsiedel-Mechenbier, E., Petros, S., Kunz, K., Schutze, B., Kluge, S., Nierhaus, A., Jarczak, D., Roedl, K., Ulrich Rohde, G. G., Grunewaldt, A., Bojunga, J., Weismann, D., Frey, A., Drayss, M., Goebeler, M. E., Flor, T., Fragner, G., Wahl, N., Totzke, J., Sayehli, C., Reill, L., Distler, M., Maselli, A., Belteczki, J., Magyar, I., Fazekas, A., Kovacs, S., Szoke, V., Szigligeti, G., Leszkoven, J., Collins, D., Reid, L., Smyth, M., Breen, P., Spain, S., Curley, G., McEvoy, N., Geoghegan, P., Clarke, J., Laffeyirbre McNicholas, J., Scully, M., Casey, S., Kernan, M., Brennan, A., Rangan, R., Tully, R., Corbett, S., McCarthy, A., Duffy, O., Burke, D., Hayes, L., Murphy, L., Neill, A., Reidy, B., O'Dwyer, M., Ryan, D., Hoiting, O., Peters, M., Rengers, E., Evers, M., Prinssen, A., van den Oever, H. L., Kruisdijk-Gerritsen, A., Simons, K., van Zuylen, T., Bouman, A., van Gulik, L., Schouten, J., Pickkers, P., Roovers, N., Klop-Riehl, M., van der Eng, H., Jonge, E. d., Wigbers, J., Del Prado, M., Haitsma Mulier, J., Peters, A. L., Romberg, B., van Bree, S., Bouw-Ruiterrbara Festen, M., van Gelder, F., van Iperen, M., Osinga, M., Schellaars, R., Tjan, D., van der Wekken, R., Melchers, M., van Zanten, A., van Nieuwkoop, K., Ottens, T., Visser, Y., Juffermans, N., Koopmans, M., Guilder, E., Butler, M., Cowdrey, K., Woollett, M., Newby, L., Chen, Y., Simmonds, C., McConnochie, R., O'Connor, C., Carter, J. R., Henderson, S., Van Der Heyden, K., Mehrtens, J., Morris, A., Morgan, S., Williams, T., Kazemi, A., Song, R., Lai, V., Girijadevi, D., Everitt, R., Russell, R., Hackin, D., Buehner, U., Williams, E., Browne, T., Grimwade, K., Goodson, J., Keet, O., Callender, O., Martynoga, R., Trask, K., Butler, A., Young, C., Lesona, E., Olatunji, S., Navarra, L., Sol Cruz, R., Perry, K., Fuchs, R., Lambert, B., Albrett, J., Jackson, C., Kirkham, S., Amaro Dos Santos Catorze, N. J., Lima Pereira, T. N., Castro Ferreira, R. M., Pereira Sousa Bastos, J. M., Oliveira Batista, T. M., Florescu, S. A., Stanciu, D., Zaharia, M. F., Kosa, A. G., Codreanu, D., Arabi, Y. M., Qasim, E. A., Tlayjeh, H., Alswaidan, L., Naidu, B., Munoz-Bermudez, R., Marin-Corral, J., Salazar Degracia, A., Parrilla Gomez, F., Mateo Lopez, M. I., Lopez, R. L., Rodriguez, J., Carcel, S., Carmona, R., de la Fuente, C., Rodriguez, M., Kaye, C., Allan, A., Summers, C., Polgarova, P., McWilliam, S. J., Hawcutt, D. B., Rad, L., O'Malley, L., Whitbread, J., Kelsall, O., Cowley, N., Wild, L., Thrush, J., Wood, H., Austin, K., Donnelly, A., Kelly, M., Smyth, N., O'Kane, S., McClintock, D., Warnock, M., Campbell, R., McCallion, E., Johnson, P., McKenna, S., Hanley, J., Currierbara Allen, A., McGoldrick, C., McMaster, M., Jha, R., Kalogirou, M., Ellis, C., Krishnamurthy, V., Deelchand, V., O'Connor, A., Silversides, J., McGuigan, P., Ward, K., O'Neill, A., Finn, S., Phillips, B., Ortiz-Ruiz de Gordoa, L., Bewley, J., Thomas, M., Sweet, K., Grimmer, L., Johnson, R., Pinnell, J., Robinson, M., Gledhill, L., Wood, T., Morgan, M., Cole, J., Hill, H., Davies, M., Williams, A., Thomas, E., Davies, R., Wise, M., Antcliffe, D., Templeton, M., Rojo, R., Coghlan, P., Smee, J., Mackay, E., Cort, J., Whileman, A., Spencer, T., Spittle, N., Beavis, S., Padmakumar, A., Dale, K., Hawes, J., Moakes, E., Gascoyne, R., Pritchard, K., Stevenson, L., Cooke, J., Nemeth-Roszpopa, K., Kasipandian, V., Patel, A., Allibone, S., Mary-Genetu, R., Ramali, M., Ghosh, A., Osagie, R., Jayasinghe Arachchige, M., Hartley, M., Bamford, P., London, E., Cawley, K., Faulkner, M., Jeffrey, H., Sundar Raj, A., Tsinaslanidis, G., Nair Khade, R., Nwajei Agha, G., Nalumansi Sekiwala, R., Smith, T., Brewer, C., Gregory, J., Limb, J., Cowton, A., O'Brien, J., Postlethwaite, K., Nikitas, N., Wells, C., Lankester, L., McMillan, H., Pulletz, M., Birch, J., Wiseman, S., Horton, S., Alegria, A., Turki, S., Elsefi, T., Crisp, N., Allen, L., Smith, M., Chukkambotla, S., Goddard, W., Duberley, S., McCullagh, I. J., Robinson, P., Patel, B., Kelly, S., Touma, O., Holland, S., Hodge, C., Taylor, H., Alderman, M., Barnes, N., Da Rocha, J., Smith, C., Brooks, N., Weerasinghe, T., Sinclair, J., Abusamra, Y., Doherty, R., Cudlipp, J., Singh, R., Yu, H., Daebis, A., Ng, C., Kendrick, S., Saran, A., Makky, A., Greener, D., Rowe-Leete, L., Edwards, A., Bland, Y., Dolman, R., Foster, T., Linnett, V., Sanderson, A., Ritzema, J., Wild, H., Khare, D., Pinder, M., Selvamoni, S., Gopinath, A., Pugh, R., Menzies, D., Lean, R., Qiu, X., Scanlon, J. J., Puxty, K., Cathcart, S., McGovern, C., Carmichael, S., Rimmer, D., Yusuff, H., Isgro, G., Brightling, C., Bourne, M., Craner, M., Boyles, R., Szakmany, T., Cherian, S., Williams, G., James, C., Waters, A., Watters, M., Prout, R., Davies, L., Pegler, S., Kyeremeh, L., Mian, A., Ostermann, M., Marotti, M., Grau Novellas, N., Bociek, A., Brett, S., Sousa Arias, S., Hall, R. E., Jain, S., Gupta, A., Holbrook, C., Henning, J., Bonner, S., Hugill, K., Cirstea, E., Wilkinson, D., Jones, J., Karlikowski, M., Sutherland, H., Wilhelmsen, E., Woods, J., North, J., Sundaran, D., Hollos, L., Coburn, S., Williams, A., Saunders, S., Hopkins, P., Smith, J., Noble, H., Depante, M. T., Clarey, E., Laha, S., Verlander, M., Williams, A., Paramasivam, E., Wilby, E., Ogg, B., Howcroft, C., Aspinwall, A., Charlton, S., Gould, R., Mistry, D., Awan, S., Bedford, C., Hall, A., Cooke, J., Gardiner-Hill, C., Maloney, C., Brunskill, N., QureshiI, H. R., Flint, N., Nicholson, S., Southin, S., Nicholson, A., Ghattaoraya, A., Harding, D., O'Halloran, S., Collins, A., Smith, E., Trues, E., Borgatta, B., Turner-Bone, I., Reddy, A., Wilding, L., Wilson, C., Surti, Z., Chamara Warnapura, L., Agno, R., Sathianathan, P., Shaw, D., Ijaz, N., Burns, D., Nisar, M., Quick, V., Alexander, C., Patel, S., Hussain, N., Croucher, Y., Langnu Rudran, E., Gilani, S., Wieder, T., Tate, M. L., Golden, D., Davey, M., Seaman, R., Felton, T., Bannard-Smith, J., Henry, J., Clark, R., Birchall, K., Pomeroy, F., Quayle, R., Wylie, K., Sukuraman, A., McNamarra, J., Makowski, A., Misztal, B., Ahmed, I., Neicker, K., Millington, S., Squires, R., Phulpoto, M., Stewart, R., Mwaura, E., Mew, L. E., Wren, L., Willams, F., Oborska, A., Maeda, R., Kalchko-Veyssal, S., Orat Prabakaran, R., Hadebe, B., Makmur, E., Nicholls, G., Innes, R., Doble, P., Graham, L., Shovelton, C., Hamlyn, V., Hawkins, N., Roynon-Reed, A., Cutler, S., Lewis, S., Lazaro, J. M., Newman, T., Austin, P., Chapman, S., Cabrelli, L., Fletcher, S., Nortje, J., Fottrell-Gould, D., Randell, G., Stammers, K., Zaman, M., Elmahi, E., Jones, A., Hall, K., Mills, G. H., Ryalls, K., Harrington, K., Bowler, H., Sall, J., Bourne, R., Borrill, Z., Duncan, T., Lamb, T., Shaw, J., Fox, C., Smith, K., Holland, S., Blackledge, B., McMorrow, L., Durrans, L., Harris, J., Moreno Cuesta, J., Xavier, K., Purohit, D., Elhassan, M., Haldeos, A., Vincent, R., Abdelrazik, M., Jenkins, S., Ganesan, A., Kumar, R., Carter, D., Bakthavatsalam, D., Rowland, M., Hutton, P., Bashyal, A., Davidson, N., Hird, C., Beer, S., Chhablani, M., Phalod, G., Kirkby, A., Archer, S., Netherton, K., Philips, B., Mullan, D., Skinner, D., Gaylard, J., Newman, J., Sathe, S. A., Roche, L., Davies, E., Turner, K., Reschreiter, H., Camsooksai, J., Patch, S., Jenkins, S., Humphrey, C., Pogson, D., Rose, S., Daly, Z., Brimfield, L., Nown, A., Parekh, D., Bergin, C., Bates, M., McGhee, C., Lynch, D., Bhandal, K., Tsakiridou, K., Bamford, A., Cooper, L., Whitehouse, T., Veenith, T., Sim, M. A., Kennedy Hay, S., Henderson, S., Nygren, M., Valentine, E., Katary, A., Bell, G., Wilcox, L., English, K., Adams, A., Phull, M., Zaidi, A., Pogreban, T., Rosaroso, L. P., Harvey, D., Lowe, B., Meredith, M., Ryan, L., Hormis, A., Walker, R., Collier, D., Kimpton, S., Oakley, S., Rooney, K., Rodden, N., Hughes, E., Thomson, N., McGlynn, D., Clark, C., Clark, P., Walden, A., Keating, L., Frise, M., Okeke, T., Jacques, N., Coles, H., Tilney, E., Vowell, E., Schuster-Bruce, M., Pitts, S., Miln, R., Purandare, L., Vamplew, L., Patel, B., Dempster, D., Gummadi, M., Dormand, N., Wang, S. F., Spivey, M., Bean, S., Burt, K., Moore, L., Day, C., Gibson, C., Gordon, E., Zitter, L., Keenan, S., Singh, J., Lynch, C., Mikusek, J., Deacon, B., Baker, E., Hickey, J., Champanerkar, S., Aitken, L., Lewis Prosser, L., Raithatha, A., Bauchmuller, K., Ahmad, N., Wiles, M., Willson, J., Grecu, I., Martin, J., Wrey Brown, C., Arias, A., Bevan, E., Craven, T. H., Hope, D., Singleton, J., Clark, S., McCulloch, C., Welters, I. D., Hamilton, D. O., Williams, K., Waugh, V., Shaw, D., Mulla, S., Waite, A., Fernandez Roman, J., Lopez Martinez, M., Puthucheary, Z., Martin, T., Santos, F., Uddin, R., Fernandez, M., Seidu, F., Somerville, A., Pakats, M. L., Dias, P., Begum, S., Shahid, T., Bhagani, S., De Neef, M., Filipe, H., Mingos, S., Maharajh, A., Pakou, G., Nandani, A., Tatham, K. C., Jhanji, S., Blackurs, E., Dela Rosaurs, A., Howle, R., Baikady, R. R., Tully, R. P., Drummond, A., Dearden, J., Philbin, J. E., Munt, S., Gopal, S., Pooni, J., Ganguly, S., Smallwood, A., Metherell, S., Vuylsteke, A., Chan, C., Victor, S., Hospital, P., Matsa, R., Gellamucho, M., Creagh-Brown, B., Tooley, J., Montague, L., De Beaux, F., Bullman, L., Kerslake, I., Demetriou, C., Mitchard, S., Ramos, L., White, K., Reay, M., Jenkins, S., Tuckwell, C., Watts, A., Traverse, E., Jennings, S., Donnison, P., Johns, M., Casey, R., Mattocks, L., Salisbury, S., Dark, P., Harvey, A., Reece, R., Doonan, D., Knowles, K., Hulme, J., Kannan, S., Joseph, S., Kinney, F., Senya, H. J., Ratnam, V., Gill, M., Kirk, J., Shelton, S., Frey, C., Scano, R., McKee, M., Murphy, P., Thomas, M., Worner, R., Faulkner, B., Gendall, E., Hayes, K., Hayley, H., Blakemore, B., Borislavova, B., Hamilton-Davies, C., Chan, C., Mfuko, C., Abbass, H., Mandadapu, V., Leaver, S., Patel, K., Farnell-Ward, S., Pepermans Saluzzio, R., Rawlins, J., Banach, D., Fernandez de Pinedo Artaraz, Z., Cabreros, L., White, I., Croft, M., Holland, N., Pereira, R., Zaki, A., Johnson, D., Jackson, M., Garrard, H., Juhaz, V., Brown, L., Roy, A., Rostron, A., Woods, L., Cornell, S., Pillai, S., Harford, R., Ivatt, H., Evans, D., Richards, S., Roberts, E., Bowen, J., Ainsworth, J., Clark, T., Foulds, A., Atkins, S., Lee, K., Barber, R., Hilldrith, A., Hewitt, C., Bremmer, P., Ward, G., Bassford, C., Brohi, F., Jagannath, V., Clark, M., Purvis, S., Wetherill, B., Dushianthan, A., Cusack, R., de Courcy-Golder, K., Salmon, K., Burnish, R., Smith, S., Jackson, S., Ruiz, W., Duke, Z., Johns, M., Male, M., Gladas, K., Virdee, S., Swabe, J., Tomlinson, H., Attwood, B., Parsons, P., Campbell, B., Smith, A., Page, V. J., Zhao, X. B., Oza, D., Abrahamson, G., Sheath, B., Ellis, C., Rhodes, J., Anderson, T., Morris, S., Xia Le Tai, C., Thomas, A., Keen, A., Tridente, A., Shuker, K., Anders, J., Greer, S., Scott, P., Millington, A., Buchanan, P., Kirk, J., Denmade, C., Sadera, G., Jacob, R., Jones, C., Hughes, D., Digby, S., Southern, D., Reddy, H., Hulse, S., Campbell, A., Garton, M., Watkins, C., Smuts, S., Quinn, A., Simpson, B., McMillan, C., Finch, C., Hill, C., Cooper, J., Budd, J., Small, C., O'Leary, R., Birch, J., Collins, E., Alexander, P. D., Ferguson, S., Sellers, K., Bradley-Potts, J., Yates, D., Birkinshaw, I., Kell, K., Scott, Z., Pearson, H., Adams, P., Vita, T., Buhay, M., Winters, J., Doherty, K., Ghaffari, M., Bagavathy, K., Donadee, C., Bryan-Morris, K., Arnold, J., Reynolds, B., Beard, G., McAdams, D., Walker, G., Gingo, M., Dunsavage, D., Saiyed, S., Hernandez, E., Goldman, J., Brown, C., Comp, S., Raczek, J., Morris, J. L., Vargas, J. J., Weiss, D., Hensley, J. W., Kochert, E., Wnuk, C., Nemeth, C., Mowery, B., Hutchinson, C., Winters, L., Martin, E., Bariola, R., Viehman, A., Daley, J., Lopus, A., Schmidhofer, M., Sackrowitz, R., Skrtich, A., Minnier, T., Wisniewski, M. K., Mayak, K., Ambrosino, R., Keen, S., Della Toffalo, S., Stambaugh, M., Trimmer, K., Perri, R., Casali, S., Medva, R., Massar, B., Beyerl, A., Burkey, J., Keeler, S., Lowery, M., Oncea, L., Daugherty, J., Sevilla, C., Woelke, A., Dice, J., Weber, L., Roth, J., Ferringer, C., Beer, D. 2021

    Abstract

    BACKGROUND: Thrombosis and inflammation may contribute to the risk of death and complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation may improve outcomes in noncritically ill patients who are hospitalized with Covid-19.METHODS: In this open-label, adaptive, multiplatform, controlled trial, we randomly assigned patients who were hospitalized with Covid-19 and who were not critically ill (which was defined as an absence of critical care-level organ support at enrollment) to receive pragmatically defined regimens of either therapeutic-dose anticoagulation with heparin or usual-care pharmacologic thromboprophylaxis. The primary outcome was organ support-free days, evaluated on an ordinal scale that combined in-hospital death (assigned a value of -1) and the number of days free of cardiovascular or respiratory organ support up to day 21 among patients who survived to hospital discharge. This outcome was evaluated with the use of a Bayesian statistical model for all patients and according to the baseline d-dimer level.RESULTS: The trial was stopped when prespecified criteria for the superiority of therapeutic-dose anticoagulation were met. Among 2219 patients in the final analysis, the probability that therapeutic-dose anticoagulation increased organ support-free days as compared with usual-care thromboprophylaxis was 98.6% (adjusted odds ratio, 1.27; 95% credible interval, 1.03 to 1.58). The adjusted absolute between-group difference in survival until hospital discharge without organ support favoring therapeutic-dose anticoagulation was 4.0 percentage points (95% credible interval, 0.5 to 7.2). The final probability of the superiority of therapeutic-dose anticoagulation over usual-care thromboprophylaxis was 97.3% in the high d-dimer cohort, 92.9% in the low d-dimer cohort, and 97.3% in the unknown d-dimer cohort. Major bleeding occurred in 1.9% of the patients receiving therapeutic-dose anticoagulation and in 0.9% of those receiving thromboprophylaxis.CONCLUSIONS: In noncritically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge with reduced use of cardiovascular or respiratory organ support as compared with usual-care thromboprophylaxis. (ATTACC, ACTIV-4a, and REMAP-CAP ClinicalTrials.gov numbers, NCT04372589, NCT04505774, NCT02735707, and NCT04359277.).

    View details for DOI 10.1056/NEJMoa2105911

    View details for PubMedID 34351721

  • Plasma Metabolites in Early Sepsis Identify Distinct Clusters Defined by Plasma Lipids. Critical care explorations Rogers, A. J., Leligdowicz, A., Contrepois, K., Jauregui, A., Vessel, K., Deiss, T. J., Belzer, A., Liu, T., Lippi, M., Ke, S., Ross, E., Zhou, H., Hendrickson, C., Gomez, A., Sinha, P., Kangelaris, K. N., Liu, K. D., Calfee, C. S., Matthay, M. A. 2021; 3 (8): e0478

    Abstract

    Unbiased global metabolomic profiling has not been used to identify distinct subclasses in patients with early sepsis and sepsis-associated acute respiratory distress syndrome. In this study, we examined whether the plasma metabolome reflects systemic illness in early sepsis and in acute respiratory distress syndrome.DESIGN: Plasma metabolites were measured in subjects with early sepsis.SETTING: Patients were admitted from the emergency department to the ICU in a plasma sample collected within 24 hours of ICU admission. Metabolic profiling of 970 metabolites was performed by Metabolon (Durham, NC). Hierarchical clustering and partial least squares discriminant clustering were used to identify distinct clusters among patients with early sepsis and sepsis-associated acute respiratory distress syndrome.INTERVENTIONS: None.MEASUREMENTS AND MAIN RESULTS: Among critically ill patients with early sepsis (n = 197), three metabolically distinct subgroups were identified, with metabolic subtype driven by plasma lipids. Group 1, with 45 subjects (23% of cohort), had increased 60-day mortality (odds ratio, 2; 95% CI, 0.99-4.0; p = 0.04 for group 1 vs all others). This group also had higher rates of vasopressor-dependent shock, acute kidney injury, and met Berlin acute respiratory distress syndrome criteria more often (all p < 0.05). Conversely, metabolic group 3, with 76 subjects (39% of cohort), had the lowest risk of 60-day mortality (odds ratio, 0.44; 95% CI, 0.22-0.86; p = 0.01) and lower rates of organ dysfunction as reflected in a lower Simplified Acute Physiology Score II (p < 0.001). In contrast, global metabolomic profiling did not separate patient with early sepsis with moderate-to-severe acute respiratory distress syndrome (n = 78) from those with sepsis without acute respiratory distress syndrome (n = 75).CONCLUSIONS: Plasma metabolomic profiling in patients with early sepsis identified three metabolically distinct groups that were characterized by different plasma lipid profiles, distinct clinical phenotypes, and 60-day mortality. Plasma metabolites did not distinguish patients with early sepsis who developed acute respiratory distress syndrome from those who did not.

    View details for DOI 10.1097/CCE.0000000000000478

    View details for PubMedID 34345827

  • Latent class analysis-derived subphenotypes are generalisable to observational cohorts of acute respiratory distress syndrome: a prospective study THORAX Sinha, P., Delucchi, K. L., Chen, Y., Zhuo, H., Abbott, J., Wang, C., Wickersham, N., McNeil, J., Jauregui, A., Ke, S., Vessel, K., Gomez, A., Hendrickson, C. M., Kangelaris, K. N., Sarma, A., Leligdowicz, A., Liu, K. D., Matthay, M. A., Ware, L. B., Calfee, C. S. 2022; 77 (1): 13-21

    Abstract

    Using latent class analysis (LCA), two subphenotypes of acute respiratory distress syndrome (ARDS) have consistently been identified in five randomised controlled trials (RCTs), with distinct biological characteristics, divergent outcomes and differential treatment responses to randomised interventions. Their existence in unselected populations of ARDS remains unknown. We sought to identify subphenotypes in observational cohorts of ARDS using LCA.LCA was independently applied to patients with ARDS from two prospective observational cohorts of patients admitted to the intensive care unit, derived from the Validating Acute Lung Injury markers for Diagnosis (VALID) (n=624) and Early Assessment of Renal and Lung Injury (EARLI) (n=335) studies. Clinical and biological data were used as class-defining variables. To test for concordance with prior ARDS subphenotypes, the performance metrics of parsimonious classifier models (interleukin 8, bicarbonate, protein C and vasopressor-use), previously developed in RCTs, were evaluated in EARLI and VALID with LCA-derived subphenotypes as the gold-standard.A 2-class model best fit the population in VALID (p=0.0010) and in EARLI (p<0.0001). Class 2 comprised 27% and 37% of the populations in VALID and EARLI, respectively. Consistent with the previously described 'hyperinflammatory' subphenotype, Class 2 was characterised by higher proinflammatory biomarkers, acidosis and increased shock and worse clinical outcomes. The similarities between these and prior RCT-derived subphenotypes were further substantiated by the performance of the parsimonious classifier models in both cohorts (area under the curves 0.92-0.94). The hyperinflammatory subphenotype was associated with increased prevalence of chronic liver disease and neutropenia and reduced incidence of chronic obstructive pulmonary disease. Measurement of novel biomarkers showed significantly higher levels of matrix metalloproteinase-8 and markers of endothelial injury in the hyperinflammatory subphenotype, whereas, matrix metalloproteinase-9 was significantly lower.Previously described subphenotypes are generalisable to unselected populations of non-trauma ARDS.

    View details for DOI 10.1136/thoraxjnl-2021-217158

    View details for Web of Science ID 000728271900001

    View details for PubMedID 34253679

    View details for PubMedCentralID PMC8688287

  • Genome-wide association studies in ARDS: SNPing the tangled web of heterogeneity. Intensive care medicine Clohisey, S., Sinha, P. 2021; 47 (7): 782-785

    View details for DOI 10.1007/s00134-021-06462-7

    View details for PubMedID 34173858

    View details for PubMedCentralID PMC8233583

  • Genome-wide association studies in ARDS: SNPing the tangled web of heterogeneity INTENSIVE CARE MEDICINE Clohisey, S., Sinha, P. 2021; 47 (7): 782-785
  • Six-month and 12-month patient outcomes based on inflammatory subphenotypes in sepsis-associated ARDS: secondary analysis of SAILS-ALTOS trial THORAX Hashem, M. D., Hopkins, R. O., Colantuoni, E., Dinglas, V. D., Sinha, P., Aronson Friedman, L., Morris, P. E., Jackson, J. C., Hough, C. L., Calfee, C. S., Needham, D. M. 2022; 77 (1): 22-30

    Abstract

    Prior acute respiratory distress syndrome (ARDS) trials have identified hypoinflammatory and hyperinflammatory subphenotypes, with distinct differences in short-term outcomes. It is unknown if such differences extend beyond 90 days or are associated with physical, mental health or cognitive outcomes.568 patients in the multicentre Statins for Acutely Injured Lungs from Sepsis trial of rosuvastatin versus placebo were included and assigned a subphenotype. Among 6-month and 12-month survivors (N=232 and 219, respectively, representing 243 unique survivors), subphenotype status was evaluated for association with a range of patient-reported outcomes (eg, mental health symptoms, quality of life). Patient subsets also were evaluated with performance-based tests of physical function (eg, 6 min walk test) and cognition.The hyperinflammatory versus hypoinflammatory subphenotype had lower overall 12-month cumulative survival (58% vs 72%, p<0.01); however, there was no significant difference in survival beyond 90 days (86% vs 89%, p=0.70). Most survivors had impairment across the range of outcomes, with little difference between subphenotypes at 6-month and 12-month assessments. For instance, at 6 months, in comparing the hypoinflammatory versus hyperinflammatory subphenotypes, respectively, the median (IQR) patient-reported SF-36 mental health domain score was 47 (33-56) vs 44 (35-56) (p=0.99), and the per cent predicted 6 min walk distance was 66% (48%, 80%) vs 66% (49%, 79%) (p=0.76).Comparing the hyperinflammatory versus hypoinflammatory ARDS subphenotype, there was no significant difference in survival beyond 90 days and no consistent findings of important differences in 6-month or 12-month physical, cognitive and mental health outcomes. These findings, when considered with prior results, suggest that inflammatory subphenotypes largely reflect the acute phase of illness and its short-term impact.

    View details for DOI 10.1136/thoraxjnl-2020-216613

    View details for Web of Science ID 000728294400001

    View details for PubMedID 34112703

    View details for PubMedCentralID PMC8660939

  • Immunotherapy in COVID-19: why, who, and when? LANCET RESPIRATORY MEDICINE Sinha, P., Calfee, C. S. 2021; 9 (6): 549-551

    View details for DOI 10.1016/S2213-2600(21)00232-0

    View details for Web of Science ID 000662049400011

    View details for PubMedID 34015326

    View details for PubMedCentralID PMC8128672

  • A neutrophil subset defined by intracellular olfactomedin 4 is associated with mortality in sepsis AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY Kangelaris, K. N., Clemens, R., Fang, X., Jauregui, A., Liu, T., Vessel, K., Deiss, T., Sinha, P., Leligdowicz, A., Liu, K. D., Zhuo, H., Alder, M. N., Wong, H. R., Calfee, C. S., Lowell, C., Matthay, M. A. 2021; 320 (5): L892-L902

    Abstract

    Sepsis is a heterogeneous syndrome clinically and biologically, but biomarkers of distinct host response pathways for early prognostic information and testing targeted treatments are lacking. Olfactomedin 4 (OLFM4), a matrix glycoprotein of neutrophil-specific granules, defines a distinct neutrophil subset that may be an independent risk factor for poor outcomes in sepsis. We hypothesized that increased percentage of OLFM4+ neutrophils on sepsis presentation would be associated with mortality. In a single-center, prospective cohort study, we enrolled adults admitted to an academic medical center from the emergency department (ED) with suspected sepsis [identified by 2 or greater systemic inflammatory response syndrome (SIRS) criteria and antibiotic receipt] from March 2016 through December 2017, followed by sepsis adjudication according to Sepsis-3. We collected 200 µL of whole blood within 24 h of admission and stained for the neutrophil surface marker CD66b followed by intracellular staining for OLFM4 quantitated by flow cytometry. The predictors for 60-day mortality were 1) percentage of OLFM4+ neutrophils and 2) OLFM4+ neutrophils at a cut point of ≥37.6% determined by the Youden Index. Of 120 enrolled patients with suspected sepsis, 97 had sepsis and 23 had nonsepsis SIRS. The mean percentage of OLFM4+ neutrophils was significantly increased in both sepsis and nonsepsis SIRS patients who died (P ≤ 0.01). Among sepsis patients with elevated OLFM4+ (≥37.6%), 56% died, compared with 18% with OLFM4+ <37.6% (P = 0.001). The association between OLFM4+ and mortality withstood adjustment for age, sex, absolute neutrophil count, comorbidities, and standard measures of severity of illness (SOFA score, APACHE III) (P < 0.03). In summary, OLFM4+ neutrophil percentage is independently associated with 60-day mortality in sepsis and may represent a novel measure of the heterogeneity of host response to sepsis.

    View details for DOI 10.1152/ajplung.00090.2020

    View details for Web of Science ID 000661574600019

    View details for PubMedID 33355521

    View details for PubMedCentralID PMC8174834

  • The Clinical Course of Coronavirus Disease 2019 in a US Hospital System: A Multistate Analysis AMERICAN JOURNAL OF EPIDEMIOLOGY Mody, A., Lyons, P. G., Guillamet, C., Michelson, A., Yu, S., Namwase, A., Sinha, P., Powderly, W. G., Woeltje, K., Geng, E. H. 2021; 190 (4): 539-552

    Abstract

    There are limited data on longitudinal outcomes for coronavirus disease 2019 (COVID-19) hospitalizations that account for transitions between clinical states over time. Using electronic health record data from a hospital network in the St. Louis, Missouri, region, we performed multistate analyses to examine longitudinal transitions and outcomes among hospitalized adults with laboratory-confirmed COVID-19 with respect to 15 mutually exclusive clinical states. Between March 15 and July 25, 2020, a total of 1,577 patients in the network were hospitalized with COVID-19 (49.9% male; median age, 63 years (interquartile range, 50-75); 58.8% Black). Overall, 34.1% (95% confidence interval (CI): 26.4, 41.8) had an intensive care unit admission and 12.3% (95% CI: 8.5, 16.1) received invasive mechanical ventilation (IMV). The risk of decompensation peaked immediately after admission; discharges peaked around days 3-5, and deaths plateaued between days 7 and 16. At 28 days, 12.6% (95% CI: 9.6, 15.6) of patients had died (4.2% (95% CI: 3.2, 5.2) had received IMV) and 80.8% (95% CI: 75.4, 86.1) had been discharged. Among those receiving IMV, 35.1% (95% CI: 28.2, 42.0) remained intubated after 14 days; after 28 days, 37.6% (95% CI: 30.4, 44.7) had died and only 37.7% (95% CI: 30.6, 44.7) had been discharged. Multistate methods offer granular characterizations of the clinical course of COVID-19 and provide essential information for guiding both clinical decision-making and public health planning.

    View details for DOI 10.1093/aje/kwaa286

    View details for Web of Science ID 000644497600007

    View details for PubMedID 33351077

    View details for PubMedCentralID PMC7799307

  • Biological Mechanisms of Cognitive and Physical Impairments after Critical Care Rethinking the Inflammatory Model? AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE Parker, A. M., Sinha, P., Needham, D. M. 2021; 203 (6): 665-667

    View details for DOI 10.1164/rccm.202010-3896ED

    View details for Web of Science ID 000629650700006

    View details for PubMedID 33142075

    View details for PubMedCentralID PMC7958509

  • Assessing the importance of interleukin-6 in COVID-19 Reply LANCET RESPIRATORY MEDICINE Leisman, D. E., Ronner, L., Pinotti, R., Taylor, M. D., Sinha, P., Calfee, C. S., Hirayama, A. V., Mastroianni, F., Turtle, C. J., Harhay, M. O., Legrand, M., Deutschman, C. S. 2021; 9 (2): E14-E15

    View details for DOI 10.1016/S2213-2600(20)30603-2

    View details for Web of Science ID 000631356600004

    View details for PubMedID 33460572

    View details for PubMedCentralID PMC7834405

  • COVID-19 ARDS is characterized by a dysregulated host response that differs from cytokine storm and is modified by dexamethasone. Research square Sarma, A., Christenson, S., Mick, E., Deiss, T., DeVoe, C., Pisco, A., Ghale, R., Jauregui, A., Byrne, A., Moazed, F., Spottiswoode, N., Sinha, P., Zha, B., Neff, N., Tan, M., Serpa, P. H., Ansel, K. M., Wilson, J., Leligdowicz, A., Seigel, E., Sirota, M., DeRisi, J., Matthay, M., Consortium, C., Hendrickson, C., Kangelaris, K., Krummel, M., Woodruff, P., Erle, D., Calfee, C., Langelier, C. 2021

    Abstract

    We performed comparative lower respiratory tract transcriptional profiling of 52 critically ill patients with the acute respiratory distress syndrome (ARDS) from COVID-19 or from other etiologies, as well as controls without ARDS. In contrast to a cytokine storm, we observed reduced proinflammatory gene expression in COVID-19 ARDS when compared to ARDS due to other causes. COVID-19 ARDS was characterized by a dysregulated host response with increased PTEN signaling and elevated expression of genes with non-canonical roles in inflammation and immunity that were predicted to be modulated by dexamethasone and granulocyte colony stimulating factor. Compared to ARDS due to other types of viral pneumonia, COVID-19 was characterized by impaired interferon-stimulated gene expression (ISG). We found that the relationship between SARS-CoV-2 viral load and expression of ISGs was decoupled in patients with COVID-19 ARDS when compared to patients with mild COVID-19. In summary, assessment of host gene expression in the lower airways of patients with COVID-19 ARDS did not demonstrate cytokine storm but instead revealed a unique and dysregulated host response predicted to be modified by dexamethasone.

    View details for DOI 10.21203/rs.3.rs-141578/v1

    View details for PubMedID 33469573

    View details for PubMedCentralID PMC7814832

  • Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes LANCET RESPIRATORY MEDICINE Leisman, D. E., Ronner, L., Pinotti, R., Taylor, M. D., Sinha, P., Calfee, C. S., Hirayama, A. V., Mastroiani, F., Turtle, C. J., Harhay, M. O., Legrand, M., Deutschman, C. S. 2020; 8 (12): 1233-1244

    Abstract

    The description of a so-called cytokine storm in patients with COVID-19 has prompted consideration of anti-cytokine therapies, particularly interleukin-6 antagonists. However, direct systematic comparisons of COVID-19 with other critical illnesses associated with elevated cytokine concentrations have not been reported. In this Rapid Review, we report the results of a systematic review and meta-analysis of COVID-19 studies published or posted as preprints between Nov 1, 2019, and April 14, 2020, in which interleukin-6 concentrations in patients with severe or critical disease were recorded. 25 COVID-19 studies (n=1245 patients) were ultimately included. Comparator groups included four trials each in sepsis (n=5320), cytokine release syndrome (n=72), and acute respiratory distress syndrome unrelated to COVID-19 (n=2767). In patients with severe or critical COVID-19, the pooled mean serum interleukin-6 concentration was 36·7 pg/mL (95% CI 21·6-62·3 pg/mL; I2=57·7%). Mean interleukin-6 concentrations were nearly 100 times higher in patients with cytokine release syndrome (3110·5 pg/mL, 632·3-15 302·9 pg/mL; p<0·0001), 27 times higher in patients with sepsis (983·6 pg/mL, 550·1-1758·4 pg/mL; p<0·0001), and 12 times higher in patients with acute respiratory distress syndrome unrelated to COVID-19 (460 pg/mL, 216·3-978·7 pg/mL; p<0·0001). Our findings question the role of a cytokine storm in COVID-19-induced organ dysfunction. Many questions remain about the immune features of COVID-19 and the potential role of anti-cytokine and immune-modulating treatments in patients with the disease.

    View details for DOI 10.1016/S2213-2600(20)30404-5

    View details for Web of Science ID 000598105700027

    View details for PubMedID 33075298

    View details for PubMedCentralID PMC7567529

  • Phenotypes and personalized medicine in the acute respiratory distress syndrome INTENSIVE CARE MEDICINE Matthay, M. A., Arabi, Y. M., Siegel, E. R., Ware, L. B., Bos, L. D. J., Sinha, P., Beitler, J. R., Wick, K. D., Curley, M. A. Q., Constantin, J., Levitt, J. E., Calfee, C. S. 2020: 2136–52

    Abstract

    Although the acute respiratory distress syndrome (ARDS) is well defined by the development of acute hypoxemia, bilateral infiltrates and non-cardiogenic pulmonary edema, ARDS is heterogeneous in terms of clinical risk factors, physiology of lung injury, microbiology, and biology, potentially explaining why pharmacologic therapies have been mostly unsuccessful in treating ARDS. Identifying phenotypes of ARDS and integrating this information into patient selection for clinical trials may increase the chance for efficacy with new treatments. In this review, we focus on classifying ARDS by the associated clinical disorders, physiological data, and radiographic imaging. We consider biologic phenotypes, including plasma protein biomarkers, gene expression, and common causative microbiologic pathogens. We will also discuss the issue of focusing clinical trials on the patient's phase of lung injury, including prevention, administration of therapy during early acute lung injury, and treatment of established ARDS. A more in depth understanding of the interplay of these variables in ARDS should provide more success in designing and conducting clinical trials and achieving the goal of personalized medicine.

    View details for DOI 10.1007/s00134-020-06296-9

    View details for Web of Science ID 000590531800001

    View details for PubMedID 33206201

    View details for PubMedCentralID PMC7673253

  • Current and evolving standards of care for patients with ARDS INTENSIVE CARE MEDICINE Menk, M., Estenssoro, E., Sahetya, S. K., Neto, A., Sinha, P., Slutsky, A. S., Summers, C., Yoshida, T., Bein, T., Ferguson, N. D. 2020; 46 (12): 2157-2167

    Abstract

    Care for patients with acute respiratory distress syndrome (ARDS) has changed considerably over the 50 years since its original description. Indeed, standards of care continue to evolve as does how this clinical entity is defined and how patients are grouped and treated in clinical practice. In this narrative review we discuss current standards - treatments that have a solid evidence base and are well established as targets for usual care - and also evolving standards - treatments that have promise and may become widely adopted in the future. We focus on three broad domains of ventilatory management, ventilation adjuncts, and pharmacotherapy. Current standards for ventilatory management include limitation of tidal volume and airway pressure and standard approaches to setting PEEP, while evolving standards might focus on limitation of driving pressure or mechanical power, individual titration of PEEP, and monitoring efforts during spontaneous breathing. Current standards in ventilation adjuncts include prone positioning in moderate-severe ARDS and veno-venous extracorporeal life support after prone positioning in patients with severe hypoxemia or who are difficult to ventilate. Pharmacotherapy current standards include corticosteroids for patients with ARDS due to COVID-19 and employing a conservative fluid strategy for patients not in shock; evolving standards may include steroids for ARDS not related to COVID-19, or specific biological agents being tested in appropriate sub-phenotypes of ARDS. While much progress has been made, certainly significant work remains to be done and we look forward to these future developments.

    View details for DOI 10.1007/s00134-020-06299-6

    View details for Web of Science ID 000587070900001

    View details for PubMedID 33156382

    View details for PubMedCentralID PMC7646492